Codes for the GHO Dimension

2020-11-30

Available codes for the GHO dimension:

## New names:
## * `` -> ...1
## * `` -> ...2
## * `` -> ...3
## New names:
## * `` -> ...3
Label ID
Ambient air pollution attributable deaths AIR_1
Ambient air pollution attributable DALYs per 100’000 children under 5 years AIR_10
Household air pollution attributable deaths AIR_11
Household air pollution attributable deaths in children under 5 years AIR_12
Household air pollution attributable deaths per 100’000 capita AIR_13
Household air pollution attributable deaths per 100’000 children under 5 years AIR_14
Household air pollution attributable DALYs AIR_15
Household air pollution attributable DALYs in children under 5 years AIR_16
Household air pollution attributable DALYs (per 100 000 population) AIR_17
Household air pollution attributable DALYs per 100’000 children under 5 years AIR_18
Population using electricity as main cooking fuel (%) AIR_19
Ambient air pollution (Annual PM10 [ug/m3]) AIR_2
Population using LPG as main cooking fuel (%) AIR_20
Population using natural gas as main cooking fuel (%) AIR_21
Population using biogas as main cooking fuel (%) AIR_22
Population using kerosene as main cooking fuel (%) AIR_23
Population using clean fuels and technologies (sum of)(%) AIR_24
Population using coal as main cooking fuel (%) AIR_25
Population using charcoal as main cooking fuel (%) AIR_26
Population using wood as main cooking fuel (%) AIR_27
Population using dung as main cooking fuel (%) AIR_28
Population using crop waste as main cooking fuel (%) AIR_29
Ambient air pollution in urban areas (Annual PM10 [μg/m3]) AIR_2_1
Ambient air pollution in urban areas (Annual PM2.5 [μg/m3]) AIR_2_2
Percentage of the total population living in cities > 100’000 inhabitants AIR_3
Population using solid fuels (sum of) (%) AIR_30
Population using others (non listed items) as main cooking fuel (%) AIR_31
Population not cooking (%) AIR_32
Missing information on cooking fuels (%) AIR_33
Total survey respondents AIR_34
Joint effects of air pollution attributable deaths AIR_35
Joint effects of air pollution attributable deaths in children under 5 years AIR_36
Joint effects of air pollution attributable deaths per 100’000 capita AIR_37
Joint effects of air pollution attributable deaths per 100’000 children under 5 years AIR_38
Household air pollution attributable DALYs (per 100 000, age-standardized) AIR_39
Percent of urban inhabitants living in cities covered by PM measurements AIR_3_1
Ambient air pollution attributable deaths in children under 5 years AIR_4
Household air pollution attributable DALYs AIR_40
Ambient air pollution attributable deaths AIR_41
Ambient air pollution attributable death rate (per 100 000 population, age-standardized) AIR_42
Ambient air pollution attributable DALYs AIR_43
DALYs attributable to ambient air pollution (age-standardized) AIR_44
Ambient air pollution attributable YLLs AIR_45
YLLs attributable to ambient air pollution (age-standardized) AIR_46
Ambient air pollution attributable death rate (per 100 000 population) AIR_5
Ambient air pollution attributable deaths (per 100 000 population, age-standardized) AIR_50
Household air pollution attributable death rate (per 100 000 population) AIR_51
Household air pollution attributable death rate (per 100 000 population, age-standardized) AIR_52
Ambient air pollution attributable deaths per 100’000 children under 5 years AIR_6
Household and ambient air pollution attributable DALYs (’000) AIR_60
Household and ambient air pollution attributable DALYs (per 100 000 capita) AIR_61
Household and ambient air pollution attributable DALYs (per 100 000 capita, age-standardized) AIR_62
Household and ambient air pollution attributable DALYs in children under 5 years (’000) AIR_63
Ambient air pollution attributable DALYs AIR_7
Ambient air pollution attributable DALYs in children under 5 years AIR_8
Ambient air pollution attributable DALYs (per 100 000 population) AIR_9
Ambient air pollution attributable DALYs (per 100 000 population, age-standardized) AIR_90
Functioning national AMR surveillance plan AMRGLASS_COORD01
Establishment of National Coordination Centre (NCC) AMRGLASS_COORD02
Nomination of National Focal Point (NFP) AMRGLASS_COORD03
Establishment of national reference laboratory (NRL) AMRGLASS_COORD04
No. of countries, territories and areas AMRGLASS_COUNTRIES01
No. of countries, territories and areas enrolled in GLASS (a) AMRGLASS_COUNTRIES02
No. of countries, territories and areas that reported information from the national surveillance system to GLASS AMRGLASS_COUNTRIES03
External Quality Assessment (EQA) provided to the national reference laboratory (NRL) AMRGLASS_QA01
External Quality Assessment (EQA) provided for bacterial identification and Antimicrobial Susceptibility Testing (AST) AMRGLASS_QA02
External Quality Assessment (EQA) provided to local laboratories participating in GLASS AMRGLASS_QA03
GLASS pathogens testing covered by External Quality Assessment (EQA) AMRGLASS_QA04
Types of Antimicrobial Susceptibility Testing (AST) standards followed by countries AMRGLASS_QA05
Number of surveillance sites reporting to GLASS: Hospitals AMRGLASS_SURVL01
Number of surveillance sites reporting to GLASS: Outpatient facilities AMRGLASS_SURVL02
Number of local clinical laboratories supporting national AMR surveillance sites AMRGLASS_SURVL03
Number of surveillance sites reporting to GLASS: In- and outpatient facilities AMRGLASS_SURVL04
Total number of surveillance sites reporting to GLASS AMRGLASS_SURVL05
Status of countries enrolled in GLASS AMR_GI_001
Status of National coordination center establishment AMR_GI_002
Status of National plans to implement and strengthen antimicrobial surveillance AMR_GI_003
Prevalence of anaemia in non-pregnant women (%) ANEMIANPW
Prevalence of anaemia in pregnant women (%) ANEMIAPW
Prevalence of anaemia in children under 5 years (%) ANEMIAU5
Government unit for treatment ATLAS_SU_0000000532
Government unit for alcohol and drugs: Location ATLAS_SU_0000000533
Government unit for alcohol: Location ATLAS_SU_0000000534
Government unit for drugs: Location ATLAS_SU_0000000535
No government unit ATLAS_SU_0000000536
Government unit for mental health/substance use: Location ATLAS_SU_0000000537
Prevalence of current cigarette smoking among adults (%) Adult_curr_cig_smoking
Prevalence of current e-cigarette use among adults (%) Adult_curr_e-cig
Prevalence of current smokeless tobacco use among adults (%) Adult_curr_smokeless
Prevalence of current tobacco smoking among adults (%) Adult_curr_tob_smoking
Prevalence of current tobacco use among adults (%) Adult_curr_tob_use
Prevalence of daily cigarette smoking among adults (%) Adult_daily_cig_smoking
Prevalence of daily e-cigarette use among adults (%) Adult_daily_e-cig
Prevalence of daily smokeless tobacco use among adults (%) Adult_daily_smokeless
Prevalence of daily tobacco smoking among adults (%) Adult_daily_tob_smoking
Prevalence of daily tobacco use among adults (%) Adult_daily_tob_use
Age range of latest adult prevalence survey (nonsmoked) Adult_nonsmoked_age_grp
Representation of latest adult prevalence survey (nonsmoked) Adult_nonsmoked_national
Name of latest adult prevalence survey (nonsmoked) Adult_nonsmoked_svy_title
Year of latest adult prevalence survey (nonsmoked) Adult_nonsmoked_svy_yr
Title of most recent survey of adults Adult_survey_title
Age range of most recent survey of adults Adult_svy_age_range
Representativeness of most recent survey of adults Adult_svy_national
Year of most recent survey of adults Adult_svy_yr
Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (crude estimate) BP_01
Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (age-standardized estimate) BP_02
Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate) BP_03
Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate) BP_04
Mean systolic blood pressure (crude estimate) BP_05
Mean systolic blood pressure (age-standardized estimate) BP_06
Cataract surgical coverage of adults aged 50 and over (%) CATARACTSURGICAL
Effective cataract surgical coverage of adults aged 50 and over (%) CATARACTSURGICALEFFECTIVE
Poverty headcount ratio at $1.25 a day (PPP) (% of population) CCO_1
Human development index rank CCO_2
Gender inequality index rank CCO_3
Literacy rate among adults aged >= 15 years (%) CCO_WHS9_85
Climate change attributable deaths CC_1
Climate change attributable DALYs (’000) CC_2
Climate change attributable deaths per 100’000 capita CC_3
Climate change attributable DALYs per 100’000 capita CC_4
Climate change attributable deaths (’000) in children under 5 years CC_5
Climate change attributable deaths per 100’000 children under 5 years CC_6
Climate change attributable DALYs (’000) in children under 5 years CC_7
Climate change attributable DALYs per 100’000 children under 5 years CC_8
Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years) CHILDMORT5TO14
Indicator 16.2.1: Proportion of children aged 1-17 years who experienced any physical punishment and/or psychological aggression by caregivers in the past month CHILDVIOL
Number of reported cases of cholera CHOLERA_0000000001
Number of reported deaths from cholera CHOLERA_0000000002
Cholera case fatality rate CHOLERA_0000000003
Raised total cholesterol (>= 5.0 mmol/L) (crude estimate) CHOL_01
Raised total cholesterol (>= 5.0 mmol/L) (age-standardized estimate) CHOL_02
Mean Total Cholesterol (age-standardized estimate) CHOL_03
Mean Total Cholesterol (crude estimate) CHOL_04
Raised total cholesterol (≥ 6.2 mmol/L) (age-standardized estimate) CHOL_05
Raised total cholesterol (≥ 6.2 mmol/L) (crude estimate) CHOL_06
Number of under-five deaths (thousands) CM_01
Number of infant deaths (thousands) CM_02
Number of neonatal deaths (thousands) CM_03
Process evaluation was employed to assess implementation Camp_airtime
Formative research was conducted prior to the campaign Camp_aud_research
Outcome evaluation was employed to assess effectiveness of the campaign Camp_eval_impact
Campaign was part of a comprehensive tobacco control programme Camp_gov_prog
Campaign was pre-tested Camp_mat_tested
Process evaluation was employed to assess implementation of the campaign Camp_media_monitor
Campaign utilized media planning Camp_media_planning
At least one national mass media campaign ran during the survey period Camp_nat
Earned media/public relations were used to promote the campaign Camp_news
Campaign ran on both national television and radio Camp_tv_radio
Congenital syphilis number of reported cases CaseCS
Disability-adjusted life years (DALYs), children aged under 5 years (000s) DALYS04Y000
Disability-adjusted life years (DALYs) per 100 000 population DALYSPER100000
Disability-adjusted life years (DALYs) total (000s) DALYSTOTAL
Deaths, children aged under 5 years DEATHS04Y
Deaths per 100 000 population DEATHSPER100000
Deaths total DEATHSTOTAL
Total density per 100 000 population: Hospitals DEVICES00
Total density per 100 000 population: Health posts DEVICES01
Total density per 100 000 population: Health centres DEVICES02
Total density per 100 000 population: District/rural hospitals DEVICES03
Total density per 100 000 population: Provincial hospitals DEVICES04
Total density per 100 000 population: Specialized hospitals DEVICES05
Availability of national standards or recommended lists of medical devices DEVICES06
Types of lists recommending health technology for high burden diseases DEVICES07
Total density per million population: Magnetic Resonance Imaging DEVICES08
Total density per million population: Computed tomography units DEVICES09
Total density per million population: Positron Emission tomography DEVICES10
Total density per million population: Gamma camera or Nuclear medicine DEVICES11
Total density per million population: Linear Accelerator DEVICES12
Type of nomenclature system DEVICES13
Use of nomenclature system DEVICES14
Health technology (medical device) national policy DEVICES15
Unit in the Ministry of Health responsible for the management of medical devices DEVICES16
Procurement of medical devices carried out at the national level DEVICES17
Availability of national list of approved medical devices for procurement or reimbursement DEVICES18
National guidelines, policies or recommendations on the procurement of medical devices DEVICES19
Availability of technical specifications of medical devices to support procurement or donations DEVICES20
Total density per million population: Telecobalt Unit DEVICES21
Total density per million population: Radiotherapy units DEVICES22
Total density per million females aged from 50 to 69 years old: Mammography units DEVICES23
Compliance of ban on promotional discounts E10_compliance
Ban on promotional discounts E10_promo_discounts
Ban on identifying non-tobacco products with tobacco brand names E11_brand_stretching
Compliance of ban on non-tobacco goods AND services identified with tobacco brand names E11_compliance
Ban on use of brand name of non-tobacco product for tobacco product E12_brand_sharing
Compliance of ban on brand name of non-tobacco products used for tobacco product E12_compliance
Ban on appearance of tobacco brands in TV and/or films (product placement) E13_brand_placement
Compliance of ban on appearance of tobacco brands in TV and/or films (product placement) E13_compliance
Compliance of ban on appearance of tobacco products in TV and/or films E14_compliance
Appearance of tobacco products in TV and/or films E14_prod_tv_films
Ban on appearance of tobacco products in TV and/or films E14a_prod_tv_films
Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images E14b_movies_anti_tob_ads
Compliance of ban on sponsored events E15_compliance
Sponsored events E15_sponsored_events
Ban on sponsorship (contributions and/or publicity of contributions) E15a_sponsorship
Ban on any form of contribution (financial or other support) to any event, activity or individual E15b_sponsor_contribution
Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals E15c_sponsor_publicity
Ban on Corporate Social Responsibility activities (CSR) E15d_csr_ban
Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities E16_csr_promo_self
Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility� activities of the tobacco companies E17_csr_promo_others
Ban on Corporate Social Responsibility activities (CSR) E17a_csr_ban
Ban on tobacco companies/the tobacco industry publicizing their CSR activities E17b_csr_promo_self
Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry E17c_csr_promo_others
Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth E18_csr_anti_tobacco_media
Law requires fines for violations of indirect advertising bans E19_indirect_ad_fines
Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images E19_movies_anti_tob_ads
Compliance of ban on advertising on national TV and radio E1_compliance
Ban on advertising on national television and radio E1_nat_tv_radio
Subnational laws or regulations exist banning some or all types of tobacco advertising, promotion and sponsorship E20_subnational_exists
Complete ban on tobacco vending machines E21_vending_machines
Law requires fines for violations of advertising bans E21a_direct_ad_fines
Law requires fines for violations of promotion and sponsorship bans E21b_indirect_ad_fines
Ban on internet sales of tobacco products E22_internet_sales_ban
Subnational bans on tobacco advertising, promotion and sponsorship authority exists E22_subnational_authority_exists
Subnational bans on tobacco advertising, promotion and sponsorship E22_subnational_exists
Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place E23_subnat_complete_bans_exist
Ban on tobacco vending machines E23_vending_machines
Ban on internet sales of tobacco products E24_internet_sales_ban
Ban on display of tobacco products at points of sale E25_ban_display_pt_of_sale
Law requires fines for violations of direct advertising bans E26_direct_ad_fines
Law requires fines for violations of indirect advertising bans E27_indirect_ad_fines
Ban on advertising on international television and radio E2_intl_tv_radio
Compliance of ban on advertising on local magazines and newspapers E3_compliance
Ban on advertising in local magazines and newspapers E3_nat_print
Ban on advertising in international magazines and newspapers E4_intl_print
Ban on billboard and outdoor advertising E5_billboards
Compliance of ban on advertising on billboards and outdoor advertising E5_compliance
Compliance of ban on advertising at point of sale E6_compliance
Ban on advertising: Point of sale E6_pt_of_sale
Ban on advertising at point of sale E6a_pt_of_sale
Ban on product display at point of sale E6b_ban_display_pt_of_sale
Ban on advertising on the internet E7_internet
Law requires fines for violations of direct advertising bans E8_direct_ad_fines
Compliance of ban on free distribution of tobacco products in the mail or through other means E9_compliance
Ban on free distribution in mail or through other means E9_free_distrib
Compliance with bans on direct advertising EC_direct_compliance
Compliance with bans on promotion and sponsorship EC_indirect_compliance
Electric field (kV/m) EMFLIMITELECTRIC
Electric field limit at 1800 MHz (V/m) EMFLIMITELECTRIC1800
Electric field limit at 900 MHz (V/m) EMFLIMITELECTRIC900
Electric field (kV/m) EMFLIMITELECTRICLF
Electric field limit (V/m) EMFLIMITELECTRICRADIO
Electric field (V/m) EMFLIMITELECTRICRF
Magnetic flux density (microT) EMFLIMITMAGNETIC
Power density (W/m^2) EMFLIMITPOWERDENSITY
Power density limit at 1800 MHz (W/m^2) EMFLIMITPOWERDENSITY1800
Power density limit at 900 MHz (W/m^2) EMFLIMITPOWERDENSITY900
Limit values EMFLIMITS
Power frequency (Hz) EMFPOWERFREQUENCY
Specific absorption rate (SAR) (W/kg) EMFSAR
Existence of standards EMFSTANDARD
Legislative status EMFSTATUS
Adolescent birth rate (births per 1,000 women aged 15 to 19) EQ_ADOBIRTH
Coverage of antenatal care (4 visits) EQ_ANC
Prevalence of obesity EQ_BMI30
People who identify the use of condoms as a way to avoid AIDS (%) EQ_CONDOMUSE
Contraceptive prevalence rate among women married or in union EQ_CONTRACEPTIVE
Households with dirt floor (%) EQ_DIRTFLOOR
Coverage of DTP3 immunization EQ_DTP3
Households with soap and water at a handwashing facility (%) EQ_HANDWASHING
HIV prevalence EQ_HIVPREV
Households that have a bednet for sleeping (%) EQ_HOUSENETS
Infant mortality per 1 000 live births EQ_INFANTMORT
Households with at least one ITN for sleeping (%) EQ_ITN
Children under five who slept under an ITN the previous night (%) EQ_ITNUNDER5
Knowlege about sexual transmission of AIDS EQ_KNHIV
Coverage of measles immunization EQ_MEAIMM
Population not using any sanitation facility (open defecation) (%) EQ_OPENDEFECATION
Prevalence of (moderate or severe) overweight in children EQ_OVERWEIGHT
Prevalence of overweight and obesity EQ_OVERWEIGHTADULT
Coverage of skilled birth attendance EQ_SBA
Women that slept under a bednet last night (%) EQ_SLEPTNETS
Proportion of urban residents living in a slum area EQ_SLUM
Households that use solid fuels for cooking (%) EQ_SOLIDFUELS
Prevalence of (moderate or severe) stunting in children EQ_STUNT
Prevalence of current cigarette smoking EQ_TOBACCO
Under-five mortality per 1 000 live births EQ_U5MORT
Children under five who slept under a bednet the previous night (%) EQ_U5SLEPTNETS
Prevalence of (moderate or severe) underweight in children EQ_UNDERWEIGHT
Population living in urban areas (%) EQ_URBPOP
Slum population in urban areas (% of total population) EQ_URBSLUM
Population using improved drinking-water sources (%) EQ_WATER
Households using an improved drinking-water source (%) EQ_WATERIMPROVED
Households using a piped drinking-water source (%) EQ_WATERPIPED
Households using a piped onto premises drinking-water source (%) EQ_WATERPREMISES
Enforce bans on tobacco advertising E_Group
Overall compliance with bans on direct advertising (score) E_compl_all_dir
Compliance with ban on advertising on national television and radio (score) E_compl_e1
Compliance with ban on promotional discounts (score) E_compl_e10
Compliance with ban on use of brand name of non-tobacco product for tobacco product (score) E_compl_e11
Compliance with ban on indentifying non-tobacco products with tobacco brand names (score) E_compl_e12
Compliance with ban on appearance of tobacco brands in TV and/or films (score) E_compl_e13
Compliance with ban on appearance of tobacco products in TV and/or films (score) E_compl_e14
Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score) E_compl_e15
Compliance with ban on advertising in local magazines and newspapers (score) E_compl_e3
Compliance with ban on billboard and outdoor advertising (score) E_compl_e5
Compliance with ban on advertising at point of sale (score) E_compl_e6
Compliance with ban on free distribution in mail or through other means (score) E_compl_e9
Overall compliance with bans on promotion and sponsorship (score) E_compl_e_all_indir
Subnational bans on advertising, promotion and sponsorship - at least one jurisdiction has a comprehensive ban in place E_comprehensive_subnat
Women of reproductive age (15−49 years) who are married or in-union who have their need for family planning satisfied with modern methods (%), UNPD FAMILYPLANNINGUNPDUHC
Households with out-of-pocket payments greater than 40% of capacity to pay for health care (food, housing and utilities approach - developed by WHO/Europe) (%) FINPROTECTION_CATA_CTPFHU_40_HH
Availability of estimates on large health expenditures as a share of total expenditure or income FINPROTECTION_CATA_ESTIMATE_AVAILABLE
Total population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (millions) FINPROTECTION_CATA_TOT_10_LEVEL_MILLION
Total population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (%) FINPROTECTION_CATA_TOT_10_LEVEL_SH
Population with household expenditures on health greater than 10% of total household expenditure or income (SDG indicator 3.8.2) (%) FINPROTECTION_CATA_TOT_10_POP
Total population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (millions) FINPROTECTION_CATA_TOT_25_LEVEL_MILLION
Total population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (%) FINPROTECTION_CATA_TOT_25_LEVEL_SH
Population with household expenditures on health greater than 25% of total household expenditure or income (SDG indicator 3.8.2) (%) FINPROTECTION_CATA_TOT_25_POP
Availability of estimates on impoverishment due to out-of-pocket health expenditures FINPROTECTION_IMPOV_ESTIMATE_AVAILABLE
Households further impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%) FINPROTECTION_IMP_BNLFHU_FURIMP_HH
Households impoverished by out-of-pocket payments (relative poverty line reflecting basic needs: food, housing, utilities) (%) FINPROTECTION_IMP_BNLFHU_P_HH
Households pushed below or further below a relative poverty line (reflecting basic needs: food, housing, utilities) by out-of-pocket payments (%) FINPROTECTION_IMP_BNLFHU_TOT_HH
Population pushed below the $1.90 a day poverty line by household health expenditures (%) FINPROTECTION_IMP_NP190_POP
Population pushed below the $3.20 a day poverty line by household health expenditures (%) FINPROTECTION_IMP_NP310_POP
Population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%) FINPROTECTION_IMP_NPRELPL_POP
Total population pushed below the $1.90 a day poverty line by household health expenditures (millions) FINPROTECTION_IMP_NP_190_LEVEL_MILLION
Total population pushed below the $1.90 a day poverty line by household health expenditures (%) FINPROTECTION_IMP_NP_190_LEVEL_SH
Total population pushed below the $3.20 a day poverty line by household health expenditures (millions) FINPROTECTION_IMP_NP_310_LEVEL_MILLION
Total population pushed below the $3.20 a day poverty line by household health expenditures (%) FINPROTECTION_IMP_NP_310_LEVEL_SH
Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (millions) FINPROTECTION_IMP_NP_REL_LEVEL_MILLION
Total population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%) FINPROTECTION_IMP_NP_REL_LEVEL_SH
Increase in poverty gap due to household health expenditures at the $1.90 a day poverty line, in cents of international dollars FINPROTECTION_IMP_PG_190
Increase in poverty gap due to household health expenditures, expressed as a proportion of the $1.90 a day poverty line (%) FINPROTECTION_IMP_PG_190_STD
Increase in poverty gap due to household health expenditures at the $3.20 a day poverty line, in cents of international dollars FINPROTECTION_IMP_PG_310
Increase in poverty gap due to household health expenditures, expressed as a proportion of the $3.20 a day poverty line (%) FINPROTECTION_IMP_PG_310_STD
Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line (60% of median daily per capita consumption or income) (%) FINPROTECTION_IMP_PG_RELPL_STD
Changes in poverty gap due to health expenditures at the $1.90 a day poverty line FINPROTECTION_P1_190_POP
Changes in poverty gap due to health expenditures at the \(3.20 a day poverty line |FINPROTECTION_P1_310_POP | |Reporting countries |GASPRP | |Proportion of isolates with resistance to azithromycin reported to WHO-GASP |GASPRSAZM | |Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefepime reported to WHO-GASP |GASPRSCFM | |Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP |GASPRSCIP | |Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP |GASPRSCRO | |Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP |GASPRSESC | |Number of isolates tested for azithromycin |GASPTIAZM | |Number of isolates tested for cefepime |GASPTICFM | |Number of isolates tested for ciprofloxacin |GASPTICIP | |Number of isolates tested for ceftriaxone |GASPTICRO | |Number of isolates tested for extended-spectrum cephalosporins |GASPTIESC | |Number of deaths |GBD_0000000036 | |GBD - population |GBD_0000000037 | |GBD - crude death rate |GBD_0000000038 | |GBD - Disability-adjusted life years (DALYS) |GBD_76 | |GBD - Years of life lost (YLL) |GBD_77 | |GBD - Years lost due to disability (YLD) |GBD_78 | |Age-standardized death rates (per 100 000 population) |GBD_ASDR | |DALY rates (per 100,000) |GBD_DALYRT | |Age-standardized DALYs (per 100,000) |GBD_DALYRTAGE | |Death rates (per 100,000) |GBD_DTHRT | |Incidence (in thousands) |GBD_INC | |Prevalence (in thousands) |GBD_PREV | |Research and development (R&D) expenditure as a proportion of GDP |GB_XPD_RSDV | |EXISTING GHO INDICATOR Number of Personal care workers (Health workforce) |GDO_ | |Identification of other plans in which dementia is integrated (Ageing) |GDO_Q2x2x1_AGE | |Identification of other plans in which dementia is integrated (Disability) |GDO_Q2x2x1_DISAB | |Identification of other plans in which dementia is integrated (Mental health) |GDO_Q2x2x1_MENTAL | |Identification of other plans in which dementia is integrated (NCD) |GDO_Q2x2x1_NCD | |National regulator approval of anti-dementia medication |GDO_q10x1 | |Availability of generic anti-dementia medication |GDO_q10x1x1 | |Availability of at least one anti-dementia medication approved for on-label use reimbursement |GDO_q10x1x2 | |Availability of atleast one adult hygiene products for people with dementia |GDO_q10x2_1AVAIL | |Availability of atleast one housing adjustment for people with dementia |GDO_q10x2_HOSUE | |Availability of atleast one assistive technology for people with dementia |GDO_q10x2_TECH | |Existence of dementia national nongovernmental organization |GDO_q11x1 | |Dementia nongovernmental organization equipped with office |GDO_q11x2x1 | |Dementia nongovernmental organization office branches (Sub-national) |GDO_q11x2x2_1 | |Dementia nongovernmental organization office branches (Local) |GDO_q11x2x2_2 | |Dementia nongovernmental organization office branches (National only) |GDO_q11x2x2_3 | |Dementia nongovernmental organization staff primarily salaried/volunteer |GDO_q11x2x3 | |Provision of governmental funding to dementia nongovernmental organization for activities/services |GDO_q11x2x5 | |Dementia nongovernmental organization's involvement in policy development |GDO_q11x2x6 | |Existence of dementia carer support services |GDO_q12x1 | |Implementation level [national/subnational] of dementia carer support services |GDO_q12x1x1 | |Existence of dedicated resources for dementia carer support services |GDO_q12x1x2 | |Existence of implementation plan for dementia carer support services |GDO_q12x1x3 | |Existence of dementia carer training and education |GDO_q12x2_1 | |Existence of psycho-social supports for dementia carers |GDO_q12x2_2 | |Existence of respite care for dementia carers |GDO_q12x2_3 | |Existence of information on legal rights for dementia carers |GDO_q12x2_4 | |Existence of financial benefits/social protection for dementia carers |GDO_q12x2_5 | |Accessibility of dementia carer training and education [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q12x2x1x1_1 | |Majority provider of dementia carer training and education (NGO) |GDO_q12x2x1x1_1NGO | |Majority provider of dementia carer training and education (Private sector) |GDO_q12x2x1x1_1PRV | |Majority provider of dementia carer training and education (Public sector) |GDO_q12x2x1x1_1PUB | |Accessibility of psycho-social supports for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q12x2x1x1_2 | |Majority provider of psycho-social supports for dementia carers (NGO) |GDO_q12x2x1x1_2NGO | |Majority provider of psycho-social supports for dementia carers (Private sector) |GDO_q12x2x1x1_2PRV | |Majority provider of psycho-social supports for dementia carers (Public sector) |GDO_q12x2x1x1_2PUB | |Accessibility of respite care for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q12x2x1x1_3 | |Majority provider of respite care for dementia carers (NGO) |GDO_q12x2x1x1_3NGO | |Majority provider of respite care for dementia carers (Private sector) |GDO_q12x2x1x1_3PRV | |Majority provider of respite care for dementia carers (Public sector) |GDO_q12x2x1x1_3PUB | |Accessibility of information on legal rights for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q12x2x1x1_4 | |Majority provider of information on legal rights for dementia carers (NGO) |GDO_q12x2x1x1_4NGO | |Majority provider of information on legal rights for dementia carers (Private sector) |GDO_q12x2x1x1_4PRV | |Majority provider of information on legal rights for dementia carers (Public sector) |GDO_q12x2x1x1_4PUB | |Accessibility of financial benefits/social protection for dementia carers [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q12x2x1x1_5 | |Majority provider of information on financial benefits/social protection for dementia carers (NGO) |GDO_q12x2x1x1_5NGO | |Majority provider of information on financial benefits/social protection for dementia carers (Private sector) |GDO_q12x2x1x1_5PRV | |Majority provider of information on financial benefits/social protection for dementia carers (Public sector) |GDO_q12x2x1x1_5PUB | |Estimated number of dementia carers receiving training and education |GDO_q12x2x1x3 | |Estimated number of dementia carers receiving psycho-social supports |GDO_q12x2x2x3 | |Estimated number of dementia carers receiving respite care |GDO_q12x2x3x3 | |Estimated number of dementia carers receiving information on legal rights |GDO_q12x2x4x3 | |Estimated number of dementia carers receiving financial benefits/social protection |GDO_q12x2x5x3 | |Existence of at least one functioning dementia awareness campaign |GDO_q13x1 | |Implementation level [national/subnational] of dementia awareness campaign |GDO_q13x1x1 | |Existence of at least one functioning risk reduction campaign |GDO_q13x3 | |Implementation level [national/subnational] of dementia risk reduction campaign |GDO_q13x3x1 | |Availability of dementia-friendly initiatives that improve accessibility |GDO_q14x1 | |Existence of dementia-friendly initiative to improve accessibility of public spaces |GDO_q14x2_1 | |Existence of dementia-friendly initiative to improve accessibility of public transportation |GDO_q14x2_2 | |Existence of dementia-friendly initiative for assistance with home modification |GDO_q14x2_3 | |Existence of dementia-friendly initiative with assistive technology for loss of capacity |GDO_q14x2_4 | |Existence of dementia-friendly initiative supporting community places for older people |GDO_q14x2_5 | |Existence of dementia-friendly initiative supporting social opportunities |GDO_q14x2_6 | |Inclusion of dementia training and education for non-health workers |GDO_q15x1 | |Existence of dementia training for volunteers |GDO_q15x2_1 | |Existence of dementia training for police and fire services |GDO_q15x2_2 | |Existence of dementia training for first responders |GDO_q15x2_3 | |Existence of dementia training for legal professionals |GDO_q15x2_4 | |Existence of dementia training for community workers |GDO_q15x2_5 | |Existence of dementia training for school children |GDO_q15x2_6 | |Existence of dementia training for financial service staff |GDO_q15x2_7 | |Existence of dementia training for retail and hospitality staff |GDO_q15x2_8 | |Routine monitoring of people with dementia |GDO_q16x1 | |Data sources used to routinely monitor people with dementia (Clinical records) |GDO_q16x1x1_1 | |Data sources used to routinely monitor people with dementia (Household surveys) |GDO_q16x1x1_2 | |Data sources used to routinely monitor people with dementia (Administrative data) |GDO_q16x1x1_3 | |Data sources used to routinely monitor people with dementia (Facility survey or records) |GDO_q16x1x1_4 | |Data sources used to routinely monitor people with dementia (Other) |GDO_q16x1x1_other | |Electronic availability of data sources used to routinely monitor people with dementia |GDO_q16x1x2_1 | |Data used to routinely monitor people with dementia can be disaggregated |GDO_q16x1x2_2 | |Availability of routine hospital admissions records for people with dementia for monitoring purposes |GDO_q16x2_1 | |Availability of routine outpatient visit records for people with dementia for monitoring purposes |GDO_q16x2_2 | |Availability of routine outpatient intervention and treatment records for people with dementia for monitoring purposes |GDO_q16x2_3 | |Availability of routine pharmaceutical records for people with dementia for monitoring purposes |GDO_q16x2_4 | |Availability of routine antipsychotic prescription records for people with dementia for monitoring purposes |GDO_q16x2_5 | |Availability and status of dementia reporting in the past two years |GDO_q16x3 | |Existence of a current dementia research plan/programme |GDO_q17x1 | |Implementation level [national/subnational] of dementia research plan/programme |GDO_q17x1x1 | |Dementia integrated into other national research plan/programme |GDO_q17x2 | |Identification of other research plans in which dementia is integrated (Mental health) |GDO_q17x2x1_1 | |Identification of other research plans in which dementia is integrated (Ageing) |GDO_q17x2x1_2 | |Identification of other research plans in which dementia is integrated (Neuro or neurodegenerative disease) |GDO_q17x2x1_3 | |Identification of other research plans in which dementia is integrated (NCD) |GDO_q17x2x1_4 | |Implementation level [national/subnational] of research plan in which dementia is integrated |GDO_q17x2x2 | |EXISTING GHO INDICATOR (SDG 9.5.1) Gross domestic R&D expenditure on health (health GERD) as a % of gross domestic product (GDP) |GDO_q18x1_1 | |Availability of funding for dementia-specific research plan/programme |GDO_q18x2 | |Total expenditure on dementia research (local currency, self-report) |GDO_q18x2x1_1 | |Total expenditure on dementia basic research (local currency, self-report) |GDO_q18x2x3_1 | |Total expenditure on dementia clinical/translational research (local currency, self-report) |GDO_q18x2x3_2 | |Total expenditure on dementia implementation research (local currency, self-report) |GDO_q18x2x3_3 | |Number of people with dementia involved in research routinely monitored |GDO_q19x2 | |Availability of investigational pharmaceutical trials for dementia |GDO_q19x3 | |Number of investigational pharmaceutical trials for dementia |GDO_q19x3x1_1 | |Inclusion of dementia in ministry portfolio |GDO_q1x1 | |Inclusion of dementia in a branch of government [health, ageing, social services, mental health, noncommunicable disease] |GDO_q1x1x1 | |Existence of dementia representative in ministry |GDO_q1x2 | |Total number of published dementia research output |GDO_q20 | |Existence of dementia national plan |GDO_q2x1 | |Availability of funding for dementia national plan |GDO_q2x1x2 | |Targets for monitoring implementation of dementia national plan |GDO_q2x1x3 | |Dementia integrated into other national plan |GDO_q2x2 | |Identification of other plans in which dementia is integrated (Other) |GDO_q2x2x1_other | |Existence of dementia sub-national plan(s) |GDO_q2x3 | |Percentage of sub-national regions covered by dementia plan |GDO_q2x3x1_1 | |Inclusion of human rights as a guiding principle of the dementia plan |GDO_q2x4_1 | |Inclusion of equity as a guiding principle of the dementia plan |GDO_q2x4_2 | |Inclusion of empowerment as a guiding principle of the dementia plan |GDO_q2x4_3 | |Inclusion of multisectoral collaboration as a guiding principles of the dementia plan |GDO_q2x4_4 | |Inclusion of universal health coverage as a guiding principle of the dementia plan |GDO_q2x4_5 | |Inclusion of dementia-friendly communities as a specific action of the dementia plan |GDO_q2x5_1 | |Inclusion of dementia risk reduction as a specific action of the dementia plan |GDO_q2x5_2 | |Inclusion of dementia diagnosis, care and support as a specific action of the dementia plan |GDO_q2x5_3 | |Inclusion of dementia workforce training as a specific action of the dementia plan |GDO_q2x5_4 | |Inclusion of support for dementia carers and families as a specific action of the dementia plan |GDO_q2x5_5 | |Inclusion of improved information system as a specific action of the dementia plan |GDO_q2x5_6 | |Inclusion of research and innovation as a specific action of the dementia plan |GDO_q2x5_7 | |Estimated population-based prevalence of depression |GDO_q35 | |Existence of dementia legislation |GDO_q3x1 | |Implementation level [national/subnational] of dementia legislation |GDO_q3x1x1_1 | |Existence of other laws that apply to the rights of people with dementia |GDO_q3x2 | |Existence of legislation for supported decision making for people with dementia |GDO_q3x3a_1 | |Existence of legislation to file appeals protecting the rights of people with dementia |GDO_q3x3a_2 | |Existence of legislation to promote community-based services for people with dementia |GDO_q3x3a_3 | |Existence of legislation to promote monitoring of human rights conditions of people with dementia in facilities where they reside |GDO_q3x3a_4 | |Existence of legislation to end coercieve practices for people with dementia |GDO_q3x3b_1 | |Existence of legislation for advanced care directives for people with dementia |GDO_q3x4_1 | |Existence of legislation to end discrimination against people with dementia |GDO_q3x4_2 | |Existence of legislation to end discrimination against carers of people with dementia |GDO_q3x4_3 | |Existence of dementia standards/ guidelines/ protocols |GDO_q4x1 | |Implementation level of dementia standards/ guidelines/ protocols (National) |GDO_q4x1x1_SQ001 | |Implementation level of dementia standards/ guidelines/ protocols (Sub-national) |GDO_q4x1x1_SQ002 | |Existence of approved government dementia standards/ guidelines/ protocols |GDO_q4x1x2 | |Existence of standards/ guidelines/ protocols for prevention and risk reduction of dementia |GDO_q4x2_1 | |Existence of standards/ guidelines/ protocols for diagnosis of dementia |GDO_q4x2_2 | |Existence of standards/ guidelines/ protocols for management of dementia |GDO_q4x2_3 | |Existence of standards/ guidelines/ protocols for other post-diagnostic supports of people with dementia |GDO_q4x2_4 | |Existence of standards/ guidelines/ protocols for treatment and support of carers and families of people with dementia |GDO_q4x2_5 | |Existence of standards/ guidelines/ protocols for advance care directives, power of attorney or guardianship for people with dementia |GDO_q4x3x4_1 | |Existence of standards/ guidelines/ protocols for palliative and end-of-life care for people with dementia |GDO_q4x3x4_2 | |Existence of standards/ guidelines/ protocols of care in nursing & residential care facilities for people with dementia |GDO_q4x3x4_3 | |Existence of standards/ guidelines/ protocols of care in hospital for people with dementia |GDO_q4x3x4_4 | |Availability of mechanisms to coordinate dementia care across sectors |GDO_q5x1 | |Identification of different sectors in dementia care coordination (Health) |GDO_q5x1x1_1 | |Identification of different sectors in dementia care coordination (Social) |GDO_q5x1x1_2 | |Identification of different sectors in dementia care coordination (Education) |GDO_q5x1x1_3 | |Identification of different sectors in dementia care coordination (Employment) |GDO_q5x1x1_4 | |Identification of different sectors in dementia care coordination (Justice) |GDO_q5x1x1_5 | |Identification of different sectors in dementia care coordination (Housing) |GDO_q5x1x1_6 | |Identification of different sectors in dementia care coordination (Civil society) |GDO_q5x1x1_7 | |Identification of different sectors in dementia care coordination (Private sector) |GDO_q5x1x1_8 | |Identification of different sectors in dementia care coordination (Other) |GDO_q5x1x1_other | |Implementation level [national/subnational] of dementia care coordination |GDO_q5x1x2 | |Presence of formal agreement/joint plan for dementia care coordination |GDO_q5x1x3 | |Availability of dementia care coordination standards/ guidelines/ protocols |GDO_q5x2 | |Number of neurologists (per 100,000) |GDO_q6x1_2 | |Number of geriatricians or psychogeriatricians (per 100,000) |GDO_q6x1_3 | |Inclusion of basic dementia competencies in training of physicians |GDO_q6x2_1 | |Inclusion of basic dementia competencies in training of specialists |GDO_q6x2_2 | |Inclusion of basic dementia competencies in training of nurses |GDO_q6x2_3 | |Inclusion of basic dementia competencies in training of pharmaceutical personnel |GDO_q6x2_4 | |Inclusion of basic dementia competencies in training of social workers |GDO_q6x2_5 | |Inclusion of basic dementia competencies in training of personal support workers |GDO_q6x2_6 | |Availability of dementia diagnostic rate |GDO_q7x1_AVAIL | |Existence of community-based health or social care services for dementia |GDO_q8x1 | |Availability of diagnostic services in community for dementia |GDO_q8x2_1 | |Availability of behaviour and psychological management in community for dementia |GDO_q8x2_2 | |Availability of psychosocial and rehabilitation services in community for dementia |GDO_q8x2_3 | |Availability of activities of daily living suppport services in community for dementia |GDO_q8x2_4 | |Availability of palliative and end-of-life care services in community for dementia |GDO_q8x2_5 | |Availability of social and financial protection for dementia |GDO_q8x2_6 | |Accessibility of diagnostic services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_1 | |Accessibility of behaviour and psychological management in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_2 | |Accessibility of psychosocial and rehabilitation services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_3 | |Accessibility of activities of daily living support services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_4 | |Accessibility of palliative and end-of-life care services in community for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_5 | |Accessibility of social and financial protection for dementia [Capital/capital and main cities/capital, main cities, rural areas] |GDO_q8x3_6 | |Majority provider of diagnostic services in community for dementia [public, private] |GDO_q8x4_1 | |Majority provider of behaviour and psychological management in community for dementia [public, private] |GDO_q8x4_2 | |Majority provider of psychosocial and rehabilitation services in community for dementia [public, private] |GDO_q8x4_3 | |Majority provider of activities of daily living support services in community for dementia [public, private] |GDO_q8x4_4 | |Majority provider of palliative and end-of-life care services in community for dementia [public, private] |GDO_q8x4_5 | |Majority provider of social and financial protection for dementia [public, private] |GDO_q8x4_6 | |Estimated number of people receiving behaviour and psychological management services in community for dementia |GDO_q8x5_2 | |Estimated number of people receiving psychosocial and rehabilitation services in community for dementia |GDO_q8x5_3 | |Estimated number of people receiving activities of daily living support services in community for dementia |GDO_q8x5_4 | |Estimated number of people receiving palliative and end-of-life care services in community for dementia |GDO_q8x5_5 | |Estimated number of people with dementia receiving social and financial protection for dementia |GDO_q8x5_6 | |Dementia care facilities [hospitals] |GDO_q9_1 | |Care facilities [long-term care] |GDO_q9_2 | |Care facilities [hospice centres] |GDO_q9_3 | |Adult day centres |GDO_q9_4 | |Outpatient health centres |GDO_q9_5 | |Outpatient social centres |GDO_q9_6 | |EXISTING GHO INDICATOR Density of hospitals (per 100 000 population) |GDO_q9x1_1 | |EXISTING GHO INDICATOR Hospital beds (per 10 000 population) (Health systems) |GDO_q9x1_2 | |Dementia-specific hospital beds (per 10,000 population) |GDO_q9x1_3 | |Geriatric-specific hospital beds (per 10,000 population) |GDO_q9x1_4 | |Total dementia hospital admissions (per 100,000) |GDO_q9x1_5 | |Estimated percentage of hospitals following national dementia standards |GDO_q9x1_7 | |Density of residential long-term care facilities (per 100,000 population) |GDO_q9x2_1 | |Residential long-term care beds (per 10 000 population) |GDO_q9x2_2 | |Dementia-specific residential long-term care beds (per 10,000 population) |GDO_q9x2_3 | |Estimated number of people with dementia living in residential long-term care |GDO_q9x2_4 | |Estimated percentage of residential long-term care facilities following national dementia standards |GDO_q9x2_5 | |Density of hospice centres (per 100,000 population) |GDO_q9x3_1 | |Hospice centre beds (per 10 000 population) |GDO_q9x3_2 | |Dementia-specific hospice care beds (per 10,000 population) |GDO_q9x3_3 | |Density of adult day centres (per 100,000 population) |GDO_q9x4_1 | |Adult day centre places (per 10,000 population) |GDO_q9x4_2 | |Dementia-specific adult day centre places (per 10,000 population) |GDO_q9x4_3 | |Density of outpatient health centres (per 100,000 population) |GDO_q9x5_1 | |Estimated number of people with dementia receiving services at outpatient health centre |GDO_q9x5_2 | |Density of outpatient social centres (per 100,000 population) |GDO_q9x6_1 | |Estimated number of people with dementia receiving services at outpatient social centre |GDO_q9x6_2 | |Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%) |GHED_CHEGDP_SHA2011 | |Current health expenditure (CHE) per capita in PPP int\) GHED_CHE_pc_PPP_SHA2011
Current health expenditure (CHE) per capita in US$ GHED_CHE_pc_US_SHA2011
External health expenditure channelled through government (EXT-G) as percentage of external health expenditure (EXT) (%) GHED_EXT-GEXT_SHA2011
External health expenditure (EXT) as percentage of current health expenditure (CHE) (%) GHED_EXTCHE_SHA2011
External health expenditure (EXT) per capita in PPP int$ GHED_EXT_pc_PPP_SHA2011
External health expenditure (EXT) per capita in US$ GHED_EXT_pc_US_SHA2011
Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%) GHED_GGHE-DCHE_SHA2011
Domestic general government health expenditure (GGHE-D) as percentage of gross domestic product (GDP) (%) GHED_GGHE-DGDP_SHA2011
Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%) GHED_GGHE-DGGE_SHA2011
Domestic general government health expenditure (GGHE-D) per capita in PPP int$ GHED_GGHE-D_pc_PPP_SHA2011
Domestic general government health expenditure (GGHE-D) per capita in US$ GHED_GGHE-D_pc_US_SHA2011
Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%) GHED_OOPSCHE_SHA2011
Out-of-pocket expenditure (OOP) per capita in PPP int$ GHED_OOP_pc_PPP_SHA2011
Out-of-pocket expenditure (OOP) per capita in US$ GHED_OOP_pc_US_SHA2011
Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%) GHED_PVT-DCHE_SHA2011
Domestic private health expenditure (PVT-D) per capita in PPP int$ GHED_PVT-D_pc_PPP_SHA2011
Domestic private health expenditure (PVT-D) per capita in US$ GHED_PVT-D_pc_US_SHA2011
Disability-adjusted life years (DALYs) GHE_DALYNUM
Disability-adjusted life years (DALYs) (per 100 000 population) GHE_DALYRATE
Years of healthy life lost due to disability (YLDs) GHE_YLDNUM
Years of healthy life lost due to disability (YLDs) (per 100 000 population) GHE_YLDRATE
Years of life lost from mortality (YLLs) GHE_YLLNUM
Years of life lost from mortality (YLLs) (per 100 000 population) GHE_YLLRATE
National universal health coverage strategy GOE_Q001
strategy refers to the use of ICT to support UHC GOE_Q002
National eHealth strategy GOE_Q003
National eHealth strategy refers to objectives of UHC GOE_Q004
National health information system (HIS) policy or strategy GOE_Q006
Public funding for eHealth GOE_Q007
Private funding for eHealth GOE_Q008
Donor/ non-public development funding for eHealth GOE_Q009
Public-private partnerships for eHealth GOE_Q010
Strategy implementation funding available for eHealth GOE_Q011
Proportion of public funding GOE_Q012
Proportion of private funding GOE_Q013
Proportion of donor/non public development funding GOE_Q014
Proportion ofpublic private partnerships funding GOE_Q015
Government-supported health internet sites provide information in multiple languages GOE_Q017
Tertiary institutions provide students of health sciences with training on eHealth GOE_Q018
Institutions offer in-service training to health professionals on ICT for health GOE_Q022
mHealth programmes are sponsored by government GOE_Q028
Regulating mobile devices and software GOE_Q030_1
Promoting standards and interoperability GOE_Q030_2
Providing guidance on privacy and security GOE_Q030_3
Providing oversight and enforcement of data ownership GOE_Q030_4
Promoting the development and adoption of mHealth GOE_Q030_5
Regulatory oversight of mobile apps for quality, safety and reliability GOE_Q031
Providing incentives and guidance for innovation research and evaluation of health GOE_Q032
Government-sponsored mHealth programmes are being evaluated GOE_Q047
Capacity GOE_Q057
Infrastructure GOE_Q058
Funding GOE_Q059
Effectiveness GOE_Q060
Cost-effectiveness GOE_Q061
Demand GOE_Q062
Legal GOE_Q063
Policy GOE_Q064
Priorities GOE_Q065
Country has telehealth policy or strategy GOE_Q069
Strategy includes objectives as to how telehealth contributes to UHC GOE_Q070
Evaluation of any government-sponsored telehealth programmes GOE_Q081
eLearning is used in pre-service education to teach health sciences students GOE_Q103
Reducing cost of delivering content GOE_Q104_1
Improving access to content and experts GOE_Q104_2
Enabling access to education where learning facilities are limited GOE_Q104_3
Pre-service eLearning programmes have been evaluated GOE_Q109
eLearning used for in-service training of health professionals GOE_Q118
Reducing cost of delivering content GOE_Q119_1
Improving access to content and experts GOE_Q119_2
Enabling access to education where learning facilities are limited GOE_Q119_3
eLearning courses accredited by continuing medical education or professional licensing bodies GOE_Q120
eLearning programmes for in-service training of health professionals have been evaluated GOE_Q122
Lack of capacity GOE_Q131
Lack of infrastructure GOE_Q132
Lack of funding GOE_Q133
Not possible to gain a health sciences degree entirely through eLearning GOE_Q134
Lack of evidence that eLearning is effective GOE_Q135
Lack of evidence over cost-effectiveness GOE_Q136
Lack of demand for eLearning programmes GOE_Q137
Lack of suitable courses available GOE_Q138
Insitutional educational policy does not include eLearning as an approach to teaching health sciences GOE_Q139
Competing educational priorities GOE_Q140
Country has national EHR GOE_Q144
Country has specific legislation governing the use of national EHR system GOE_Q146
Lack of capacity GOE_Q153
Lack of infrastructure GOE_Q154
Lack of funding GOE_Q155
lack of evidence showing effectiveness of EHR GOE_Q156
Lack of evidence showing cost-effectiveness or EHR GOE_Q157
Lack of demand by health professionals and patients GOE_Q158
Lack of legislation or regulations covering use of EHR GOE_Q159
National strategy does not promote the adoption of EHR GOE_Q160
Lack of national or international standards for interoperability of EHR GOE_Q161
Competing health system priorities GOE_Q162
to define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth GOE_Q168
to address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria GOE_Q169
to protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format GOE_Q170
to protect the privacy of individuals’ health-related data held in electronic format as an EHR GOE_Q171
which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR GOE_Q172
which governs the sharing of digital data between health professionals in health services in other countries through the use of an EHR GOE_Q173
which allows for the sharing of personal and health data between research entities GOE_Q174
which allows individuals electronic access to their own health-related data when held in an EHR GOE_Q175
which allows individuals to demand that their own data be corrected when held in an EHR if it is known to be inaccurate GOE_Q176
which allows individuals to demand the deletion of health-related data from their EHR GOE_Q177
Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice GOE_Q178
Country has national policy or strategy on the use of social media by government organizations GOE_Q181
Policy or strategy makes specific reference tothe use of social media in the health domain GOE_Q182
Country has national policy or strategy regulating the use of big data in the health sector GOE_Q196
Country has national policy or strategy regulating the use of big data by private companies GOE_Q197
Effective standards and best practices for data capture not fully established GOE_Q198
Insufficient incentives for data sharing GOE_Q199
Capacity building required for new skills GOE_Q200
Privacy and security laws need to be in place GOE_Q201
Research into new analytical methods needs occur to meet the challenges of working with big data GOE_Q202
Lack of integration between various health services GOE_Q203
Estimated number of people (all ages) living with HIV HIV_0000000001
Number of adults aged 15 and over living with HIV HIV_0000000002
Number of women aged 15 and over living with HIV HIV_0000000003
Number of children under 15 living with HIV HIV_0000000004
HIV prevalence rate among adults (15-49) HIV_0000000005
Number of deaths due to HIV/AIDS HIV_0000000006
Testing and counselling facilities, reported number HIV_0000000007
Testing and counselling facilities, estimated number per 100 000 adult population HIV_0000000008
Reported number of people receiving antiretroviral therapy HIV_0000000009
Reported number of people receiving antiretroviral therapy, month and year of report HIV_0000000010
Reported number of children receiving antiretroviral therapy HIV_0000000011
Reported number of children receiving antiretroviral therapy, month and year of report HIV_0000000012
Pregnant women tested for HIV, reported number HIV_0000000013
Pregnant women tested for HIV, estimated coverage (%) HIV_0000000014
Number of pregnant women living with HIV who received antiretrovirals (excluding single dose Nevirapine) for preventing mother-to-child transmission HIV_0000000015
Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, reporting period HIV_0000000016
Number of people aged 15 years and over who received HIV testing and counselling, reported number HIV_0000000017
People aged 15 years and over who received HIV testing and counselling, estimated number per 1000 adult population HIV_0000000018
Number of people aged 15 years and over who received HIV testing and counselling, reporting period HIV_0000000019
Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission HIV_0000000020
Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods HIV_0000000021
Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines HIV_0000000022
Estimated number of children needing antiretroviral therapy based on WHO methods HIV_0000000023
Estimated antiretroviral therapy coverage among children HIV_0000000024
Testing and counselling facilities, reporting period HIV_0000000025
Number of new HIV infections HIV_0000000026
Reported number of tests performed where results were received by a person (testing volume) HIV_0000000027
Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population HIV_0000000028
Reported number of tests performed where results were received by a person (testing volume), reporting period HIV_0000000029
Estimated antiretroviral therapy coverage among people living with HIV (%) HIV_ARTCOVERAGE
Number of nursing personnel HRH_01
Number of physicians HRH_02
Number of midwifery personnel HRH_03
Number of pharmacists HRH_04
Number of pharmaceutical technicians/assistants HRH_05
Number of community health workers HRH_06
Number of traditional birth attendants HRH_07
Number of radiographers HRH_08
Number of other health workers HRH_09
Number of dental technicians/assistants HRH_10
Number of health management & support workers HRH_11
Number of environment and public health workers HRH_12
Number of laboratory scientists HRH_13
Number of laboratory technicians/assistants HRH_14
Number of dentists HRH_15
Number of traditional medicine practitioners HRH_16
Number of medical assistants HRH_17
Number of personal care workers HRH_18
Number of pharmaceutical personnel HRH_19
Number of laboratory health workers HRH_20
Number of dentistry personnel HRH_21
Number of community and traditional health workers HRH_22
Number of other health workers HRH_23
Number of nursing and midwifery personnel HRH_24
Pharmaceutical personnel density (per 1000 population) HRH_25
Physicians density (per 1000 population) HRH_26
Laboratory health workers density (per 1000 population) HRH_27
Dentistry personnel density (per 1000 population) HRH_28
Community and traditional health workers density (per 1000 population) HRH_29
Other health workers density (per 1000 population) HRH_30
Environmental and public health workers density (per 1000 population) HRH_31
Health management & support workers density (per 1000 population) HRH_32
Nursing and midwifery personnel density (per 1000 population) HRH_33
Biomedical engineers density (per 10 000 population) HRH_40
Number of licensed qualified surgeons actively working HRH_41
Number of licensed qualified obstetricians actively working HRH_42
Number of licensed qualified anaesthesiologists actively working HRH_43
Number of biomedical engineers HRH_44
Biomedical technicians density (per 10 000 population) HRH_45
Number of biomedical technicians HRH_46
Countries that have a comprehensive national health sector policy/ strategy/ plan with goals and targets updated within the last 5 years HSS_COMPREHENSIVEHEALTHPOLICY
Countries that have monitored the progress of their national health policy/strategy/plan regularly HSS_MONITORPROGRESS
Countries that have passed legislation on Universal Health Coverage (UHC) HSS_UHCLEGISLATION
Medical doctors (per 10 000 population) HWF_0001
Medical doctors (number) HWF_0002
Generalist medical practitioners (number) HWF_0003
Specialist medical practitioners (number) HWF_0004
Medical doctors not further defined (number) HWF_0005
Nursing and midwifery personnel (per 10 000 population) HWF_0006
Nursing and midwifery personnel (number) HWF_0007
Nursing personnel (number) HWF_0008
Midwifery personnel (number) HWF_0009
Dentists (per 10 000 population) HWF_0010
Dentists (number) HWF_0011
Dental Assistants and Therapists (number) HWF_0012
Dental Prosthetic Technicians (number) HWF_0013
Pharmacists (per 10 000 population) HWF_0014
Pharmacists (number) HWF_0015
Pharmaceutical Technicians and Assistants (number) HWF_0016
Environmental and Occupational Health and Hygiene Professionals (number) HWF_0017
Environmental and Occupational Health Inspectors and Associates (number) HWF_0018
Medical and Pathology Laboratory scientists (number) HWF_0019
Medical and Pathology Laboratory Technicians (number) HWF_0020
Physiotherapists (number) HWF_0021
Physiotherapy Technicians and Assistants (number) HWF_0022
Traditional and Complementary Medicine Professionals (number) HWF_0023
Community Health Workers (number) HWF_0024
Medical doctors (%) HWF_0025
Nursing personnel (%) HWF_0026
Handwashing with soap after using the toilet (%) HWWS_1
Handwashing with soap after cleaning child’s stool (%) HWWS_2
ICD-11 implementation progress level ICD11_IMPL_LVL
Legislation IHR01
Coordination IHR02
Surveillance IHR03
Response IHR04
Preparedness IHR05
Risk communication IHR06
Human resources IHR07
Laboratory IHR08
Points of entry IHR09
Zoonosis IHR10
Food safety IHR11
Chemical IHR12
Radionuclear IHR13
Legislation and Financing IHRSPAR_CAPACITY01
IHR Coordination and National IHR Focal Point Functions IHRSPAR_CAPACITY02
Zoonotic Events and the Human-animal Interface IHRSPAR_CAPACITY03
Food Safety IHRSPAR_CAPACITY04
Laboratory IHRSPAR_CAPACITY05
Surveillance IHRSPAR_CAPACITY06
Human Resources IHRSPAR_CAPACITY07
National Health Emergency Framework IHRSPAR_CAPACITY08
Health Service Provision IHRSPAR_CAPACITY09
Risk Communication IHRSPAR_CAPACITY10
Points of Entry IHRSPAR_CAPACITY11
Chemical Events IHRSPAR_CAPACITY12
Radiation Emergencies IHRSPAR_CAPACITY13
Proportion of vaccination cards seen (%) IMMUNIZATION_VACCINATIONCARDSSEEN
Percentage of sites for which carbamate resistance was reported IR_CARBAMATE_EXTENT
Carbamate resistance reported for at least one site IR_CARBAMATE_PRESENCE
Number of insecticide classes to which resistance was reported IR_INSECTICIDERESISTANCE_PREV
Percentage of sites for which organochlorine resistance was reported IR_ORGANOCHLORINE_EXTENT
Organochlorine resistance reported for at least one site IR_ORGANOCHLORINE_PRESENCE
Percentage of sites for which organophosphate resistance was reported IR_ORGANOPHOSPHATE_EXTENT
Organophosphate resistance reported for at least one site IR_ORGANOPHOSPHATE_PRESENCE
Percentage of sites for which pyrethroid resistance was reported IR_PYRETHROID_EXTENT
Pyrethroid resistance reported for at least one site IR_PYRETHROID_PRESENCE
Percentage of individuals using the Internet ITU_ICT_1
Mobile-cellular telephone subscriptions per 100 inhabitants ITU_ICT_2
ICT Development Index (IDI) ITU_IDI
ICT Development Index (IDI) rank ITU_IDI_RANK
Low birth weight (in thousands) LBW_NUMBER
Low birth weight, prevalence (%) LBW_PREVALENCE
Legally-binding controls on lead paint LEADCONTROL
Name of legislation for lead controls on lead paint LEADCONTROLEGISLATION
Description of legislation for lead controls on lead paint LEADCONTROLEGISLATIONDESC
Percentage of the children under 15 years with blood lead levels above 5ug/dl LEAD_1
Lead attributable DALYs per 100’000 children under 5 years LEAD_10
Percentage of the children under 15 years with blood lead levels above 10ug/dl LEAD_2
Percentage of the adults (15+ years) with blood lead levels above 5ug/dl LEAD_3
Percentage of the adults (15+ years) with blood lead levels above 10ug/dl LEAD_4
Lead attributable deaths LEAD_5
Lead attributable DALYs (’000) LEAD_6
Lead attributable deaths per 100’000 capita LEAD_7
Lead attributable DALYs per 100’000 capita LEAD_8
Lead attributable DALYs (’000) in children under 5 years LEAD_9
Disability-adjusted life years (DALYs) due to leptospirosis LEPTO_DALY
Disability-adjusted life years (DALYs) (per 100 000 population) due to leptospirosis LEPTO_DALY100K
Estimated leptospirosis incidence (per 100 000 population) LEPTO_MORBIDITY
Estimated leptospirosis deaths (per 100 000 population) LEPTO_MORTALITY
Years of healthy life lost to disability (YLDs) due to leptospirosis LEPTO_YLD
Years of healthy life lost to disability (YLDs) (per 100 000 population) due to leptospirosis LEPTO_YLD100K
Years of life lost (YLLs) due to leptospirosis LEPTO_YLL
Years of life lost (YLLs) (per 100 000 population) due to leptospirosis LEPTO_YLL100K
nMx - age-specific death rate between ages x and x+n LIFE_0000000029
nqx - probability of dying between ages x and x+n LIFE_0000000030
lx - number of people left alive at age x LIFE_0000000031
ndx - number of people dying between ages x and x+n LIFE_0000000032
nLx - person-years lived between ages x and x+n LIFE_0000000033
Tx - person-years lived above age x LIFE_0000000034
ex - expectation of life at age x LIFE_0000000035
Malaria - number of reported deaths MALARIA001
Estimated number of malaria cases MALARIA002
Estimated number of malaria deaths MALARIA003
Number of under-five deaths from malaria MALARIA004
Malaria incidence per 100 000 population MALARIA005
All-cause outpatient cases MALARIA_15029
All-cause inpatient cases MALARIA_15030
All-cause inpatient deaths MALARIA_15031
Total RDT examined MALARIA_15032
Total RDT positive MALARIA_15033
Total microscopy examined MALARIA_15034
Total microscopy positive MALARIA_15035
Number of P. falciparum MALARIA_15036
Number of P. vivax MALARIA_15037
Number of mixed infections MALARIA_15040
Suspected malaria cases MALARIA_15043
Malaria outpatient cases MALARIA_15049
Malaria inpatient cases MALARIA_15056
Malaria attributed deaths MALARIA_15059
RDT Positive cases at community level MALARIA_15063
Number of reported presumed and confirmed malaria cases MALARIA_15065
ANC first attendance MALARIA_15077
IPT 1st dose MALARIA_15079
IPT 2nd dose MALARIA_15080
IPT 3rd dose MALARIA_15081
Microscopy slides/RDTs examined MALARIA_15095
Microscopy slides/RDTs positive MALARIA_15096
Total number of conventional Insecticide Treated Nets (ITNs) + LLINS sold or delivered MALARIA_15116
Total number of Long Lasting Insecticide Treated Nets (LLINs) sold or delivered MALARIA_15117
Spraying cycle MALARIA_15130
Number of households sprayed at least once MALARIA_15136
Number of households targeted for spraying MALARIA_15137
Number people targeted for protection by IRS MALARIA_15138
Number of people protected by IRS MALARIA_15139
Number of ACT only treatment doses received (public facilities and community) MALARIA_15150
Population MALARIA_15279
Government health budget (USD) MALARIA_15283
Government budget for malaria (USD) MALARIA_15284
Contributions from the Global Fund (USD) MALARIA_15287
Contributions from the Wolrdbank (USD) MALARIA_15288
European Union (USD) MALARIA_15309
Gov. expenditure on malaria (USD) MALARIA_15310
Number of health facility reports received per year (Outpatient) MALARIA_16201
Number of health facilities (Outpatient) MALARIA_16202
Number of reports expected per health facility per year (Outpatient) MALARIA_16203
Number of Admin 2 reports received per year (Outpatient) MALARIA_16205
Number of Admin 2 units (Outpatient) MALARIA_16206
Number of reports expected per Admin 2 per year (Outpatient) MALARIA_16207
RDT tested at community level MALARIA_16209
Cases at community level (presumed and confirmed) MALARIA_16210
Examined (by microscopy and RDT)(Active case detection) MALARIA_16211
Positive (by microscopy and RDT)(Active case detection) MALARIA_16212
Number of houses or structures targeted MALARIA_16221
Number of houses or structures sprayed at least once MALARIA_16222
Number distributed through mass campaign MALARIA_16223
Number distributed through ANC MALARIA_16224
Number distributed through EPI MALARIA_16225
Number distributed through other channels MALARIA_16226
Number of malaria cases treated with ACT in public facilities MALARIA_16227
Number of RDTs delivered (public facilities and community) MALARIA_16228
Number of P. falciparum (RDT test) MALARIA_16229
Number of other plamodium species (RDT test) MALARIA_16230
All-cause deaths (including malaria death) (Vital registration) MALARIA_16231
Malaria deaths (including confirmed deaths) (Vital registration) MALARIA_16232
Other (NGOs, foundations,etc) MALARIA_16233
Programme Management (PM) MALARIA_16234
Entomology and vector control (ITN, IRS, others) MALARIA_16235
Surveillance, Monitoring and Evaluation (SME) MALARIA_16236
Diagnosis and case manangement (incl. IPT) MALARIA_16237
Communications and Advocacy (CAD) MALARIA_16238
Training MALARIA_16239
Others MALARIA_16240
High endemic or risk areas ( RMI > 1) MALARIA_16252
Low endemic or epidemic-prone areas ( RMI < 1) MALARIA_16253
Malaria-free areas (no indigenous transmission) MALARIA_16254
Number of ACT only treatment doses received (public facilities only) MALARIA_16261
Total number of ACT treatment courses distributed MALARIA_16262
Number of malaria cases treated with ACT (Community level) MALARIA_16263
WHO MALARIA_16264
UNICEF MALARIA_16265
Other UN agencies MALARIA_16266
PMI MALARIA_16267
Other bilaterals MALARIA_16268
Number of health facility reports received per year (Inpatient) MALARIA_16270
Number of health facilities (Inpatient) MALARIA_16271
Number of reports expected per health facility per year (Inpatient) MALARIA_16272
Number of Admin 2 reports received per year (Inpatient) MALARIA_16273
Number of Admin 2 units (Inpatient) MALARIA_16274
Number of reports expected per Admin 2 per year (Inpatient) MALARIA_16275
Number of conventional insecticide-treated nets (ITNs) sold or delivered MALARIA_20126
Insecticide used MALARIA_20129
Total number of 1st line treatment course distributed MALARIA_20132
Household Net Possession - Percentage with at least one (Any type of mosquito net ) MALARIA_30514
Household Net Possession - Percentage with more than one (Any type of mosquito net ) MALARIA_30515
Household Net Possession - Average number of nets per household (Any type of mosquito net ) MALARIA_30516
Household Net Possession - Percentage with at least one (Ever treated mosquito net ) MALARIA_30517
Household Net Possession - Percentage with more than one (Ever treated mosquito net ) MALARIA_30518
Household Net Possession - Average number of ever treated nets per household (Ever treated mosquito net ) MALARIA_30519
Household Net Possession - Percentage with at least one (Insecticide treated mosquito nets (ITNs) ) MALARIA_30520
Household Net Possession - Percentage with more than one (Insecticide treated mosquito nets (ITNs) ) MALARIA_30521
Household Net Possession - Average number of ITNs per household (Insecticide treated mosquito nets (ITNs) ) MALARIA_30522
Household Net Possession - (Number of households ) MALARIA_30523
IPT and Anti-malarial Treatment - Percentage who took 2+ doses SP/Fansidar MALARIA_30526
Prompt Treatment - Percentage who took antimalarial drugs (Among children under age five with fever) MALARIA_30532
Prompt Treatment - Percentage who took antimalarial drugs same or next day (Among children under age five with fever) MALARIA_30533
Children with fever - Percentage of children who took drug: SP/ Fansidar MALARIA_30535
Children with fever - Percentage of children who took drug: Chloroquine MALARIA_30536
Children with fever - Percentage of children who took drug: Combination with artemisinin MALARIA_30539
Children with fever - Percentage of children who took drug the same or next day: SP/ Fansidar MALARIA_30541
Children with fever - Percentage of children who took drug the same or next day: Chloroquine MALARIA_30542
Children with fever - Percentage of children who took drug the same or next day: Combination with artemisinin MALARIA_30545
Use of mosquito nets - Percentage of under 5 who slept under any net last night MALARIA_30548
Use of mosquito nets - Percentage of under 5 who slept under an ever treated net last night MALARIA_30549
Use of mosquito nets - Percentage of under 5 who slept under an ITN last night MALARIA_30550
Use of mosquito nets - Number of children under 5 MALARIA_30555
Use of mosquito nets - Percentage of all women age 15-49 who Slept under any net last night MALARIA_30556
Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ever treated net last night MALARIA_30557
Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ITN last night MALARIA_30558
Use of mosquito nets - Number of pregnant women MALARIA_30559
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under any net last night MALARIA_30560
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ever treated net last night MALARIA_30561
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ITN last night MALARIA_30562
Imported cases MALARIA_40105
Households with at least one insecticide-treated mosquito net (ITN) and/or indoor residual spraying (IRS) in the past 12 months (%) MALARIA_HOUSEHOLDITNIRS
Percentage of pregnant women attending ANC at least once and receiving IPTp3 (%) MALARIA_IPTP3
Population in malaria-endemic areas who slept under an insecticide-treated bed net (ITN) the previous night (%) MALARIA_ITNPOP
Pregnant women sleeping under insecticide-treated nets the previous night (%) MALARIA_ITNPREG
Population protected by ITN or IRS (%) MALARIA_POP_ITN_IRS
Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%) MCV2
Infant mortality rate (probability of dying between birth and age 1 per 1000 live births) MDG_0000000001
Adolescent birth rate (per 1000 women aged 15-19 years) MDG_0000000003
Contraceptive prevalence (%) MDG_0000000005
Contraceptive prevalence, among girls aged 15-19 (%) MDG_0000000005_AGE1519
Unmet need for family planning (%) MDG_0000000006
Unmet need for family planning, among girls aged 15-19 (%) MDG_0000000006_AGE1519
Under-five mortality rate (probability of dying by age 5 per 1000 live births) MDG_0000000007
Median availability of selected generic medicines (%) - Public MDG_0000000010
Median consumer price ratio of selected generic medicines - Public MDG_0000000011
Antiretroviral therapy coverage among people with advanced HIV infection (%) MDG_0000000012
Children aged <5 years sleeping under insecticide-treated nets (%) MDG_0000000013
Children aged <5 years with fever who received treatment with any antimalarial (%) MDG_0000000014
Prevalence of condom use by adults during higher-risk sex (15-49) (%) MDG_0000000015
Deaths due to malaria (per 100 000 population) MDG_0000000016
Deaths due to tuberculosis among HIV-negative people (per 100 000 population) MDG_0000000017
Deaths due to tuberculosis among HIV-positive people (per 100 000 population) MDG_0000000018
Prevalence of HIV among adults aged >=15 years (per 100 000 population) MDG_0000000019
Incidence of tuberculosis (per 100 000 population per year) MDG_0000000020
Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%) MDG_0000000021
Tuberculosis detection rate under DOTS (%) MDG_0000000022
Prevalence of tuberculosis (per 100 000 population) MDG_0000000023
Tuberculosis treatment success under DOTS (%) MDG_0000000024
Births attended by skilled health personnel (%) MDG_0000000025
Births attended by skilled health personnel, among girls aged 15-19 (%) MDG_0000000025_AGE1519
Maternal mortality ratio (per 100 000 live births) MDG_0000000026
Children aged <5 years stunted (%) MDG_0000000027
Population below minimum level of dietary energy consumption MDG_0000000028
Prevalence of HIV among adults aged 15 to 49 (%) MDG_0000000029
Smear-positive tuberculosis case-detection rate (%) MDG_0000000030
Smear-positive tuberculosis treatment-success rate (%) MDG_0000000031
Maternal mortality ratio (per 100 000 live births) - Country reported estimates MDG_0000000032
Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%) MDG_0000000033
Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines MDG_0000000034
OOP as a % of THE MEDS
Generic MEDS0_0_0
Population MEDS1_01_01
GDP MEDS1_01_03
Gross domestic product per capita MEDS1_01_05
Life Expectancy M MEDS1_02_01
Life Expectancy F MEDS1_02_02
Infant mortality MEDS1_02_03
Under 5 Mortality MEDS1_02_04
NCD mortality rate MEDS1_02_11
CVD and Diabetes mortality rate MEDS1_02_12
Cancer mortality rate MEDS1_02_13
HIV mortality rate MEDS1_02_14
TB mortality rate MEDS1_02_15
Malaria mortality rate MEDS1_02_16
Total Pharmaceutical Expenditure (millions US\() |MEDS201110200 | |Total Pharmaceutical Expenditure per capita (US\))rate) MEDS201120200C
Share of Total Pharmaceutical Expenditure in Total Health Expenditure (%) MEDS2011400C
Share of Public Pharmaceutical Expenditure in Total Pharmaceutical Expenditure (%) MEDS2011600C
Public Pharmaceutical Expenditure per capita (US\() |MEDS201170200C | |Market share of generic pharmaceuticals by value (%) |MEDS2012100S | |Density of pharmacists (per 10 000 population) |MEDS2020200C | |THE |MEDS2_01_01_02 | |THE per capita |MEDS2_01_03_02 | |Public Health Expenditure |MEDS2_01_04_02 | |Public Health Expenditure as a % of Government Expenditure |MEDS2_01_05 | |Public Health Expenditure of a % of THE |MEDS2_01_06 | |Public Health Expenditure per capita |MEDS2_01_07_02 | |Private Health Expenditure % of THE |MEDS2_01_08 | |Population covered by a public health service orr insurance plan |MEDS2_01_09 | |Population covered by private health insurance |MEDS2_01_10 | |Total pharmaceutical expenditure |MEDS2_01_11_02 | |Total pharmaceutical expenditure per capita |MEDS2_01_12_02 | |Share of total pharmaceutical expenditure in gross domestic product (%) |MEDS2_01_13 | |Share of total pharmaceutical expenditure in total health expenditure (%) |MEDS2_01_14 | |Share of public pharmaceutical expenditures in total pharmaceutical expenditures (US\)) MEDS2_01_15_02
Share of public pharmaceutical expenditures in total pharmaceutical expenditures (%) MEDS2_01_15_02_01
Private TPE MEDS2_01_18_02
Market share of generic pharmaceuticals by value (%) MEDS2_01_21
OOP as a % of Private Health Expenditure MEDS2_01_24
Premiums for private health plans as a % of private health expenditure MEDS2_01_26
Pharmacists MEDS2_02_01
Density of pharmacist (per 10.000) MEDS2_02_02
Presence of National Medicines Policy MEDS3010400
Presence of National Medicines Policy implementation plan MEDS3010700
Right of access to essential medicines MEDS3011000
For the pharmaceutical sector MEDS3011302
Presence of National Health Policy MEDS3_01_01
NHP Implementation plan exists MEDS3_01_02
Presence of national medicines policy MEDS3_01_04
Presence of national medicines policy implementation plan MEDS3_01_07
Presence of National Clinical Laboratory Policy MEDS3_01_08
NCLP implementation plan exists MEDS3_01_09
Right of access to essential medicines MEDS3_01_10
Official guidelines on medicine donations exist MEDS3_01_11
Pharmaceutical policy implementation is regularly monitored MEDS3_01_12_01
Presence of national good governance policy MEDS3_01_13
Policy to manage conflict of interest issues MEDS3_01_14
Formal code of conduct for public officials MEDS3_01_15
Whistle Blowing mechanism MEDS3_01_16
Market share of domestic manufacturers (%) MEDS4020300
Legal provision for granting patents on: Pharmaceuticals MEDS4_01_02_01
Legal provision for granting patents on: Laboratory Supplies MEDS4_01_02_02
Legal provision for granting patents on: Medical Supplies MEDS4_01_02_03
Legal provision for granting patents on: Medical Equipment MEDS4_01_02_04
TRIPS legislated through national legislation MEDS4_01_04
Trasitional period eligibility MEDS4_01_06
Compulsory Licensing MEDS4_01_07_01
Bolar exemption MEDS4_01_07_02
Parallel importing MEDS4_01_08
Legal provisions related to: Data exclusivity MEDS4_01_10
Legal provisions related to: Patent Extension MEDS4_01_11
Legal provisions for the linkage between patent status and market authorization MEDS4_01_12
Number of licensed pharmaceutical manufacturers MEDS4_02_01
Manufacturing capacity: R&D new API MEDS4_02_02_01
Manufacturing capacity: Production API MEDS4_02_02_02
Manufacturing capacity: Production formulations MEDS4_02_02_03
Manufacturing capacity: Repackaging of finished dose forms MEDS4_02_02_04
Market share of domestic manufacturers by value (%) MEDS4_02_03
Market share of domestic manufactures by volume (%) MEDS4_02_05
Existence of formal Medicines Regulatory Authority MEDS5010200
Website of the formal Medicines Regulatory Authority MEDS5010700
Market Authorization for all pharmaceutical products required MEDS5020100
Number of registered pharmaceutical products MEDS5020600
Registration Fee pharmaceutical containing New Chemical Entity MEDS5021700S
Registration Fee generic pharmaceutical product MEDS5021800S
Inspectors are allowed to inspect premises where pharmaceutical activities are performed MEDS5030200
Pharmaceutical manufacturers must comply with Good Manufacturing Practices MEDS5050200
Licensing private pharmacies obligatory MEDS5050900
National Quality Control Laboratory exists MEDS5060200
Legal provisions control promoting and advertising of prescription medicine MEDS5070100
Ban on Direct to Consumer Pharmaceutical Advertising MEDS5070300
Legal provisions exist requiring authorization for conducting Clinical Trials by the MRA MEDS5080100
Annual consumption of Morphine (mg/capita) MEDS5090300
National pharmacovigilance centre linked to the MRA exists MEDS5100400
Number of reports submitted in the last two year by the pharmacovigilance centre MEDS5100800
Legal provisions for establishing MRA MEDS5_01_01
Formal medicines regulatory authority exists MEDS5_01_02
MRA part of MoH MEDS5_01_04_01
MRA semi-autonomous MEDS5_01_04_02
Function of MRA: Market Authorization MEDS5_01_05_01
Function of MRA: Inspection MEDS5_01_05_02
Function of MRA: Import Control MEDS5_01_05_03
Function of MRA: Licensing MEDS5_01_05_04
Function of MRA: Market control MEDS5_01_05_05
Function of MRA: Quality control MEDS5_01_05_06
Function of MRA: Advertising MEDS5_01_05_07
Function of MRA: Clinical trials MEDS5_01_05_08
Function of MRA: Pharmacovigilance MEDS5_01_05_09
Medicines regulatory authority has it own website MEDS5_01_07
MRA receives external technical assistance MEDS5_01_08
MRA involved in harmonization / collaboration activities MEDS5_01_09
Assessment of medicines regulatory system conducted in last 5 years MEDS5_01_10
Funding of MRA: Government MEDS5_01_11
Funding of MRA: Fees for service MEDS5_01_12
Funding of MRA: Other funding MEDS5_01_13
Funding of MRA: Revenues derived from RA kept in RA MEDS5_01_14
RA uses computerized information management system MEDS5_01_15
Market authorization for all pharmaceutical products is required MEDS5_02_01
Mechnaisms for exceptions / waiver of registration MEDS5_02_02
Mutual recognition MEDS5_02_03
Public transparency of criteria for MA application assessment MEDS5_02_04
WHO prequalification programme information used for product registration MEDS5_02_05
Number of registered pharmaceuticals MEDS5_02_06
List of pharmaceuticals with defined periodicity required to be publicly available MEDS5_02_07
Medicines registration includes INN MEDS5_02_08
Fee required for Marketing Authorization applications MEDS5_02_09
Fee for pharmaceuticals containing new chemical entity MEDS5_02_17
Registration fee generic pharmaceutical product MEDS5_02_18
Legal provisions for the appointment of government pharmaceutical officials MEDS5_03_01
Inspectors are allowed to inspect premises where pharmaceutical activities are performed MEDS5_03_02
Inspection a pre-requisite for licensing of: Public MEDS5_03_03_01
Inspection a pre-requisite for licensing of: Private MEDS5_03_03_02
Inspection requirements the same for public and private facilities MEDS5_03_04
Local manufacturers - GMP compliance MEDS5_03_05_01
Private Wholesalers MEDS5_03_05_02
Retail distributors MEDS5_03_05_03
Public pharmacies and stores MEDS5_03_05_04
Pharmacies and dispensing points of health facilities MEDS5_03_05_05
Authorization to import medicines required MEDS5_04_01
Sampling of imported products for testing permitted MEDS5_04_02
Importation of medicines through authorized ports of entry MEDS5_04_03
Inspection of pharmaceutical products at authorized ports of entry permitted MEDS5_04_04
Licensing required for: Manufacturers MEDS5_05_01
Pharmaceutical manufacturers must comply good manufacturing practices MEDS5_05_02
Good Manufacturing Practices (GMP) published MEDS5_05_03
Licensing required for: Importers MEDS5_05_04
Licensing required for: Wholesalers MEDS5_05_05
Wholesalers and distributors to comply with Good Distribution Practices MEDS5_05_06
National Good Distribution Practice requirements published MEDS5_05_07
Pharmacists to be registered MEDS5_05_08
Licensing private pharmacies obligatory MEDS5_05_09
Licensing required for: public pharmacies MEDS5_05_10
National Good Pharmacy Practice Guidelines published MEDS5_05_11
List of all licensed pharmaceutical facilities (publication legally required) MEDS5_05_12
Legislation supports Pharmaceutical market regulation MEDS5_06_01
Quality control testing laboratory is available MEDS5_06_02
Quality control laboratory is part of medication regulatory authority MEDS5_06_02_01
Testing services contracted out by regulatory authority MEDS5_06_02_02
For quality monitoring in public sector (pharmacy stores and health facilities) MEDS5_06_04_01
For quality monitoring in private sector (retail outlets) MEDS5_06_04_02
When there are complaints / problems MEDS5_06_04_03
For product registration MEDS5_06_04_04
For public procurement prequalification MEDS5_06_04_05
For public program products prior to acceptance and/or distribution MEDS5_06_04_06
Number of quality control samples tested in past two years MEDS5_06_06
Number of samples that failed the testing in two years MEDS5_06_07
Legal provisions control promoting and advertising of prescription medicine MEDS5_07_01
Ban on direct to consumer pharmaceutical advertising MEDS5_07_03
Pre-approval for medicines advertisements and promotional materials required MEDS5_07_04
Guidelines for advertising and promotion of non-prescription medicines MEDS5_07_05
Code of conduct for advertising by MA holders exists and is publicly available MEDS5_07_06
Code of conduct applies to: Both MEDS5_07_06_01
Voluntary adherence to code MEDS5_07_06_02
Code contains formal process for complaints and sanctions MEDS5_07_06_03
Up to date list of complaints and sanctions publicly available MEDS5_07_06_04
Legal provisions exist requiring authorization for conducting clinical trials by the medical regulatory authority MEDS5_08_01
Clinical Trials require ethics committee/institutional review board approval MEDS5_08_02
Registration of clinical trials in international/national/regional registry MEDS5_08_03
Single convention on narcotic drugs, 1961 MEDS5_09_01_01
The 1972 protocol amending the single convention on narcotic drugs, 1961 MEDS5_09_01_02
Convention on psychotropic substances, 1971 MEDS5_09_01_03
United nations convention against the illicit traffic in narcotic drugs and psychotropic substances, 1988 MEDS5_09_01_04
Laws for the control of narcotic and psychotropic substances, and precursors exist MEDS5_09_02
Annual morphine consumption (mg/capita) MEDS5_09_03
PV activities legally established within MRA mandate MEDS5_10_01
MA holders required to continuously monitor safety of products and report to MRA MEDS5_10_02
Legal provisions for monitoring of ADR exist MEDS5_10_03
National pharmacovigilance center linked to the medicines regulatory authority MEDS5_10_04
Number of reports submitted in the last two years by the national pharmacovigilance center MEDS5_10_04_02
NPC publishes ADR bulletin MEDS5_10_04_03
No. of ADRs on database MEDS5_10_07
Number of reports of adverse drug reactions submitted in the last two years by the national pharmacovigilance center MEDS5_10_08
No. of ADRs submitted to Uppsala database MEDS5_10_09_01
Children <5 years receive free medicines MEDS6010102
Pregnant women receive free medicines MEDS6010103
All medicines included in the EML MEDS6010201
Social (health) fund is providing at least partial medicine coverage MEDS6010300
System in place to monitor prices of medicines MEDS6030100
Duties on imported active pharmaceutical ingredients MEDS6060100
Duties on imported finished pharmaceutical products MEDS6060200
Value Added Tax is levied on finished pharmaceuticals products MEDS6060300
Patients who cannot afford them received free medicines MEDS6_01_01_01
Children under 5 receive free medicines MEDS6_01_01_02
Pregnant women receive free medicines MEDS6_01_01_03
Elderly received free medicines MEDS6_01_01_04
All essential medicines are free MEDS6_01_02_01
Free medicines for any non communicable diseases MEDS6_01_02_02
Free medicines for Malaria MEDS6_01_02_03
Free medicines for TB MEDS6_01_02_04
Free medicines for STD MEDS6_01_02_05
Free medicines for HIV MEDS6_01_02_06
Free vaccines for EPI MEDS6_01_02_07
National or social health insurance providing at least partial medicines coverage MEDS6_01_03
Providing medicines that are on the Essential Medicines List for inpatients MEDS6_01_03_01
Providing medicines that are on the Essential Medicines List for outpatients MEDS6_01_03_02
Private health insurance schemes provide medicines coverage MEDS6_01_04
Private health insurance provides coverage for medicines which are on the EML MEDS6_01_04_01
Co-payments/ fee requirements for consultations MEDS6_02_01
Co-payments/ fee requirements for medicines MEDS6_02_02
Revenues from fees used to pay salaries of health workers MEDS6_02_03
Medicine pricing regulations MEDS6_03_01
Pricing provisions aimed at: Manufacturers MEDS6_03_01_01
Pricing provisions aimed at: Wholesalers MEDS6_03_01_02
Pricing provisions aimed at: Retailers MEDS6_03_01_03
Duties on active pharmaceutical ingredients MEDS6_06_01
Duties on finished pharmaceutical products MEDS6_06_02
Value added taxes on pharmaceutical products MEDS6_06_03
Duty rate on active pharmaceutical ingredients MEDS6_06_07
Duty rate on finished pharmaceutical products MEDS6_06_08
Value added taxes rate MEDS6_06_09
Public sector tender awards are publicly available MEDS7010400
Availability of key medicines at the Central Medical Store in percentage (%) MEDS7020900S
Public sector procurement is decentralized MEDS7_01_01_01
Public sector procurement is decentralized and centralized MEDS7_01_01_02
Public sector procurement is the reponsibility of procurement agency that is part of MOH MEDS7_01_02_01
Public sector procurement is the reponsibility of procurement agency that is semi autonomous MEDS7_01_02_02
Public sector procurement is the reponsibility of procurement agency that is autonomous MEDS7_01_02_03
A government procurement agency procures all public goods MEDS7_01_02_04
Public sector requests for tender documents are publicly available MEDS7_01_03
Public sector awards are publicly available MEDS7_01_04
Procurement is based on prequalification of suppliers MEDS7_01_05
The government supply system department has a central medical store MEDS7_02_01
There are national guidelines on Good Distribution Practices MEDS7_02_03
There is a licensing authority that issues GDP licenses MEDS7_02_04
The licensing authority accredits public distribution facilities MEDS7_02_04_01
A list of GDP certified warehouses in the public sector exists MEDS7_02_05
A list of GDP certified distributors in the public sector exists MEDS7_02_06
Availability of key medicines at the central medical store MEDS7_02_09
Legal provisions exist for licensing wholesales in private sector MEDS7_03_01
Legal provisions exist for licensing distributors in private sector MEDS7_03_02
A list of GDP certified wholsesalers in the private sector exists MEDS7_03_03
A list of GDP certified distributors in the private sector exists MEDS7_03_04
National Essential Medicine List exists MEDS8010100
Standard Treatment Guidelines for common illnesses are made by Ministry of Health MEDS8010200
National Standard Treatment Guidelines specific to paediatric conditions exist MEDS8010500
National Medicines Information Center provides information on medicines MEDS8010800
Existence of National strategy to contain antimicrobial resistance MEDS8011200
Public sector MEDS8021201
Private sector MEDS8021202
Substitution of generic equivalents at the point of dispensing in public sector facilities is allowed MEDS8030400
Substitution of generic equivalents at the point of dispensing in private sector facilities is allowed MEDS8030500
Essential medicines list exists MEDS8_01_01
Number of medicines on essential medicines list MEDS8_01_01_01
Written process for selecting medicines on the EML MEDS8_01_01_02
Written process is publicly available MEDS8_01_01_03
Mechanism to align EML and STG MEDS8_01_01_04
Standard treatment guidelines for common illnesses produced by the ministry of health MEDS8_01_02
STG specific to primary care exists MEDS8_01_03
STG specific to secondary care exists MEDS8_01_04
National standard treatment guidelines for children MEDS8_01_05
% of public health facilities with copy EML (mean) MEDS8_01_06
% of public health facilities with copy STG (mean) MEDS8_01_07
National medicines information center exists MEDS8_01_08
Public education campaigns on rational medicine use topics have been conducted in previous two years MEDS8_01_09
A survey on rational medicine use has been conducted in the previous two years MEDS8_01_10
A national committee exists to monitor and promote rational use of medicines MEDS8_01_11
National strategy to contain antimicrobial resistance exists MEDS8_01_12
AMR strategy has been updated in 2010 or later MEDS8_01_12_01
EML includes formulations specific for children MEDS8_01_14
There are explicitly documented criteria for the selection of medicines on the EML MEDS8_01_15
There is a formal committee for the selection of products on the EML MEDS8_01_16
Conflict of interest declarations are required from members of national EML committee MEDS8_01_16_01
National medicines formulary exists MEDS8_01_17
Existence of a funded national intersectoral taskforce to coordinate the promotion of appropriate use of antimicrobials MEDS8_01_18
A national reference lab has responsibility for coordinating epidemiological surveillance of AMR MEDS8_01_19
Legal provisions exist to govern the licensing and prescribing practices of prescriber MEDS8_02_01
Legal provisions exist to restrict dispensing by prescribers MEDS8_02_02
Prescribers in the private sector dispense medicine MEDS8_02_03
Regulations require hospitals to organize/develop DTCs MEDS8_02_04
More than half of referral hospital have a DTC MEDS8_02_05
More than half of general hospitals have a DTC MEDS8_02_06
More than half of regions/provinces have a DTC MEDS8_02_07
Core medical training includes: concept of EML MEDS8_02_08_01
Core medical training includes: Use for STGS MEDS8_02_08_02
Core medical training includes: Pharmacovigilance MEDS8_02_08_03
Core medical training includes: Problem based pharmacotherapy MEDS8_02_08_04
Mandatory continuing education that includes pharmaceutical issues is required for doctors MEDS8_02_09
Mandatory continuing education that includes pharmaceutical issues is required for nurses MEDS8_02_10
Mandatory continuing education that includes pharmaceutical issues is required for paramedical staff MEDS8_02_11
Public sector generic prescribing is obligatory MEDS8_02_12_01
Private sector generic prescribing is obligatory MEDS8_02_12_02
Average number of medicines prescribed per patient contact in public health facilities MEDS8_02_13
% of medicines prescribed in outpatient public health care facilities that are on the EML MEDS8_02_14
Percentage of medicines in outpatient public health care facilities that are prescribed by INN name MEDS8_02_15
Percentage of patients in outpatient public health care facilities receiving antibiotics MEDS8_02_16
Percentage of patients in outpatient public health care facilities receiving injections MEDS8_02_17
Percentage of medicines adequately labelled in public health facilities MEDS8_02_19
Diarrhoea in children treated with ORS MEDS8_02_23
Legal provisions exist to govern dispensing practices of pharmaceutical personnel MEDS8_03_01
Core pharmacist training includes: EML MEDS8_03_02_01
Core pharmacist training includes: Use of STG MEDS8_03_02_02
Core pharmacist training includes: drug information MEDS8_03_02_03
Core pharmacist training includes: clinical pharmacology MEDS8_03_02_04
Core pharmacist training includes: medicines supply management MEDS8_03_02_05
Mandatory continuing education that includes rational use of medicines is required for pharmacists MEDS8_03_03
Generic substitution permitted in public sector MEDS8_03_04
Generic substitution permitted in private sector MEDS8_03_05
Antibiotics are sometimes sold OTC without prescription MEDS8_03_06
Injectables are sometimes sold OTC without prescription MEDS8_03_07
Nurses sometimes prescribe prescription-only medicines MEDS8_03_10_01
Pharmacists sometimes prescribe prescription-only medicines MEDS8_03_10_02
Paramedics sometimes prescribe prescription-only medicines MEDS8_03_10_03
Personnel with less than one month training sometimes prescribe prescription-only medicines MEDS8_03_10_04
Number of suspected meningitis deaths reported MENING_1
Number of suspected meningitis cases reported MENING_2
Number of meningitis epidemic districts MENING_3
Mental health policy MH_1
Mental health outpatient facilities (per 100 000 population) MH_10
Mental health day treatment facilities (per 100 000 population) MH_11
Age-standardized suicide rates (per 100 000 population) MH_12
Beds for mental health in general hospitals (per 100 000 population) MH_13
Community residential facilities (per 100 000 population) MH_14
Beds in community residential facilities (per 100 000 population) MH_15
Beds in mental hospitals (per 100 000 population) MH_16
Mental hospitals (per 100 000 population) MH_17
Mental health units in general hospitals (per 100 000 population) MH_18
Mental hospital admissions (per 100 000 population) MH_19
Mental health plan MH_2
Outpatient visits (per 100 000 population) MH_20
Total workforce in mental health sector (per 100 000 population) MH_21
Occupational therapists in mental health sector (per 100 000 population) MH_22
Other non-specialized doctors in mental health sector (per 100 000 population) MH_23
Mental health units in general hospitals admissions (per 100 000 population) MH_24
Stand-alone policy or plan for mental health MH_25
Year the law was enacted (latest revision) MH_26
Publication year of the policy or plan (latest revision) MH_27
Stand-alone law for mental health MH_3
Government expenditures on mental health as a percentage of total government expenditures on health (%) MH_4
Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%) MH_5
Psychiatrists working in mental health sector (per 100 000 population) MH_6
Nurses working in mental health sector (per 100 000 population) MH_7
Social workers working in mental health sector (per 100 000 population) MH_8
Psychologists working in mental health sector (per 100 000 population) MH_9
Adolescent mortality rate (per 100 000 population) MORTADO
Number of deaths MORT_100
Deaths per 1 000 live births MORT_200
Distribution of causes of death among children aged < 5 years (%) MORT_300
Deaths per 100 000 population MORT_400
Number of deaths MORT_500
Mortality - deaths (country) MORT_58
Mortality - population (country) MORT_59
Projection of number of deaths MORT_600
Mortality - crude death rate per 100 000 population MORT_61
Mortality - live births (country) MORT_63
Projection of deaths per 100 000 population MORT_700
Number of maternal deaths MORT_MATERNALNUM
Estimate of current cigarette smoking prevalence (%) M_Est_cig_curr
Current cigarette smoking, crude adjusted M_Est_cig_curr_crude
Estimate of current cigarette smoking prevalence (%) (age-standardized rate) M_Est_cig_curr_std
Estimate of daily cigarette smoking prevalence (%) M_Est_cig_daily
Daily cigarette smoking, crude adjusted M_Est_cig_daily_crude
Estimate of daily cigarette smoking prevalence (%) (age-standardized rate) M_Est_cig_daily_std
Estimate of current tobacco smoking prevalence (%) M_Est_smk_curr
Estimate of current tobacco smoking prevalence (%) (age-standardized rate) M_Est_smk_curr_std
Estimate of daily tobacco smoking prevalence (%) M_Est_smk_daily
Estimate of daily tobacco smoking prevalence (%) (age-standardized rate) M_Est_smk_daily_std
Estimate of current tobacco use prevalence (%) M_Est_tob_curr
Current tobacco smoking, crude adjusted M_Est_tob_curr_crude
Estimate of current tobacco use prevalence (%) (age-standardized rate) M_Est_tob_curr_std
Estimate of daily tobacco use prevalence (%) M_Est_tob_daily
Daily tobacco smoking, crude adjusted M_Est_tob_daily_crude
Estimate of daily tobacco use prevalence (%) (age-standardized rate) M_Est_tob_daily_std
Monitor M_Group
Adult indicator 1 rate M_def_1_prev_adult
Youth indicator 1 rate M_def_1_prev_youth
Adult indicator 1 definition M_def_1_text_adult
Youth indicator 1 definition M_def_1_text_youth
Adult indicator 2 rate M_def_2_prev_adult
Youth indicator 2 rate M_def_2_prev_youth
Adult indicator 2 definition M_def_2_text_adult
Youth indicator 2 definition M_def_2_text_youth
Adult survey age range - smokeless M_smkless_age_range_adult
Youth survey age range - smokeless M_smkless_age_range_youth
Adult smokeless tobacco use indicator definition M_smkless_def_text_adult
Youth smokeless tobacco use indicator definition M_smkless_def_text_youth
Adult smokeless tobacco use indicator rate M_smkless_prev_adult
Youth smokeless tobacco use indicator rate M_smkless_prev_youth
Name of survey of adults - smokeless M_smkless_survey_title_adult
Name of survey of youth - smokeless M_smkless_survey_title_youth
Representativeness of survey of adults - smokeless M_smkless_svy_national_adult
Representativeness of survey of youth - smokeless M_smkless_svy_national_youth
Year of survey of adults - smokeless M_smkless_svy_yr_adult
Year of survey of youth - smokeless M_smkless_svy_yr_youth
Name of survey of adults M_survey_title_adult
Name of survey of youth M_survey_title_youth
Adult survey age range M_svy_age_adult
Youth survey age range M_svy_age_youth
Representativeness of survey of adults M_svy_national_adult
Representativeness of youth survey M_svy_national_youth
Year of latest adult prevalence survey M_svy_yr_adult
Year of survey of youth M_svy_yr_youth
Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease NCDMORT3070
Prevalence of underweight among adults, BMI < 18.5 (age-standardized estimate) (%) NCD_BMI_18A
Prevalence of underweight among adults, BMI < 18.5 (crude estimate) (%) NCD_BMI_18C
Prevalence of overweight among adults, BMI ≥ 25 (age-standardized estimate) (%) NCD_BMI_25A
Prevalence of overweight among adults, BMI ≥ 25 (crude estimate) (%) NCD_BMI_25C
Prevalence of obesity among adults, BMI ≥ 30 (age-standardized estimate) (%) NCD_BMI_30A
Prevalence of obesity among adults, BMI ≥ 30 (crude estimate) (%) NCD_BMI_30C
Mean BMI (kg/m²) (age-standardized estimate) NCD_BMI_MEAN
Mean BMI (kg/m²) (crude estimate) NCD_BMI_MEANC
Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (age-standardized estimate) (%) NCD_BMI_MINUS2A
Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%) NCD_BMI_MINUS2C
Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (age-standardized estimate) (%) NCD_BMI_PLUS1A
Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%) NCD_BMI_PLUS1C
Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (age-standardized estimate) (%) NCD_BMI_PLUS2A
Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%) NCD_BMI_PLUS2C
Cancers, deaths per 100,000 (age-standardized estimate) NCD_CA
Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) NCD_CARDIO
General availability of ACE inhibitors in the public health sector NCD_CCS_ACE
General availability of Angiotensin II receptor blockers (ARBs) in the public health sector NCD_CCS_ARB
General availability of acetic acid visualization at the primary health care level NCD_CCS_AceticAcid
Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol NCD_CCS_AlcPlan
General availability of aspirin (100 mg) in the public health sector NCD_CCS_Aspirin
General availability of beta blockers in the public health sector NCD_CCS_BetaBlkrs
General availability of colon cancer screening at the primary health care level NCD_CCS_BowelCancer
General availability of breast cancer screening (by palpation or mammogram) at the primary health care level NCD_CCS_BreastCancer
General availability of bronchodilators in the public health sector NCD_CCS_Bronchodilators
General availability of CC blockers in the public health sector NCD_CCS_CCBlkrs
Existence of operational policy/strategy/action plan for chronic respiratory diseases NCD_CCS_CRDPlan
Existence of operational policy/strategy/action plan for cardiovascular diseases NCD_CCS_CVDPlan
Existence of operational policy/strategy/action plan for cancer NCD_CCS_CancerPlan
Existence and scope of cancer registry NCD_CCS_CancerReg
Existence of population-based cancer registry NCD_CCS_CancerRegNational
General availability of cervical cytology at the primary health care level NCD_CCS_CervCy
General availability of chemotherapy in the public health system NCD_CCS_Chemo
General availability of total cholesterol measurement at the primary health care level NCD_CCS_CholMsmt
Existence of partnerships/collaborations for implementing key activities related to NCDs NCD_CCS_Collab
Availability and stage of implementation of guidelines/protocols/standards for the management of diabetes NCD_CCS_DiabGuide
Existence of operational policy/strategy/action plan for diabetes NCD_CCS_DiabPlan
Existence of a diabetes registry NCD_CCS_DiabetesReg
General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level NCD_CCS_DiabetesTest
Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs NCD_CCS_DietPlan
Earmarking of taxes from fiscal interventions to influence behaviour change used to fund health promotion programmes or a health promotion foundation NCD_CCS_Earmarking
General availability of electrocardiogram at the primary health care level NCD_CCS_Electrocard
General availability of glibenclamide in the public health sector NCD_CCS_Gliben
General availability of diabetes testing (by HbA1c) at the primary health care level NCD_CCS_HbA1c
General availability of hydrocortisone injections in the public health sector NCD_CCS_Hydrocort
Availability and stage of implementation of guidelines/protocols/standards for the management of raised blood pressure / hypertension NCD_CCS_HypGuide
General availability of insulin in the public health sector NCD_CCS_Insulin
General availability of ipratropium bromide in the public health sector NCD_CCS_Ipratro
General availability of metformin in the public health sector NCD_CCS_Metformin
Existence of any policies on marketing of foods to children NCD_CCS_Mkting
Existence of a national multisectoral commission, agency or mechanism for NCDs NCD_CCS_MultisecComm
Existence of at least one operational multisectoral national policy, strategy or action plan that integrates several noncommunicable diseases and shared risk factors in conformity with the global/regional noncommunicable disease action plans 2013?2020 NCD_CCS_MultisecNCDPlan
Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach NCD_CCS_NCDGuide
Existence of a set of national NCD indicators and has set time-bound national targets for these indicators NCD_CCS_NCDIndicators
Existence of Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs NCD_CCS_NCDUnit
Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs NCD_CCS_NCDUnit_Operational
General availability of nicotine replacement therapy in the public health sector NCD_CCS_Nicotine
General availability of oral morphine in the public health sector NCD_CCS_OralMorph
Existence of operational policy/strategy/action plan to reduce physical inactivity NCD_CCS_PAPlan
Has a STEPS survey or a comprehensive health examination survey every 5 years NCD_CCS_PM3_Surv
General availability of prednisolone tabs in the public health sector NCD_CCS_Prednis
Existence of risk factor surveillance for selected risk factors (harmful alcohol use, diet, physical inactivity, and tobacco use) NCD_CCS_RFSurv
General availability of radiotherapy in the public health system NCD_CCS_RadioTherapy
General availability of renal replacement therapy (by dialysis or transplantation) in the public health system NCD_CCS_RenalTherapy
General availability of retinal photocoagulation in the public health system NCD_CCS_RetinalPho
Existence of tax on sugar-sweetened beverages NCD_CCS_SSBTAX
General availability of salbutamol in the public health sector NCD_CCS_Salb
Existence of any policies to reduce population salt consumption NCD_CCS_SaltPol
Existence of national policies on saturated fatty acids NCD_CCS_SatFat
Existence of national policies on saturated fatty acids / trans-fats NCD_CCS_SatTransFat
General availability of peak flow measurement spirometry at the primary health care level NCD_CCS_Spirom
General availability of statins in the public health sector NCD_CCS_Statins
General availability of steroid inhalers in the public health sector NCD_CCS_Steroid
Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets NCD_CCS_SurvMonRep9NCD
General availability of tamoxifen in the public health sector NCD_CCS_Tamox
Implementation of fiscal interventions to influence behaviour change NCD_CCS_Taxes
General availability of thiazide diuretics in the public health sector NCD_CCS_Thiazide
Existence of operational policy/strategy/action plan to decrease tobacco use NCD_CCS_TobPlan
Existence of national policies on trans-fatty acid elimination NCD_CCS_TransFat
General availability of urine testing for albumin NCD_CCS_UrineAlbumin
General availability of beta blockers in the public health sector NCD_CCS_betablockers
General availability of bone marrow transplantation in the public health system NCD_CCS_bone_marrow
Existence of national screening program for breast cancer NCD_CCS_breastcancerscreening
Most widely used screening method in national cervical cancer screening program NCD_CCS_cervicalcancermethod
Coverage of national cervical cancer screening program (%) NCD_CCS_cervicalcancerpgmcvg
Type of national cervical cancer screening program NCD_CCS_cervicalcancerpgmtype
Existence of national screening program for cervical cancer NCD_CCS_cervicalcancerscreening
General availability of coronary bypass or stenting in the public health system NCD_CCS_coronary
General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level NCD_CCS_diabtest
General availability of dialysis in the public health system NCD_CCS_dialysis
Implementation of diet and/or physical activity public awareness program NCD_CCS_dietpaaware
Existence of national HPV vaccination programme NCD_CCS_hpv
Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors NCD_CCS_integNCDplan
Existence of operational policy/strategy/action plan for oral health NCD_CCS_oralhealthplan
Implementation of physical activity public awareness program NCD_CCS_paaware
General availability of palliative care in community or home-based care in the public health system NCD_CCS_palliative_home
General availability of palliative care in primary health care in the public health system NCD_CCS_palliative_prim
General availability of retinal photocoagulation in the public health system NCD_CCS_photocoag
General availability of renal replacement by transplantation in the public health system NCD_CCS_renaltrans
Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities NCD_CCS_rheum
Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease NCD_CCS_rheumfollowup
Existence of a register of patients who had rheumatic fever and rheumatic heart disease NCD_CCS_rheumreg
Availability of cardiovascular risk stratification in 50% or more primary health care facilities NCD_CCS_riskstrat
Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities NCD_CCS_stroke
General availability of sulphonylurea(s) in the public health sector NCD_CCS_sulphonylurea
Existence of a set of time-bound national targets based on WHO guidance NCD_CCS_targets
General availability of thrombolytic therapy in the public health system NCD_CCS_thrombolytic
Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) NCD_CHRON
All NCDs, deaths per 100,000 (age-standardized estimate) NCD_DTH_PER
Total NCD Deaths (in thousands) NCD_DTH_TOT
Mean fasting blood glucose (mmol/l) (age-standardized estimate) NCD_GLUC_01
Mean fasting blood glucose (mmol/l) (crude estimate) NCD_GLUC_02
Raised fasting blood glucose (>= 7.0 mmol/L or on medication) (crude estimate) NCD_GLUC_03
Raised fasting blood glucose (>=7.0 mmol/L or on medication)(age-standardized estimate) NCD_GLUC_04
Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%) NCD_PAA
Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%) NCD_PAC
Prevalence of insufficient physical activity among school going adolescents aged 11-17 (crude estimate) NCD_PAC_ADO
NCD deaths under age 60 (percent of all NCD deaths) NCD_UNDER60
NCD deaths under age 70 (percent of all NCD deaths) NCD_UNDER70
Basis for NHA estimate NHABASIS
General government expenditure on health as percentage of gross domestic product NHAGGHEGDP
Out-of-Pocket expenditure on health as percentage of total health expenditure?? NHAOOPSTHE
Prepaid plans as percentage of total health expenditure? NHAPREPAIDTHE
Number of full-time equivalent staff in national agency NTCP_FTE
National agency for tobacco control exists NTCP_agcy
Budget year NTCP_budget_year
National tobacco control budget - currency reported NTCP_curr
Annual budget for tobacco control in currency reported NTCP_govt_exp
Government objectives on tobacco control exist NTCP_govt_obj
Budget year NTCP_usd
Number of new reported cases of Buruli ulcer NTD_1
Dracunculiasis certification status of countries at the beginning of the year NTD_2
Year country was certified NTD_2_YEAR_CERTIFIED
Annual incidence of dracunculiasis cases NTD_3
Number of new reported cases of human African trypanosomiasis (T.b. gambiense) NTD_4
Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense) NTD_5
Status of elimination of trachoma as a public health problem NTD_6
Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem NTD_7
Number of people who received treatment with antibiotics for trachoma NTD_8
Number of cases of bejel reported NTD_BEJELNUM
Status of bejel endemicity NTD_BEJELSTATUS
Dracunculiasis cases NTD_DRACASES
Status of endemicity of cutaneous leishmaniasis NTD_LEISHCEND
Number of cases of cutaneous leishmaniasis reported NTD_LEISHCNUM
Number of imported cases of cutaneous leishmaniasis reported NTD_LEISHCNUM_IM
Status of endemicity of visceral leishmaniasis NTD_LEISHVEND
Number of cases of visceral leishmaniasis reported NTD_LEISHVNUM
Number of imported cases of visceral leishmaniasis reported NTD_LEISHVNUM_IM
Leprosy - Proportion of new child (less than 15 years of age) cases among new cases NTD_LEPR10
Leprosy - Number of female new cases NTD_LEPR11
Leprosy - Proportion of female new cases among new cases NTD_LEPR12
New child (less than 15 years of age) leprosy cases rate per 1 000 000 population of children NTD_LEPR13
Leprosy - New cases detection rate per 100 000 population NTD_LEPR2
Leprosy - Number of cases registered for treatment NTD_LEPR3
Leprosy - Registered cases per 10 000 population NTD_LEPR4
Leprosy - Number of new G2D cases NTD_LEPR5
Leprosy - Proportion of new G2D cases among new cases NTD_LEPR6
Leprosy - New leprosy cases with G2D rate per 1 000 000 population NTD_LEPR7
Leprosy - Number of new child (less than 15 years of age) cases NTD_LEPR8
Leprosy - Number of new child (less than 15 years of age) cases detected with G2D NTD_LEPR9
Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis NTD_ONCHEMO
Status of endemicity of onchocerciasis NTD_ONCHSTATUS
Reported number of individuals treated for onchocerciasis NTD_ONCTREAT
Number of cases of pinta reported NTD_PINTANUM
Status of pinta endemicity NTD_PINTASTATUS
Reported number of human rabies deaths NTD_RAB2
Number of people operated for trachomatous trichiasis NTD_TRA5
Status of endemicity of Taenia solium NTD_TSOL1
Presence of porcine cysticercosis NTD_TSOL2
Number of pigs in the country NTD_TSOL3
Practice of backyard pig production NTD_TSOL4
Inequality-adjusted Human Development Index NTD_TSOL5
Population with access to improved sanitation NTD_TSOL6
Status of yaws endemicity NTD_YAWSEND
Number of cases of yaws reported NTD_YAWSNUM
Number of confirmed yaws cases reported NTD_YAWSNUM_CONF
Number of suspected yaws cases reported NTD_YAWSNUM_SUSP
Overweight numbers (in millions) NUTOVERWEIGHTNUM
Overweight prevalence NUTOVERWEIGHTPREV
Prevalence of adults aged ≥ 15 years who are moderately and severely thin (BMI <17.0) NUTRITION_0
Prevalence of adults aged ≥ 15 years who are severely thin (BMI <16.0) NUTRITION_1
Prevalence of adults aged ≥ 15 years who are mildly thin (BMI 17.0-18.49) NUTRITION_2
Proportion of children aged 6-23 months who receive a minimum acceptable diet NUTRITION_2005
Minimum dietary diversity (%) NUTRITION_2006
Minimum meal frequency (%) NUTRITION_2007
Prevalence of adults aged ≥ 15 years who are moderately thin (BMI 16.0-16.99) NUTRITION_3
Children aged <5 years wasted for age (%) NUTRITION_564
Prevalence of adults aged ≥ 15 years who are pre-obese (%) (BMI 25.0-29.99) NUTRITION_565
Prevalence of adults aged ≥ 15 years who are overweight (%) (BMI ? 25.0) NUTRITION_566
Prevalence of adults aged ≥ 15 years who are in normal range (%) (BMI 18.5-24.99) NUTRITION_567
Prevalence of adults aged ≥ 15 years who are underweight (%) (BMI <18.5) NUTRITION_568
Continued breastfeeding at 1 year (%) NUTRITION_569
Early initiation of breastfeeding (%) NUTRITION_570
Exclusive breastfeeding under 4 months (%) NUTRITION_571
Continued breastfeeding at 2 years (%) NUTRITION_572
Children ever breastfed (%) NUTRITION_573
Duration of any breastfeeding NUTRITION_574
Duration of exclusive breastfeeding NUTRITION_575
Introduction of solid, semi-solid or soft foods and breast milk (%) NUTRITION_576
Bottle feeding rate 0-11.9 months (%) NUTRITION_577
Bottle feeding rate 0-23.9 months (%) NUTRITION_578
Exclusive breastfeeding under 6 months (%) NUTRITION_579
Prevalence of stunted children aged <5 years (% height-for-age <-2 SD) NUTRITION_HA_2
Prevalence of underweight children aged <5 years (% weight-for-age <-2 SD) (%) NUTRITION_WA_2
Prevalence of overweight children aged <5 years (% weight-for-height >+2 SD) NUTRITION_WH2
Prevalence of wasted children aged <5 years (% weight-for-height <-2 SD) NUTRITION_WH_2
Prevalence of severely wasted children aged <5 years (% weight-for-height <-3 SD) NUTRITION_WH_3
Severe wasting numbers (in millions) NUTSEVWASTINGNUM
Severe wasting prevalence NUTSEVWASTINGPREV
Stunting numbers (in millions) NUTSTUNTINGNUM
Stunting prevalence NUTSTUNTINGPREV
Underweight numbers (in millions) NUTUNDERWEIGHTNUM
Underweight prevalence NUTUNDERWEIGHTPREV
Wasting numbers (in millions) NUTWASTINGNUM
Wasting prevalence NUTWASTINGPREV
Decayed, missing, or filled teeth OA_DMFT
Occupational risk factors attributable deaths OCC_1
Occupational carcinogens attributable DALYs (’000) OCC_10
Occupational carcinogens attributable deaths per 100’000 capita OCC_11
Occupational carcinogens attributable DALYs per 100’000 capita OCC_12
Occupational noise attributable DALYs (’000) OCC_13
Occupational noise attributable DALYs per 100’000 capita OCC_14
Occupational ergonomic stressors attributable deaths OCC_15
Occupational ergonomic stressors attributable DALYs (’000) OCC_16
Occupational ergonomic stressors attributable deaths per 100’000 capita OCC_17
Occupational ergonomic stressors attributable DALYs per 100’000 capita OCC_18
Occupational injuries attributable deaths OCC_19
Occupational risk factors attributable DALYs (’000) OCC_2
Occupational injuries attributable DALYs (’000) OCC_20
Occupational injuries attributable deaths per 100’000 capita OCC_21
Occupational injuries attributable DALYs per 100’000 capita OCC_22
Occupational risk factors attributable deaths per 100’000 capita OCC_3
Occupational risk factors attributable DALYs per 100’000 capita OCC_4
Occupational airborne particulates attributable deaths OCC_5
Occupational airborne particulates attributable DALYs (’000) OCC_6
Occupational airborne particulates attributable deaths per 100’000 capita OCC_7
Occupational airborne particulates attributable DALYs per 100’000 capita OCC_8
Occupational carcinogens attributable deaths OCC_9
Donor commitments (Million, constant 2009 US\() |ODA_1 | |Commitments to recipient countries (Million, constant 2009 US\)) ODA_2
Donor disbursements (Million, constant 2009 US\() |ODA_3 | |Disbursements to recipient countries (Million, constant 2009 US\)) ODA_4
Kidney transplants (absolute number) ORGANKIDNEYNUM
Kidney transplants (per million) ORGANKIDNEYRATE
Liver transplants (absolute number) ORGANLIVERNUM
Liver transplants (per million) ORGANLIVERRATE
Population (millions) ORGANPOP
Total actual deceased donors (absolute number) ORGANTOTALDECNUM
Total actual deceased donors (per million) ORGANTOTALDECRATE
Total organs transplanted (absolute number) ORGANTOTALNUM
Total organs transplanted (per million) ORGANTOTALRATE
Smoking cessation support is available in the community O_Avail_community
Treatment for tobacco dependence available in health clinics or other primary care facilities O_Avail_hlthSPACEclin
Smoking cessation support is available in health clinics or other primary care facilities O_Avail_hlth_clin
Smoking cessation support is available in hospitals O_Avail_hosp
Smoking cessation support is available in offices of health professionals O_Avail_off_hlth_prof
Smoking cessation support is available in other settings O_Avail_other
Bupropion - cost covered O_Bup_ins
Bupropion - legally sold O_Bup_sold
Bupropion - place available O_Bup_where
Cytisine - cost covered O_Cytisine_ins
Cytisine - legally sold O_Cytisine_sold
Cytisine - place available O_Cytisine_where
Offer help to quit tobacco use O_Group
Smoking cessation support is cost-covered in the community O_Ins_community
Smoking cessation support is cost-covered in health clinics or other primary care facilities O_Ins_hlth_clin
Smoking cessation support is cost-covered in hospitals O_Ins_hosp
Smoking cessation support is cost-covered in offices of health professionals O_Ins_off_hlth_prof
Smoking cessation support is cost-covered in other settings O_Ins_other
Nicotine replacement therapy - on the Essential Medicines List O_NRT_EML
Nicotine replacement therapy - cost covered O_NRT_ins
Nicotine replacement therapy - legally sold O_NRT_sold
Nicotine replacement therapy - place available O_NRT_where
Access to a toll-free quit line O_Quitline
Varenicline - cost covered O_Varen_ins
Varenicline - legally sold O_Varen_sold
Varenicline - place available O_Varen_where
Subnational smoke-free legislation authority exists P10_subnat_auth_exists
Fines for violations of smoke-free laws P11_fines_any
Fines on the establishment for violations of smoke-free laws P12_fines_establishment
Fines on the patrons of establishments for violations of smoke-free laws P13_fines_smoker
Dedicated funds for enforcement of smoke-free laws P14_funds_for_enforce
Citizen complaints and investigations of violations of smoke-free laws P15_complaints
Comprehensive bans in place subnationally P16_subnat_complete_bans_exist
Compliance of ban on smoking in HEALTH-CARE FACILITIES P1_compliance
Smoke-free health-care facilities (national legislation) P1_healthcare
Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES P2_compliance
Smoke-free education facilities except universities (national legislation) P2_education
Compliance of ban on smoking in UNIVERSITIES P3_compliance
Smoke-free universities (national legislation) P3_universities
Compliance of ban on smoking in GOVERNMENT FACILITIES P4_compliance
Smoke-free government facilities (national legislation) P4_govt
Compliance of ban on smoking in INDOOR OFFICES P5_compliance
Smoke-free indoor offices (national legislation) P5_indoor_off
Compliance of ban on smoking in RESTAURANTS P6_compliance
Smoke-free restaurants (national legislation) P6_restaurants
Compliance of ban on smoking in PUBS AND BARS P7_compliance
Smoke-free pubs, bars and cafés (national legislation) P7_pubs
Compliance of ban on smoking in PUBLIC TRANSPORT P8_compliance
Smoke-free public transport (national legislation) P8_pub_transp
Smoke-free other indoor public places (national legislation) P9_all_other
Pneumococcal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%) PCV3
Compliance with regulations on smoke-free environments (national legislation) PC_sfe_compliance
Population with primary reliance on clean fuels and technologies for cooking (in millions) PHE_HHAIR_POP_CLEAN_FUELS
Population with primary reliance on polluting fuels and technologies for cooking (in millions) PHE_HHAIR_POP_POLLUTING_FUELS
Proportion of population with primary reliance on clean fuels and technologies for cooking (%) PHE_HHAIR_PROP_POP_CLEAN_FUELS
Proportion of population with primary reliance on polluting fuels and technologies for cooking (%) PHE_HHAIR_PROP_POP_POLLUT_FUELS
Prevalence of anaemia in women of reproductive age (%) PREVANEMIA
Protect from tobacco smoke P_Group
Overall compliance with regulations on smoke-free environments (score) P_compl_all_sfe
Compliance with smoke-free health-care facilities law (score) P_compl_p1
Compliance with smoke-free education facilities except universities law (score) P_compl_p2
Compliance with smoke-free universities law (score) P_compl_p3
Compliance with smoke-free government facilities law (score) P_compl_p4
Compliance with smoke-free indoor offices law (score) P_compl_p5
Compliance with smoke-free restaurants law (score) P_compl_p6
Compliance with smoke-free pubs and bars law (score) P_compl_p7
Compliance with smoke-free public transport law (score) P_compl_p8
Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place P_comprehensive_subnat
Number of places smoke-free (national legislation) P_count_places_sf
Comprehensive bans in place subnationally P_subnat_complete_ban_exists
Antenatal care attendees who were positive for syphilis (%) PercposANC
Men who have sex with men (MSM) with active syphilis (%) PercposMSM
Sex workers with active syphilis (%) PercposSW
Women accessing antenatal care (ANC) services who were tested for syphilis (%) PerctestedANC
Antenatal care attendees positive for syphilis who received treatment (%) PerctreatedANC
Existence of any national radon activity RADON_Q201
Existence of any subnational radon activity RADON_Q202
Existence of national radon survey(s) RADON_Q301
National radon concentration levels RADON_Q302
Existence of national radon database RADON_Q303
Data in national radon database RADON_Q303a
Data in national radon database RADON_Q304
Existence of national radon map RADON_Q305
Existence of national radon action plan RADON_Q401
Existence of national radon action plan - Years covered RADON_Q401_1
Existence of national radon action plan - Years covered RADON_Q401a
Existence of national radon regulations RADON_Q402
Radon in building regulations for new buildings RADON_Q403
Radon in building regulations for existing buildings i.e. renovation/remodeling/major alteration RADON_Q404
Radon in national drinking-water regulations RADON_Q405
Existence of national reference level for dwellings RADON_Q501
Reference level for dwellings (Bq/m3) RADON_Q501_1
Reference level for dwellings and buildings with high public occupancy (Bq/m3) RADON_Q501b
Existence of national reference level for buildings with high public occupancy RADON_Q502
Reference level for buildings with high public occupancy (Bq/m3) RADON_Q502_1
Reference level for workplaces (Bq/m3) RADON_Q502b
Existence of national reference level for workplaces RADON_Q503
Reference level for workplaces (Bq/m3) RADON_Q503_1
Existence of official protocols for radon measurements RADON_Q601
Radon concentration measurements for new buildings RADON_Q602
Radon concentration measurements for existing buildings RADON_Q603
Radon concentration measurements for workplaces RADON_Q604
Authorization/accreditation required for official radon measurement providers RADON_Q605
Mandatory preventive measures (new buildings) RADON_Q701
Mandatory mitigation measures if legal value is exceeded (existing buildings) RADON_Q702
Financial support provided for mitigation (existing dwellings) RADON_Q703
Authorization required for prevention/mitigation service providers RADON_Q704
Official standards/guidelines for prevention/mitigation RADON_Q705
Existence of training for mitigation providers RADON_Q706
Inclusion of radon education for building professionals RADON_Q707
Existence of national radon risk communication strategy RADON_Q801
Inclusion of radon measurements in property transactions RADON_Q802
Inclusion of radon in different national strategies RADON_Q803
Inclusion of radon in national lung cancer reporting and screening strategy RADON_Q804
Inclusion of radon in national tobacco control strategy RADON_Q805
Inclusion of radon in national indoor air quality strategy RADON_Q806
Inclusion of radon in national energy conservation strategy RADON_Q807
Intimate partner violence prevalence among ever partnered women (%) RHR_IPV
Non-partner sexual violence prevalence (%) RHR_NPSV
Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%) ROTAC
Point prevalence (%), alcohol use disorders, 15+ years RSUD_1
National survey on substance use among children and adolescents RSUD_10
Government unit/official responsible for prevention for substance use RSUD_100
Data on substance use disorders disseminated in national annual reports RSUD_11
Ministry/office that takes primary responsibility for prevention for substance use RSUD_110
Substance use policy at the national level RSUD_12
Five years change in international cooperation for prevention for substance use RSUD_120
Substance use policy at the national level, level of integration RSUD_13
Government unit/official responsible for treatment of substance use disorders RSUD_130
Policy documents on the pharmacological treatment of substance use disorders RSUD_14
Ministry/office that takes primary responsibility for treatment of substance use disorders RSUD_140
Guidelines on the pharmacological treatment of substance use disorders RSUD_15
Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders RSUD_150
Legislative provision for treatment and rehabilitation of substance use disorders RSUD_16
Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders RSUD_160
Legislative provision for compulsory treatment RSUD_17
Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs RSUD_170
Drug courts RSUD_18
Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs RSUD_180
Programmes diverting clients from the justice system towards treatment RSUD_19
Five years change in international cooperation for treatment of substance use disorders RSUD_190
Point prevalence (%), drug use disorders, 15+ years RSUD_2
Confidentiality of health records on substance use disorders protected by law RSUD_20
Confidentiality of people in treatment for substance use disorders RSUD_200
Government unit for substance use disorder treatment RSUD_21
Voluntary treatment for people with alcohol use disorders in the criminal justice system RSUD_210
Budget line for substance use disorder treatment RSUD_22
Voluntary treatment for people with drug use disorders in the criminal justice system RSUD_220
Financing method for substance use disorder treatment RSUD_23
Compulsory treatment for people with alcohol use disorders in the criminal justice system RSUD_230
Treatment services for alcohol use disorders, free of charge RSUD_24
Compulsory treatment for people with drug use disorders in the criminal justice system RSUD_240
Treatment services for drug use disorders, free of charge RSUD_25
Five-year change in government resources for prevention for substance use RSUD_250
Governement benefits for persons with substance use disorders RSUD_26
Five-year change in government resources for treatment of substance use disorders RSUD_260
Government benefits for alcohol use disorders, subsidy or disability pension RSUD_27
Financing methods for treatment for alcohol use disorders RSUD_270
Government benefits for drug use disorders, subsidy or disability pension RSUD_28
Financing methods for treatment for drug use disorders RSUD_280
Sector for inpatient detoxification of alcohol use disorders RSUD_29
Hypothecated taxes to be spent on prevention and treatment for substance use disorders RSUD_290
Age-standardized death rates, alcohol and drug use disorders, per 100 000 RSUD_3
Sector for inpatient treatment of alcohol dependence RSUD_30
Government benefits for people with alcohol use disorders RSUD_300
Sector for outpatient treatment of alcohol dependence RSUD_31
Government benefits for people with drug use disorders RSUD_310
Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions RSUD_32
Main sector for treatment for alcohol use disorders RSUD_320
Sector for residential long-term rehabilitation of alcohol use disorders RSUD_33
Main sector for treatment for drug use disorders RSUD_330
Sector for inpatient detoxification of drug use disorders RSUD_34
Treatment programmes for children and adolescents with alcohol use disorders RSUD_340
Sector for inpatient treatment of drug dependence RSUD_35
Treatment programmes for children and adolescents with drug use disorders RSUD_350
Sector for outpatient treatment of drug dependence RSUD_36
Specialized treatment facilities for substance use disorders RSUD_360
Sector for substitution maintenance therapy of opioid dependence RSUD_37
Specialized treatment facilities for alcohol use disorders RSUD_370
Sector for residential long-term rehabilitation of drug use disorders RSUD_38
Specialized treatment facilities for drug use disorders RSUD_380
Treatment system for substance use disorders RSUD_39
Self-help groups RSUD_390
Age-standardized death rates, drug use disorders, per 100 000 RSUD_4
Treatment setting for substance use disorders, most common RSUD_40
Main substance at treatment entry RSUD_400
Specialized treatment services for drug use disoders and HIV/AIDS RSUD_41
Reported treatment coverage for substance dependence RSUD_410
Specialized treatment services for substance use disorders and TB RSUD_42
Guidelines on pharmacological treatment for substance use disorders RSUD_420
Open access services for substance use disorders RSUD_43
Pharmacotherapy with methadone RSUD_430
Treatment slots for alcohol and drug use disorders, outpatient, per 10 000 RSUD_44
Pharmacotherapy with buprenorphine RSUD_440
Beds for the treatment of substance use disorders, per 100 000 RSUD_45
Pharmacotherapy with buprenorphine/naloxone RSUD_450
Length of stay for inpatient detoxification, days RSUD_46
Access restrictions to maintenance treatment RSUD_460
Length of stay for inpatient short-term treatment, days RSUD_47
Timeframe for maintenance treatment of opioid dependence RSUD_470
Length of stay for inpatient long-term residential treatment, days RSUD_48
Registration of medications for alcohol dependence and withdrawal RSUD_480
Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance) RSUD_49
Registration of medications for opioid dependence RSUD_490
Age-standardized DALYs, alcohol and drug use disorders, per 100 000 RSUD_5
Timeframe of opioid agonist treatment RSUD_50
Registration of medications for opioid withdrawal RSUD_500
Methadone used for the treatment of opioid dependence RSUD_51
Registration of naloxone for injection for opioid overdose RSUD_510
Methadone used for detoxification or maintenance RSUD_52
Availability of naloxone RSUD_520
Methadone formulation used for the treatment of opiod dependence RSUD_53
Screening and brief intervention for substance use in primary health care RSUD_530
Buprenorphine used for the treatment of opioid dependence RSUD_54
Screening and brief intervention for substance use in antenatal services RSUD_540
Buprenorphine used for detoxification or maintenance RSUD_55
Recommendations for screening and brief interventions for substance use in primary health care RSUD_550
Buprenorphine/naloxone used for the treatment of opioid dependence RSUD_56
Recommendations for screening and brief interventions for substance use in antenatal services RSUD_560
Buprenorphine/naloxone used for detoxification or maintenance RSUD_57
Groups and agencies involved in prevention programs RSUD_570
Methadone provision in clinical and community-based settings RSUD_58
Prevention programmes for alcohol RSUD_580
Buprenorphine provision in clinical and community-based settings RSUD_59
Prevention programmes for specific populations for alcohol RSUD_590
Age-standardized DALYs, drug use disorders, per 100 000 RSUD_6
Buprenorphine/naloxone provision in clinical and community-based settings RSUD_60
Prevention programmes for drugs RSUD_600
Supervision requirements for methadone administration RSUD_61
Prevention programmes for specific populations for drugs RSUD_610
Supervision requirements for buprenorphine administration RSUD_62
HIV, Hepatitis counselling and treatment availability in specialized facilities and services RSUD_620
Supervision requirements for buprenorphine/naloxone administration RSUD_63
Programmes readily available RSUD_630
Prescription requirements for methadone RSUD_64
Standards of treatment and care for public specialized treatment facilities RSUD_640
Prescription requirements for buprenorphine RSUD_65
Special treatment programmes for gambling disorder RSUD_650
Prescription requirements for buprenorphine/naloxone RSUD_66
Treatment programmes for women with alcohol use disorders RSUD_660
Commencement of treatment with opioid agonists RSUD_67
Treatment programmes for women with drug use disorders RSUD_670
Pharmacotherapy used for the management of alcohol withdrawal RSUD_68
Special housing services for alcohol use disorders RSUD_680
Pharmacotherapy used for the management of benzodiazepine withdrawal RSUD_69
Special housing services for drug use disorders RSUD_690
Psychoactive substance causing entry into treatment RSUD_7
Pharmacotherapy used for the management of cannabis withdrawal RSUD_70
Employment services for alcohol use disorders RSUD_700
Essential list of medicines RSUD_71
Employment services for drug use disorders RSUD_710
Essential list of medicines, pharmacotherapy for substance use disorders RSUD_72
Open access interventions for alcohol RSUD_720
Government unit for substance use disorder prevention RSUD_73
Open access interventions for drugs RSUD_730
Budget line for substance use disorder prevention RSUD_74
Health professionals providing treatment for alcohol and drug use disorders RSUD_740
Funding method for substance use disorder prevention RSUD_75
Standards of care for professionals providing treatment for alcohol and drug use disorders RSUD_750
Prevention activities for substance use disorders, main focus RSUD_76
Educational attainment in prevention RSUD_760
Programmes for the prevention of substance use disorders for special populations RSUD_77
Postgraduate training programme in prevention RSUD_770
Screening and brief interventions for substance use and substance use disorders RSUD_78
Continuing professional development in prevention RSUD_780
Harm reduction programmes for IDUs RSUD_79
Educational attainment in treatment RSUD_790
Epidemiological data collection system for substance use disorders RSUD_8
Health professionals mostly involved in treatment of substance use disorders RSUD_80
Postgraduate training programme in treatment RSUD_800
Clinical supervision of health care staff RSUD_81
Continuing professional development in treatment RSUD_810
Standards of care for health professionals RSUD_82
Epidemiological data collection for substance use RSUD_820
Standards of care for health professionals, maintenance RSUD_83
Service delivery data collection for substance use RSUD_830
Standards of care for health professionals, human rights RSUD_84
Regular reports on epidemiological and service delivery data for substance use RSUD_840
NGOs for alcohol use disorders RSUD_85
System of monitoring alcohol involvement in forensic pathology RSUD_850
NGOs for drug use disorders RSUD_86
System of monitoring drugs involvement in forensic pathology RSUD_860
Self-help groups for substance use disorders RSUD_87
Epidemiological data collection system for substance use among children and adolescents RSUD_870
Groups and agencies for the prevention of substance use disorders RSUD_88
Epidemiological data collection system for substance use among children and adolescents RSUD_880
Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance) RSUD_89
Treatment programmes for children and adolescents with alcohol use disorders RSUD_890
Service delivery data collection system for substance use disorders RSUD_9
Treatment programmes for children and adolescents with drug use disorders RSUD_900
Population RS_1845
Income level RS_193
Number of registered vehicles RS_194
Estimated number of road traffic deaths RS_196
Estimated road traffic death rate (per 100 000 population) RS_198
Existence of a national drink-driving law RS_204
Definition of drink-driving by BAC RS_205
Blood Alcohol Concentration (BAC) limit for drivers RS_207
Attribution of road traffic deaths to alcohol (%) RS_208
Existence of a national seat-belt law RS_209
Applicability of seat-belt law to all occupants RS_210
Seat-belt wearing rate (%) RS_212
Existence of a national child-restraint law RS_213
Existence of national speed limits RS_214
Adaptation of national speed limit at a local level RS_215
Specification of national speed law by vehicle type RS_216
Maximum speed limits RS_217
Existence of a national motorcycle helmet law RS_218
Applicability of national motorcycle helmet law to all occupants RS_219
Applicability of national motorcycle helmet law to all road types RS_221
Applicability of national motorcycle helmet law to all engine types RS_222
Requirement of motorcycle helmet use to adhere to standard RS_223
Law requires helmet to be fastened RS_223_BIS
Motorcycle helmet wearing rate (%) RS_224
Existence of a road safety lead agency RS_225
Existence of a national road safety strategy RS_228
Availability of funding for national road safety strategy RS_229
Existence of a national policy on walking and cycling RS_231
Existence of a national policy on public transport RS_232
Existence of road safety audit for all new roads RS_233
Existence of road safety audit for existing roads RS_234
Type of driving tests for new drivers RS_235
Existence of mandatory vehicle insurance RS_236
Existence of a formal pre-hospital care system RS_237
Existence of a universal access telephone number for pre-hospital care RS_238
Reported % of seriously injured patients transported by ambulance RS_239
Training in medical emergency - available for doctors RS_240
Training in medical emergency - available for nurses RS_241
Vehicle standards RS_242
Distribution of road traffic deaths by type of road user (%) RS_246
Gross national income per capita (Atlas method) RS_576
Average - taxes as a % of cigarette price - ad valorem excise R_Ad_val_average
Most sold brand of cigarettes - taxes as a % of price - ad valorem excise R_Ad_val_estimate
Average - cigarette currency R_Curr_average
Cheapest brand of cigarettes - currency reported R_Curr_lowest_cost
Most sold brand of cigarettes - currency reported R_Curr_mp
Premium brand of cigarettes - currency reported R_Curr_premium_cost
Raise taxes on tobacco R_Group
Average - taxes as a % of cigarette price - other taxes R_Other_average
Most sold brand of cigarettes - taxes as a % of price - other taxes R_Other_estimate
Average - cigarette price in currency R_Price_average_curr
Average - cigarette price in international dollars R_Price_average_ppp
Average - cigarette price in US$ at official exchange rates R_Price_average_usd
Cheapest brand of cigarettes - price in currency reported R_Price_lowest_cost_estimate
Cheapest brand of cigarettes - price in international dollars R_Price_lowest_cost_ppp
Cheapest brand of cigarettes - price in US$ at official exchange rates R_Price_lowest_cost_usd
Cheapest brand of cigarettes - price in currency reported R_Price_lowest_estimate
Cheapest brand of cigarettes - price in international dollars R_Price_lowest_ppp
Cheapest brand of cigarettes - price in US$ at official exchange rates R_Price_lowest_usd
Most sold brand of cigarettes - price in currency reported R_Price_mp_estimate
Premium brand of cigarettes - price in US$ at official exchange rates R_Price_mp_estimate (2018 data only)
Most sold brand of cigarettes - price in international dollars R_Price_mp_ppp
Most sold brand of cigarettes - price in US$ at official exchange rates R_Price_mp_usd
Premium brand of cigarettes - price in currency reported R_Price_premium_estimate
Premium brand of cigarettes - price in international dollars R_Price_premium_ppp
Premium brand of cigarettes - price in US$ at official exchange rates R_Price_premium_usd
Average - taxes as a % of cigarette price - specific excise R_Sp_excise_average
Most sold brand of cigarettes - taxes as a % of price - specific excise R_Sp_excise_estimate
Tobacco excises have been increased in the last two years however due to price variability the effect is not necessarily apparent in the tax indicators. R_Tob_tax_incr_text
Average - taxes as a % of cigarette price - value added tax R_VAT_average
Most sold brand of cigarettes - taxes as a % of price - value added tax R_VAT_estimate
Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks) R_admin_duty_free_allowance
Ban on sale of duty-free or excise-free cigarettes R_admin_duty_free_banned
Tax administration: Bans or limits on duty free imports by travellers R_admin_duty_free_limited
Tax administration: Tax stamps applied on tobacco products R_admin_tax_stamps
Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes R_admin_tax_stamps_cig
Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products R_admin_tax_stamps_other
Affordability - category of change since 2008 (more affordable/less affordable/no change) R_afford_cat
Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand R_afford_gdp
Affordability: Cigarettes are less affordable in 2014 compared to 2008 R_afford_less
Price dispersion: Share of cheapest brand price in premium brand price (%) (the higher the % the smaller the gap) R_afford_price_dispersion
Affordability: Price dispersion: share of cheapest brand price in premium brand price (the higher the % the smaller the gap) R_afford_price_dispersion_%
Specific tax component automatically adjusted for inflation (or other) R_afford_tax_auto_adjust
Reported use of earmarked tobacco taxes R_earmarking
Tobacco excises increased over the survey period R_excise_incr
Minimum specific tax applied in ad valorem or mixed excise regime R_excise_min_specific
Tax structure: Excise tax proportion of price R_excise_proportion
Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT) R_excise_retail_price_base
Greater reliance on specific tax in mixed excise regime R_excise_specific_reliance
Type of excise tax applied. R_excise_type
Uniform excise tax applied Yes (Uniform), No (Tiered/varying rates) R_excise_uniform_varied
Average - taxes as a % of cigarette price - import duties R_imp_duty_average
Most sold brand of cigarettes - taxes as a % of price - import duties R_imp_duty_estimate
A minimum price policy is implemented R_min_price_policy
Average - taxes as a % of cigarette price - total tax R_total_tax_average
Most sold brand of cigarettes - taxes as a % of price - total tax R_total_tax_estimate
Congenital syphilis rate per 100 000 live births RateCS
Tobacco tax revenues - valued added tax (VAT) and other sales taxes Rev_VAT
Tobacco tax revenues - currency reported Rev_curr
Tobacco tax revenues - total excise (specific and ad valorem) Rev_excise
Tobacco tax revenues - total revenues Rev_govt_total
Tobacco tax revenues - import duties and all other taxes Rev_imp_other
Tobacco tax revenues - tobacco product types included Rev_type
Tobacco tax revenues - year reported Rev_year
Alcohol, consumption of pure alcohol by type of beverage (%) SA_0000001398
Alcohol, consumption of pure alcohol by type of beverage (%) SA_0000001398_ARCHIVED
Consumption by type of alcoholic beverage - market share (%) SA_0000001399
Consumption by type of alcoholic beverage - market share (%) SA_0000001399_ARCHIVED
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001400
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001400_ARCHIVED
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average SA_0000001401
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average SA_0000001401_ARCHIVED
Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010 SA_0000001402
Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010 SA_0000001402_ARCHIVED
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) SA_0000001403
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) SA_0000001403_ARCHIVED
Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol SA_0000001404
Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol SA_0000001404_ARCHIVED
Alcohol, tourist consumption (in litres of pure alcohol) SA_0000001405
Alcohol, tourist consumption (in litres of pure alcohol) SA_0000001405_ARCHIVED
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001406
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001406_ARCHIVED
Alcohol, abstainers lifetime (%) SA_0000001409
Alcohol, abstainers lifetime (%) SA_0000001409_ARCHIVED
Abstainers (15-19 years), lifetime (%) SA_0000001410
Abstainers (15-19 years), lifetime (%) SA_0000001410_ARCHIVED
Alcohol, abstainers past 12 months (%) SA_0000001411
Alcohol, abstainers past 12 months (%) SA_0000001411_ARCHIVED
Abstainers (15-19 years), past 12 months (%) SA_0000001412
Abstainers (15-19 years), past 12 months (%) SA_0000001412_ARCHIVED
Alcohol, consumers past 12 months (%) SA_0000001413
Alcohol, consumers past 12 months (%) SA_0000001413_ARCHIVED
Alcohol, former drinkers (%) SA_0000001414
Alcohol, former drinkers (%) SA_0000001414_ARCHIVED
Alcohol, heavy episodic drinking (population) past 30 days (%) SA_0000001415
Alcohol, heavy episodic drinking (population) past 30 days (%) SA_0000001415_ARCHIVED
Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%) SA_0000001416
Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%) SA_0000001416_ARCHIVED
Alcohol, patterns of drinking score SA_0000001417
Alcohol, patterns of drinking score SA_0000001417_ARCHIVED
Age-standardized DALYs, alcohol use disorders, per 100,000 SA_0000001418
Age-standardized DALYs, alcohol use disorders, per 100,000 SA_0000001418_ARCHIVED
Age-standardized DALYs, breast cancer, per 100,000 SA_0000001419
Age-standardized DALYs, breast cancer, per 100,000 SA_0000001419_ARCHIVED
Age-standardized DALYs, colon and rectum cancers, per 100,000 SA_0000001420
Age-standardized DALYs, colon and rectum cancers, per 100,000 SA_0000001420_ARCHIVED
Age-standardized DALYs, diabetes mellitus, per 100,000 SA_0000001421
Age-standardized DALYs, diabetes mellitus, per 100,000 SA_0000001421_ARCHIVED
Age-standardized DALYs, drownings, per 100,000 SA_0000001422
Age-standardized DALYs, drownings, per 100,000 SA_0000001422_ARCHIVED
Age-standardized DALYs, falls, per 100,000 SA_0000001423
Age-standardized DALYs, falls, per 100,000 SA_0000001423_ARCHIVED
Age-standardized DALYs, fires, per 100,000 SA_0000001424
Age-standardized DALYs, fires, per 100,000 SA_0000001424_ARCHIVED
Age-standardized DALYs, ischaemic heart disease, per 100,000 SA_0000001425
Age-standardized DALYs, ischaemic heart disease, per 100,000 SA_0000001425_ARCHIVED
Age-standardized DALYs, liver cancer, per 100,000 SA_0000001426
Age-standardized DALYs, liver cancer, per 100,000 SA_0000001426_ARCHIVED
Age-standardized DALYs, liver cirrhosis, per 100,000 SA_0000001427
Age-standardized DALYs, liver cirrhosis, per 100,000 SA_0000001427_ARCHIVED
Age-standardized DALYs, maternal conditions, per 100,000 SA_0000001428
Age-standardized DALYs, maternal conditions, per 100,000 SA_0000001428_ARCHIVED
Age-standardized DALYs, mouth and oropharynx cancer, per 100,000 SA_0000001429
Age-standardized DALYs, mouth and oropharynx cancer, per 100,000 SA_0000001429_ARCHIVED
Age-standardized DALYs, oesophagus cancer, per 100,000 SA_0000001430
Age-standardized DALYs, oesophagus cancer, per 100,000 SA_0000001430_ARCHIVED
Age-standardized DALYs, poisoning, per 100,000 SA_0000001431
Age-standardized DALYs, poisoning, per 100,000 SA_0000001431_ARCHIVED
Age-standardized DALYs, prematurity and low birth rate, per 100,000 SA_0000001432
Age-standardized DALYs, prematurity and low birth rate, per 100,000 SA_0000001432_ARCHIVED
Age-standardized DALYs, road traffic accidents, per 100,000 SA_0000001433
Age-standardized DALYs, road traffic accidents, per 100,000 SA_0000001433_ARCHIVED
Age-standardized DALYs, self-inflicted injury, per 100,000 SA_0000001434
Age-standardized DALYs, self-inflicted injury, per 100,000 SA_0000001434_ARCHIVED
Age-standardized DALYs, other unintentional injuries, per 100,000 SA_0000001435
Age-standardized DALYs, other unintentional injuries, per 100,000 SA_0000001435_ARCHIVED
Age-standardized DALYs, violence, per 100,000 SA_0000001436
Age-standardized DALYs, violence, per 100,000 SA_0000001436_ARCHIVED
Age-standardized death rates, alcohol use disorders, per 100,000 SA_0000001437
Age-standardized death rates, alcohol use disorders, per 100,000 SA_0000001437_ARCHIVED
Age-standardized death rates, breast cancer, per 100,000 SA_0000001438
Age-standardized death rates, breast cancer, per 100,000 SA_0000001438_ARCHIVED
Age-standardized death rates, colon and rectum cancers, per 100,000 SA_0000001439
Age-standardized death rates, colon and rectum cancers, per 100,000 SA_0000001439_ARCHIVED
Age-standardized death rates, diabetes mellitus, per 100,000 SA_0000001440
Age-standardized death rates, diabetes mellitus, per 100,000 SA_0000001440_ARCHIVED
Age-standardized death rates, drownings, per 100,000 SA_0000001441
Age-standardized death rates, drownings, per 100,000 SA_0000001441_ARCHIVED
Age-standardized death rates, falls, per 100,000 SA_0000001442
Age-standardized death rates, falls, per 100,000 SA_0000001442_ARCHIVED
Age-standardized death rates, fires, per 100,000 SA_0000001443
Age-standardized death rates, fires, per 100,000 SA_0000001443_ARCHIVED
Age-standardized death rates, ischaemic heart disease, per 100,000 SA_0000001444
Age-standardized death rates, ischaemic heart disease, per 100,000 SA_0000001444_ARCHIVED
Age-standardized death rates, liver cancer, per 100,000 SA_0000001445
Age-standardized death rates, liver cancer, per 100,000 SA_0000001445_ARCHIVED
Age-standardized death rates, liver cirrhosis, per 100,000 SA_0000001446
Age-standardized death rates, liver cirrhosis, per 100,000 SA_0000001446_ARCHIVED
Age-standardized death rates, maternal conditions, per 100,000 SA_0000001447
Age-standardized death rates, maternal conditions, per 100,000 SA_0000001447_ARCHIVED
Age-standardized death rates, mouth and oropharynx cancer, per 100,000 SA_0000001448
Age-standardized death rates, mouth and oropharynx cancer, per 100,000 SA_0000001448_ARCHIVED
Age-standardized death rates, oesophagus cancer, per 100,000 SA_0000001449
Age-standardized death rates, oesophagus cancer, per 100,000 SA_0000001449_ARCHIVED
Age-standardized death rates, poisoning, per 100,000 SA_0000001450
Age-standardized death rates, poisoning, per 100,000 SA_0000001450_ARCHIVED
Age-standardized death rates, prematurity and low birth rate, per 100,000 SA_0000001451
Age-standardized death rates, prematurity and low birth rate, per 100,000 SA_0000001451_ARCHIVED
Age-standardized death rates, road traffic accidents, per 100,000 SA_0000001452
Age-standardized death rates, road traffic accidents, per 100,000 SA_0000001452_ARCHIVED
Age-standardized death rates, self-inflicted injury, per 100,000 SA_0000001453
Age-standardized death rates, self-inflicted injury, per 100,000 SA_0000001453_ARCHIVED
Age-standardized death rates, other unintentional injuries, per 100,000 SA_0000001454
Age-standardized death rates, other unintentional injuries, per 100,000 SA_0000001454_ARCHIVED
Age-standardized death rates, violence, per 100,000 SA_0000001455
Age-standardized death rates, violence, per 100,000 SA_0000001455_ARCHIVED
Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000 SA_0000001456
Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000 SA_0000001456_ARCHIVED
Liver cirrhosis, age-standardized death rates (15+), per 100,000 population SA_0000001457
Liver cirrhosis, age-standardized death rates (15+), per 100,000 population SA_0000001457_ARCHIVED
Age-standardized death rates (15+ years), poisoning, per 100,000 SA_0000001458
Age-standardized death rates (15+ years), poisoning, per 100,000 SA_0000001458_ARCHIVED
Road traffic injuries, age-standardized death rates (15+), per 100,000 population SA_0000001459
Road traffic injuries, age-standardized death rates (15+), per 100,000 population SA_0000001459_ARCHIVED
Age-standardized death rates (15+ years), violence, per 100,000 SA_0000001460
Age-standardized death rates (15+ years), violence, per 100,000 SA_0000001460_ARCHIVED
Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI SA_0000001461
Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI SA_0000001461_ARCHIVED
Alcohol use disorders (15+), 12 month prevalence (%) with 95% SA_0000001462
Alcohol use disorders (15+), 12 month prevalence (%) with 95% SA_0000001462_ARCHIVED
Alcoholic psychosis, incidence, per 100,000 SA_0000001463
Alcoholic psychosis, incidence, per 100,000 SA_0000001463_ARCHIVED
Cautions and arrests for drink-driving, per 100,000 population SA_0000001464
Cautions and arrests for drink-driving, per 100,000 population SA_0000001464_ARCHIVED
Hospital discharges, alcohol-related injuries and poisoning, per 100,000 SA_0000001465
Hospital discharges, alcohol-related injuries and poisoning, per 100,000 SA_0000001465_ARCHIVED
Hospital discharges, alcoholic liver disease, per 100,000 SA_0000001466
Hospital discharges, alcoholic liver disease, per 100,000 SA_0000001466_ARCHIVED
Perceived trend in alcohol-related harm and consequences SA_0000001467
Perceived trend in alcohol-related harm and consequences SA_0000001467_ARCHIVED
Treatment admissions (inpatient), alcohol dependence, per 100,000 SA_0000001468
Treatment admissions (inpatient), alcohol dependence, per 100,000 SA_0000001468_ARCHIVED
Treatment admissions (inpatient), alcoholic psychosis, per 100,000 SA_0000001469
Treatment admissions (inpatient), alcoholic psychosis, per 100,000 SA_0000001469_ARCHIVED
Alcohol-related road traffic crashes, per 100,000 population SA_0000001470
Alcohol-related road traffic crashes, per 100,000 population SA_0000001470_ARCHIVED
Alcohol-related road traffic crashes (% of all traffic crashes) SA_0000001471
Alcohol-related road traffic crashes (% of all traffic crashes) SA_0000001471_ARCHIVED
Alcohol-related injury mortality, per 1,000 SA_0000001472
Alcohol-related injury mortality, per 1,000 SA_0000001472_ARCHIVED
Alcohol-related disease mortality, per 100,000 (15+ years) SA_0000001473
Alcohol-related disease mortality, per 100,000 (15+ years) SA_0000001473_ARCHIVED
Alcoholic excise tax revenue as a per cent of government revenue SA_0000001474
Alcoholic excise tax revenue as a per cent of government revenue SA_0000001474_ARCHIVED
Annual revenues from alcohol excise tax in millions US$ SA_0000001475
Annual revenues from alcohol excise tax in millions US$ SA_0000001475_ARCHIVED
Alcohol expenditure as a per cent of total household expenditure SA_0000001476
Alcohol expenditure as a per cent of total household expenditure SA_0000001476_ARCHIVED
Social costs of alcohol use in millions US$ SA_0000001477
Social costs of alcohol use in millions US$ SA_0000001477_ARCHIVED
Adopted written national policy on alcohol SA_0000001502
Adopted written national policy on alcohol SA_0000001502_ARCHIVED
Alcoholic beverage legally defined SA_0000001503
Alcoholic beverage legally defined SA_0000001503_ARCHIVED
Alcohol use is banned SA_0000001504
Alcohol use is banned SA_0000001504_ARCHIVED
Surrogate alcohol consumption is a problem SA_0000001505
Surrogate alcohol consumption is a problem SA_0000001505_ARCHIVED
National legislation to prevent illegal alcohol SA_0000001506
National legislation to prevent illegal alcohol SA_0000001506_ARCHIVED
Advertising restrictions on national television SA_0000001507
Advertising restrictions on national television SA_0000001507_ARCHIVED
Advertising restrictions on cable television SA_0000001508
Advertising restrictions on cable television SA_0000001508_ARCHIVED
Advertising restrictions on national radio SA_0000001509
Advertising restrictions on national radio SA_0000001509_ARCHIVED
Advertising restrictions on local radio SA_0000001510
Advertising restrictions on local radio SA_0000001510_ARCHIVED
Advertising restrictions in print media SA_0000001511
Advertising restrictions in print media SA_0000001511_ARCHIVED
Advertising restrictions at cinemas SA_0000001512
Advertising restrictions at cinemas SA_0000001512_ARCHIVED
Advertising restrictions on billboards SA_0000001513
Advertising restrictions on billboards SA_0000001513_ARCHIVED
Advertising restrictions at point-of-sale SA_0000001514
Advertising restrictions at point-of-sale SA_0000001514_ARCHIVED
Advertising restrictions on the internet SA_0000001515
Advertising restrictions on the internet SA_0000001515_ARCHIVED
Restrictions on product placement on national television SA_0000001516
Restrictions on product placement on national television SA_0000001516_ARCHIVED
Restrictions on product placement on cable television SA_0000001517
Restrictions on product placement on cable television SA_0000001517_ARCHIVED
Age limits on-premise service SA_0000001518
Age limits on-premise service SA_0000001518_ARCHIVED
Minimum legal drinking age SA_0000001519
Minimum legal drinking age SA_0000001519_ARCHIVED
Legal blood alcohol concentration (BAC) limits SA_0000001520
Legal blood alcohol concentration (BAC) limits SA_0000001520_ARCHIVED
Random breath testing (RBT) use SA_0000001521
Random breath testing (RBT) use SA_0000001521_ARCHIVED
Mandatory driver education for habitual offenders SA_0000001522
Mandatory driver education for habitual offenders SA_0000001522_ARCHIVED
Prices for alcoholic beverages (average, US\() |SA_0000001523 | |Prices for alcoholic beverages (average, US\)) SA_0000001523_ARCHIVED
Trend in real price of alcoholic beverages relative to CPI over the past five years SA_0000001524
Trend in real price of alcoholic beverages relative to CPI over the past five years SA_0000001524_ARCHIVED
Off-premise sales restrictions on days SA_0000001525
Off-premise sales restrictions on days SA_0000001525_ARCHIVED
Off-premise sales restrictions on hours SA_0000001526
Off-premise sales restrictions on hours SA_0000001526_ARCHIVED
Off-premise sales restrictions on places SA_0000001527
Off-premise sales restrictions on places SA_0000001527_ARCHIVED
Off-premise sales restrictions on outlet density SA_0000001528
Off-premise sales restrictions on outlet density SA_0000001528_ARCHIVED
Off-premise sales restrictions at specific events SA_0000001529
Off-premise sales restrictions at specific events SA_0000001529_ARCHIVED
Off-premise sales restrictions at petrol stations SA_0000001530
Off-premise sales restrictions at petrol stations SA_0000001530_ARCHIVED
On-premise sales restrictions on days SA_0000001531
On-premise sales restrictions on days SA_0000001531_ARCHIVED
On-premise sales restrictions on hours SA_0000001532
On-premise sales restrictions on hours SA_0000001532_ARCHIVED
On-premise sales restrictions on places SA_0000001533
On-premise sales restrictions on places SA_0000001533_ARCHIVED
On-premise sales restrictions on outlet density SA_0000001534
On-premise sales restrictions on outlet density SA_0000001534_ARCHIVED
On-premise sales restrictions at specific events SA_0000001535
On-premise sales restrictions at specific events SA_0000001535_ARCHIVED
On-premise sales restrictions to intoxicated persons SA_0000001536
On-premise sales restrictions to intoxicated persons SA_0000001536_ARCHIVED
Restrictions on sponsorship of sporting events SA_0000001537
Restrictions on sponsorship of sporting events SA_0000001537_ARCHIVED
Restrictions on sponsorship of youth events SA_0000001538
Restrictions on sponsorship of youth events SA_0000001538_ARCHIVED
Restrictions on sales promotion from producers (parties, events) SA_0000001539
Restrictions on sales promotion from producers (parties, events) SA_0000001539_ARCHIVED
Restrictions on sales promotion from retailers (sales below cost) SA_0000001540
Restrictions on sales promotion from retailers (sales below cost) SA_0000001540_ARCHIVED
Restrictions on sales promotion from owners of pubs and bars (alcohol for free) SA_0000001541
Restrictions on sales promotion from owners of pubs and bars (alcohol for free) SA_0000001541_ARCHIVED
Government monopoly on production SA_0000001542
Government monopoly on production SA_0000001542_ARCHIVED
Government monopoly on retail sales SA_0000001543
Government monopoly on retail sales SA_0000001543_ARCHIVED
Licence required for production SA_0000001544
Licence required for production SA_0000001544_ARCHIVED
Licence required for retail sales SA_0000001545
Licence required for retail sales SA_0000001545_ARCHIVED
Excise tax as a per cent of the retail price of alcoholic beverages SA_0000001546
Excise tax as a per cent of the retail price of alcoholic beverages SA_0000001546_ARCHIVED
Excise duty (average) per hectolitre in Euros SA_0000001547
Excise duty (average) per hectolitre in Euros SA_0000001547_ARCHIVED
Excise tax as a per cent of the total retail price for 1 litre of pure alcohol SA_0000001548
Excise tax as a per cent of the total retail price for 1 litre of pure alcohol SA_0000001548_ARCHIVED
Duty paid or excise stamp on alcohol container SA_0000001549
Duty paid or excise stamp on alcohol container SA_0000001549_ARCHIVED
Excise tax on alcoholic beverages SA_0000001550
Excise tax on alcoholic beverages SA_0000001550_ARCHIVED
Value-added tax (VAT) on alcohol (%) SA_0000001551
Value-added tax (VAT) on alcohol (%) SA_0000001551_ARCHIVED
Value-added tax (VAT), (%) SA_0000001552
Value-added tax (VAT), (%) SA_0000001552_ARCHIVED
Restrictions on alcohol use in public places SA_0000001553
Restrictions on alcohol use in public places SA_0000001553_ARCHIVED
Health warning labels on alcohol advertising SA_0000001554
Health warning labels on alcohol advertising SA_0000001554_ARCHIVED
Health warning labels on alcohol containers SA_0000001555
Health warning labels on alcohol containers SA_0000001555_ARCHIVED
Awareness activities SA_0000001647
Awareness activities SA_0000001647_ARCHIVED
Information, education, prevention SA_0000001648
Information, education, prevention SA_0000001648_ARCHIVED
National drinking guidelines SA_0000001649
National drinking guidelines SA_0000001649_ARCHIVED
Standard drink measures, in grams per unit SA_0000001650
Standard drink measures, in grams per unit SA_0000001650_ARCHIVED
Monitoring SA_0000001651
Monitoring SA_0000001651_ARCHIVED
Interventions, projects, training SA_0000001652
Interventions, projects, training SA_0000001652_ARCHIVED
Treatment, services SA_0000001653
Treatment, services SA_0000001653_ARCHIVED
Surveys, research SA_0000001654
Surveys, research SA_0000001654_ARCHIVED
Counselling SA_0000001655
Counselling SA_0000001655_ARCHIVED
Production in 1000s hectolitres SA_0000001676
Production in 1000s hectolitres SA_0000001676_ARCHIVED
Imports in 1000s hectolitres SA_0000001677
Imports in 1000s hectolitres SA_0000001677_ARCHIVED
Sales of beer in 1000s hectolitres SA_0000001678
Sales of beer in 1000s hectolitres SA_0000001678_ARCHIVED
Exports of beer (barley) in 1000s hectolitres SA_0000001679
Exports of beer (barley) in 1000s hectolitres SA_0000001679_ARCHIVED
Perceived trend in production SA_0000001680
Perceived trend in production SA_0000001680_ARCHIVED
Perceived trend in imports SA_0000001681
Perceived trend in imports SA_0000001681_ARCHIVED
Perceived trend in sales SA_0000001682
Perceived trend in sales SA_0000001682_ARCHIVED
Perceived trend in exports SA_0000001683
Perceived trend in exports SA_0000001683_ARCHIVED
Sales of wine in 1000s hectolitres SA_0000001684
Sales of wine in 1000s hectolitres SA_0000001684_ARCHIVED
Sales of spirits in 1000s hectolitres SA_0000001685
Sales of spirits in 1000s hectolitres SA_0000001685_ARCHIVED
Exports of wine (grape) in 1000s hectolitres SA_0000001686
Exports of wine (grape) in 1000s hectolitres SA_0000001686_ARCHIVED
Exports of spirits in 1000s hectolitres SA_0000001687
Exports of spirits in 1000s hectolitres SA_0000001687_ARCHIVED
Total (recorded+unrecorded) alcohol per capita (15+) consumption SA_0000001688
Total (recorded+unrecorded) alcohol per capita (15+) consumption SA_0000001688_ARCHIVED
Age-standardized DALYs, cerebrovascular disease, per 100,000 SA_0000001689
Age-standardized DALYs, cerebrovascular disease, per 100,000 SA_0000001689_ARCHIVED
Age-standardized death rates, cerebrovascular disease, per 100,000 SA_0000001690
Age-standardized death rates, cerebrovascular disease, per 100,000 SA_0000001690_ARCHIVED
Central coordinating entity for alcohol policy implementation SA_0000001691
Central coordinating entity for alcohol policy implementation SA_0000001691_ARCHIVED
Framework of national alcohol policy SA_0000001692
Framework of national alcohol policy SA_0000001692_ARCHIVED
Level of adoption of national alcohol policy SA_0000001693
Level of adoption of national alcohol policy SA_0000001693_ARCHIVED
Sectors represented in national alcohol policy SA_0000001694
Sectors represented in national alcohol policy SA_0000001694_ARCHIVED
Cautions and arrests for public drunkenness, per 100,000 population SA_0000001695
Cautions and arrests for public drunkenness, per 100,000 population SA_0000001695_ARCHIVED
Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities) SA_0000001696
Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities) SA_0000001696_ARCHIVED
Adopted written national policy on alcohol, year adopted SA_0000001697
Adopted written national policy on alcohol, year adopted SA_0000001697_ARCHIVED
Adopted written national policy on alcohol, year revised SA_0000001698
Adopted written national policy on alcohol, year revised SA_0000001698_ARCHIVED
Age limits off-premise sales SA_0000001699
Age limits off-premise sales SA_0000001699_ARCHIVED
Consumer information on alcohol and health at points of sale SA_0000001700
Consumer information on alcohol and health at points of sale SA_0000001700_ARCHIVED
Educational programmes involving target groups in school curriculum SA_0000001701
Educational programmes involving target groups in school curriculum SA_0000001701_ARCHIVED
Brief interventions as health promotion/disease prevention SA_0000001702
Brief interventions as health promotion/disease prevention SA_0000001702_ARCHIVED
Server training on a regular basis SA_0000001703
Server training on a regular basis SA_0000001703_ARCHIVED
Data collection on alcohol-related health indicators SA_0000001704
Data collection on alcohol-related health indicators SA_0000001704_ARCHIVED
System for monitoring alcohol-related harm SA_0000001705
System for monitoring alcohol-related harm SA_0000001705_ARCHIVED
National treatment policy for alcohol use disorders SA_0000001706
National treatment policy for alcohol use disorders SA_0000001706_ARCHIVED
Persons with alcohol use disorders receiving treatment (%) SA_0000001707
Persons with alcohol use disorders receiving treatment (%) SA_0000001707_ARCHIVED
Designation of alcohol tax revenues to health services SA_0000001708
Designation of alcohol tax revenues to health services SA_0000001708_ARCHIVED
National surveys on drink-driving SA_0000001709
National surveys on drink-driving SA_0000001709_ARCHIVED
Public-funded alcohol research/monitoring programmes SA_0000001710
Public-funded alcohol research/monitoring programmes SA_0000001710_ARCHIVED
Public funds designated for alcohol research/monitoring programmes, in Euros SA_0000001711
Public funds designated for alcohol research/monitoring programmes, in Euros SA_0000001711_ARCHIVED
Community-based interventions/projects involving stakeholders SA_0000001712
Community-based interventions/projects involving stakeholders SA_0000001712_ARCHIVED
Interventions/projects actively involving young people and civil society SA_0000001713
Interventions/projects actively involving young people and civil society SA_0000001713_ARCHIVED
Training in screening and brief interventions for alcohol problems SA_0000001714
Training in screening and brief interventions for alcohol problems SA_0000001714_ARCHIVED
Counselling to children in families with alcohol problems SA_0000001715
Counselling to children in families with alcohol problems SA_0000001715_ARCHIVED
Counselling to pregnant women with alcohol problems SA_0000001716
Counselling to pregnant women with alcohol problems SA_0000001716_ARCHIVED
Prevention/counselling at workplaces for those with alcohol problems SA_0000001717
Prevention/counselling at workplaces for those with alcohol problems SA_0000001717_ARCHIVED
Action Plan for implementation of alcohol policy SA_0000001718
Action Plan for implementation of alcohol policy SA_0000001718_ARCHIVED
Advertising restrictions on social media SA_0000001719
Advertising restrictions on social media SA_0000001719_ARCHIVED
Restrictions on product placement in films/movies SA_0000001720
Restrictions on product placement in films/movies SA_0000001720_ARCHIVED
Importance of measures for enhancing compliance with age limits SA_0000001721
Importance of measures for enhancing compliance with age limits SA_0000001721_ARCHIVED
Government support for community action SA_0000001722
Government support for community action SA_0000001722_ARCHIVED
Community-based interventions involving stakeholders SA_0000001723
Community-based interventions involving stakeholders SA_0000001723_ARCHIVED
National guidelines for implementing effective community-based interventions SA_0000001724
National guidelines for implementing effective community-based interventions SA_0000001724_ARCHIVED
National alcohol policy specifically involves young people activities SA_0000001725
National alcohol policy specifically involves young people activities SA_0000001725_ARCHIVED
Penalties for drink driving SA_0000001726
Penalties for drink driving SA_0000001726_ARCHIVED
Sobriety checkpoints SA_0000001727
Sobriety checkpoints SA_0000001727_ARCHIVED
Detection of marketing infringements SA_0000001728
Detection of marketing infringements SA_0000001728_ARCHIVED
Penalties for marketing infringements SA_0000001729
Penalties for marketing infringements SA_0000001729_ARCHIVED
Price measures SA_0000001730
Price measures SA_0000001730_ARCHIVED
Level of taxation adjusted for inflation SA_0000001731
Level of taxation adjusted for inflation SA_0000001731_ARCHIVED
New types of alcoholic beverages emerging SA_0000001732
New types of alcoholic beverages emerging SA_0000001732_ARCHIVED
Consumer information about calories, additives, etc on containers SA_0000001733
Consumer information about calories, additives, etc on containers SA_0000001733_ARCHIVED
Number of standard alcoholic drinks displayed on containers SA_0000001734
Number of standard alcoholic drinks displayed on containers SA_0000001734_ARCHIVED
Alcohol content displayed on containers SA_0000001735
Alcohol content displayed on containers SA_0000001735_ARCHIVED
Action Plan for implementation of alcohol policy SA_0000001736
Action Plan for implementation of alcohol policy SA_0000001736_ARCHIVED
Alcohol, regional per capita (15+) consumption (in litres of pure alcohol) SA_0000001737
Alcohol, regional per capita (15+) consumption (in litres of pure alcohol) SA_0000001737_ARCHIVED
Regional alcohol per capita (15+) consumption- total SA_0000001738
Regional alcohol per capita (15+) consumption- total SA_0000001738_ARCHIVED
Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI SA_0000001739
Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI SA_0000001739_ARCHIVED
Alcohol-attributable Years of Life Lost (YLL) score SA_0000001740
Alcohol-attributable Years of Life Lost (YLL) score SA_0000001740_ARCHIVED
Alcohol-attributable fractions (15+), liver cirrhosis deaths (%) SA_0000001741
Alcohol-attributable fractions (15+), liver cirrhosis deaths (%) SA_0000001741_ARCHIVED
Alcohol-attributable fractions (15+), road traffic crash deaths (%) SA_0000001742
Alcohol-attributable fractions (15+), road traffic crash deaths (%) SA_0000001742_ARCHIVED
Alcohol-attributable fractions, all-cause deaths (%) SA_0000001743
Alcohol-attributable fractions, all-cause deaths (%) SA_0000001743_ARCHIVED
Alcohol, regional prevalence of alcohol dependence (%) SA_0000001744
Alcohol, regional prevalence of alcohol dependence (%) SA_0000001744_ARCHIVED
Alcohol, regional prevalence of alcohol use disorders (%) SA_0000001745
Alcohol, regional prevalence of alcohol use disorders (%) SA_0000001745_ARCHIVED
Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025 SA_0000001746
Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025 SA_0000001746_ARCHIVED
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI SA_0000001747
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI SA_0000001747_ARCHIVED
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001748
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001748_ARCHIVED
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001749
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001749_ARCHIVED
Average daily intake in grams of alcohol among drinkers SA_0000001750
Average daily intake in grams of alcohol among drinkers SA_0000001750_ARCHIVED
Alcohol, average daily intake in grams among drinkers with 95%CI SA_0000001751
Alcohol, average daily intake in grams among drinkers with 95%CI SA_0000001751_ARCHIVED
Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016 SA_0000001752
Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016 SA_0000001752_ARCHIVED
Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI SA_0000001753
Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI SA_0000001753_ARCHIVED
Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI SA_0000001754
Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI SA_0000001754_ARCHIVED
15-19 years old heavy episodic drinkers (population), % with 95%CI SA_0000001755
15-19 years old heavy episodic drinkers (population), % with 95%CI SA_0000001755_ARCHIVED
15-19 years old heavy episodic drinkers (drinkers only), % SA_0000001756
15-19 years old heavy episodic drinkers (drinkers only), % SA_0000001756_ARCHIVED
15-19 years old abstainers, lifetime (%) SA_0000001757
15-19 years old abstainers, lifetime (%) SA_0000001757_ARCHIVED
15-19 years old former drinkers (%) SA_0000001758
15-19 years old former drinkers (%) SA_0000001758_ARCHIVED
15-19 years old, current drinkers (%) SA_0000001759
15-19 years old, current drinkers (%) SA_0000001759_ARCHIVED
15-19 years old total alcohol consumption in litres of pure alcohol SA_0000001760
15-19 years old total alcohol consumption in litres of pure alcohol SA_0000001760_ARCHIVED
National guidelines for the prevention and reduction of alcohol-related harm in schools SA_0000001761
National guidelines for the prevention and reduction of alcohol-related harm in schools SA_0000001761_ARCHIVED
National guidelines for alcohol problem prevention and counselling at workplaces SA_0000001762
National guidelines for alcohol problem prevention and counselling at workplaces SA_0000001762_ARCHIVED
Workplace representatives nationally involved to prevent and address alcohol-related harm SA_0000001763
Workplace representatives nationally involved to prevent and address alcohol-related harm SA_0000001763_ARCHIVED
Server training SA_0000001764
Server training SA_0000001764_ARCHIVED
Legal obligation for schools to include alcohol use prevention SA_0000001765
Legal obligation for schools to include alcohol use prevention SA_0000001765_ARCHIVED
Legal obligation for schools to interact with parents regarding education and well-being SA_0000001766
Legal obligation for schools to interact with parents regarding education and well-being SA_0000001766_ARCHIVED
Legislation on alcohol testing at workplaces SA_0000001767
Legislation on alcohol testing at workplaces SA_0000001767_ARCHIVED
Standard drink defined SA_0000001768
Standard drink defined SA_0000001768_ARCHIVED
National systems for monitoring alcohol consumption and harms SA_0000001769
National systems for monitoring alcohol consumption and harms SA_0000001769_ARCHIVED
Regular reports from national monitoring systems SA_0000001770
Regular reports from national monitoring systems SA_0000001770_ARCHIVED
Comprehensive and regular reporting of alcohol situation SA_0000001771
Comprehensive and regular reporting of alcohol situation SA_0000001771_ARCHIVED
Clinical guidelines for brief interventions SA_0000001772
Clinical guidelines for brief interventions SA_0000001772_ARCHIVED
National surveys on adult alcohol consumption SA_0000001773
National surveys on adult alcohol consumption SA_0000001773_ARCHIVED
National surveys on youth alcohol consumption SA_0000001774
National surveys on youth alcohol consumption SA_0000001774_ARCHIVED
National surveys on heavy espisodic drinking SA_0000001775
National surveys on heavy espisodic drinking SA_0000001775_ARCHIVED
Data collection on Foetal Alcohol Syndome SA_0000001776
Data collection on Foetal Alcohol Syndome SA_0000001776_ARCHIVED
Data collected on harm from alcohol at workplace SA_0000001777
Data collected on harm from alcohol at workplace SA_0000001777_ARCHIVED
New types of alcoholic beverages emerging SA_0000001778
New types of alcoholic beverages emerging SA_0000001778_ARCHIVED
Level of enforcement of BAC limits SA_0000001779
Level of enforcement of BAC limits SA_0000001779_ARCHIVED
15-years old any alcoholic beverage consumed at least once in lifetime, (%) SA_0000001780
15-years old any alcoholic beverage consumed at least once in lifetime, (%) SA_0000001780_ARCHIVED
15-years old any alcoholic beverage consumed in past 12 months, (%) SA_0000001781
15-years old any alcoholic beverage consumed in past 12 months, (%) SA_0000001781_ARCHIVED
15-years old first drink at 13 years or younger, (%) SA_0000001782
15-years old first drink at 13 years or younger, (%) SA_0000001782_ARCHIVED
15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001783
15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001783_ARCHIVED
15-years old, any alcoholic beverage consumed at least once a week, (%) SA_0000001784
15-years old, any alcoholic beverage consumed at least once a week, (%) SA_0000001784_ARCHIVED
15-years old ever got drunk in the past 30 days, (%) SA_0000001785
15-years old ever got drunk in the past 30 days, (%) SA_0000001785_ARCHIVED
13-15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001786
13-15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001786_ARCHIVED
13-15-years old first drink before age 14, (%) SA_0000001787
13-15-years old first drink before age 14, (%) SA_0000001787_ARCHIVED
Alcohol-related road traffic crashes with fatalities, per 100,000 population SA_0000001788
Alcohol-related road traffic crashes with fatalities, per 100,000 population SA_0000001788_ARCHIVED
Alcohol-related crimes (% of all crimes) SA_0000001789
Alcohol-related crimes (% of all crimes) SA_0000001789_ARCHIVED
National drinking guidelines SA_0000001790
National drinking guidelines SA_0000001790_ARCHIVED
Graduated licensing SA_0000001791
Graduated licensing SA_0000001791_ARCHIVED
National legislation to prevent illegal alcohol sales SA_0000001792
National legislation to prevent illegal alcohol sales SA_0000001792_ARCHIVED
Penalties for drink driving, repeated offense SA_0000001793
Penalties for drink driving, repeated offense SA_0000001793_ARCHIVED
Licensing required for exports of alcoholic beverages SA_0000001794
Licensing required for exports of alcoholic beverages SA_0000001794_ARCHIVED
Licensing required for imports of alcoholic beverages SA_0000001795
Licensing required for imports of alcoholic beverages SA_0000001795_ARCHIVED
Licensing required for wholesale/distribution of alcoholic beverages SA_0000001796
Licensing required for wholesale/distribution of alcoholic beverages SA_0000001796_ARCHIVED
Licenses issued for production, change since 2010 SA_0000001797
Licenses issued for production, change since 2010 SA_0000001797_ARCHIVED
Licenses issued for retail sale, change since 2010 SA_0000001798
Licenses issued for retail sale, change since 2010 SA_0000001798_ARCHIVED
Licenses issued for wholesale/distribution, change since 2010 SA_0000001799
Licenses issued for wholesale/distribution, change since 2010 SA_0000001799_ARCHIVED
Monopoly on exports of alcoholic beverages SA_0000001800
Monopoly on exports of alcoholic beverages SA_0000001800_ARCHIVED
Monopoly on imports of alcoholic beverages SA_0000001801
Monopoly on imports of alcoholic beverages SA_0000001801_ARCHIVED
Monopoly on wholesale /distribution of alcoholic beverages SA_0000001802
Monopoly on wholesale /distribution of alcoholic beverages SA_0000001802_ARCHIVED
Health warning labels on pregnancy SA_0000001803
Health warning labels on pregnancy SA_0000001803_ARCHIVED
Health warning labels on under-age drinking SA_0000001804
Health warning labels on under-age drinking SA_0000001804_ARCHIVED
Health warning labels on drink-driving SA_0000001805
Health warning labels on drink-driving SA_0000001805_ARCHIVED
Legal requirement for size of health warning labels SA_0000001806
Legal requirement for size of health warning labels SA_0000001806_ARCHIVED
Cancer, age-standardized death rates (15+), per 100,000 population SA_0000001807
Cancer, age-standardized death rates (15+), per 100,000 population SA_0000001807_ARCHIVED
Alcohol-attributable fractions (15+), cancer deaths SA_0000001808
National system of epidemiological data collection for alcohol use SA_0000001809
National system of epidemiological data collection for alcohol use SA_0000001809_ARCHIVED
National system of data collection based on health service delivery SA_0000001810
National system of data collection based on health service delivery SA_0000001810_ARCHIVED
Report with epidemiological data on lcohol use and AUDs SA_0000001811
Report with epidemiological data on lcohol use and AUDs SA_0000001811_ARCHIVED
Report with data from health services on alcohol use and AUDs SA_0000001812
Report with data from health services on alcohol use and AUDs SA_0000001812_ARCHIVED
National organization for monitoring alcohol SA_0000001813
National organization for monitoring alcohol SA_0000001813_ARCHIVED
Taxation of ethanol production SA_0000001814
Taxation of ethanol production SA_0000001814_ARCHIVED
Ethanol tax deducted from excise tax SA_0000001815
Ethanol tax deducted from excise tax SA_0000001815_ARCHIVED
Tax incentives for production low/no alcohol content beer SA_0000001816
Tax incentives for production low/no alcohol content beer SA_0000001816_ARCHIVED
Tax incentives for production of other alcoholic beverages SA_0000001817
Tax incentives for production of other alcoholic beverages SA_0000001817_ARCHIVED
Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2020 and 2025 SA_0000001818
Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2020 and 2025 SA_0000001818_ARCHIVED
Heavy episodic drinking (youth 15 -19 years) past 30 days (%) SA_0000001819
Heavy episodic drinking (youth 15 -19 years) past 30 days (%) SA_0000001819_ARCHIVED
Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%) SA_0000001820
Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%) SA_0000001820_ARCHIVED
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001821
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001821_ARCHIVED
Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001822
Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001822_ARCHIVED
Alcohol, tourist consumption (in litres of pure alcohol) SA_0000001823
Alcohol, tourist consumption (in litres of pure alcohol) SA_0000001823_ARCHIVED
Alcohol, regional alcohol per capita (15+) consumption (in litres of pure alcohol) SA_0000001824
Alcohol, regional alcohol per capita (15+) consumption (in litres of pure alcohol) SA_0000001824_ARCHIVED
Regional prevalence, AAFs (15+), liver cirrhosis deaths (%) SA_0000001825
Regional prevalence, AAFs (15+), liver cirrhosis deaths (%) SA_0000001825_ARCHIVED
Regional prevalence, AAFs (15+), road traffic crash deaths (%) SA_0000001826
Regional prevalence, AAFs (15+), road traffic crash deaths (%) SA_0000001826_ARCHIVED
Regional prevalence, AAFs (15+), cancer SA_0000001827
Regional prevalence, AAFs (15+), cancer SA_0000001827_ARCHIVED
Regional prevalence, AAFs ,all-cause deaths (%) SA_0000001828
Regional prevalence, AAFs ,all-cause deaths (%) SA_0000001828_ARCHIVED
Average price 500 mls Beer in US$ SA_0000001829
Average price 500 mls Beer in US$ SA_0000001829_ARCHIVED
Average price 750 mls Wine in US$ SA_0000001830
Average price 750 mls Wine in US$ SA_0000001830_ARCHIVED
Average price 500 mls Spirits in US$ SA_0000001831
Average price 500 mls Spirits in US$ SA_0000001831_ARCHIVED
Alcohol-attributable all-cause deaths per 100,000, age standardized SA_0000001832
Alcohol-attributable DALYs per 100,000 people (age standardized) SA_0000001833
Percent of all DALYs attributable to alcohol SA_0000001834
Alcohol-related road traffic deaths, per 100,000 population SA_0000001835
Alcohol-related road traffic deaths (% of all road traffic deaths) SA_0000001836
Alcohol poisoning deaths, per 100,000 population SA_0000001837
Alcohol-related cardiomyopathy deaths (% of all cardiomyopathy deaths) SA_0000001838
Adolescent birth rate (births per 1 000 women aged 15-19) SDGABR
Ambient and household air pollution attributable death rate (per 100 000 population) SDGAIRBOD
Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized) SDGAIRBODA
Completeness of cause-of-death data (%) SDGCODCOMPLETENESS
Estimated direct deaths from major conflicts (per 100 000 population) SDGCONFLICT
Average death rate due to natural disasters (per 100 000 population) SDGDISASTER
Married or in-union women of reproductive age who have their need for family planning satisfied with modern methods (%) SDGFP
Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%) SDGFPALL
Proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis SDGHEALTHFACILITIESESSENTIALMEDS
Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%) SDGHEPHBSAGPRV
New HIV infections (per 1000 uninfected population) SDGHIV
New HIV infections among adults 15-24 years old (per 1000 uninfected population) SDGHIV1524
Girls aged 15 years old that received the recommended doses of HPV vaccine (%) SDGHPVRECEIVED
Average of 13 International Health Regulations core capacity scores, 1st version of the questionnaire SDGIHR
Average of 13 International Health Regulations core capacity scores, SPAR version SDGIHR2018
Proportion of ever-partnered women and girls aged 15-49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months SDGIPV
Malaria incidence (per 1 000 population at risk) SDGMALARIA
Reported number of people requiring interventions against NTDs SDGNTDTREATMENT
Total net official development assistance to medical research and basic health sectors per capita (constant 2014 US\(), by recipient |SDGODA | |Total net official development assistance to medical research and basic health sectors per capita (US\)), by recipient country SDGODA01
Official development assistance for medical research and basic health sectors as a percentage of GNI (%), by donor country SDGODA02
Amount of water- and sanitation-related official development assistance that is part of a government-coordinated spending plan (constant 2016 US$ millions) SDGODAWS
Out-of-pocket expenditure as a percentage of total expenditure on health SDGOOP
Concentrations of fine particulate matter (PM2.5) SDGPM25
Mortality rate attributed to unintentional poisoning (per 100 000 population) SDGPOISON
Proportion of population with primary reliance on clean fuels and technologies (%) SDGPOLLUTINGFUELS
Age-standardized road traffic mortality (per 100 000 population) SDGROADAGE
Proportion of births attended by skilled health personnel (%) SDGSAB
Skilled health professionals density (per 10 000 population) SDGSHP
Crude suicide rates (per 100 000 population) SDGSUICIDE
Prevalence of current tobacco use among persons aged 15 years and older (age-standardized rate) SDGTOBACCO
Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2) SDGWSHBOD
Number of deaths attributed to non-communicable diseases, by type of disease and sex SDG_SH_DTH_RNCOM
Number of suicide deaths SDG_SH_STA_SCIDEN
Children aged 36-59 months who are developmentally on track in at least three of the following domains: literacy-numeracy, physical development, social-emotional development and learning (%) SE_DEV_ONTRK
Proportion of children in grades 2/3 achieving at least a minimum proficiency level in mathematics (%) SE_G23_MATH
Proportion of children in grades 2/3 achieving at least a minimum proficiency level in reading (%) SE_G23_RDG
Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in mathematics (%) SE_LSC_MATH
Proportion of children at the end of lower secondary achieving at least a minimum proficiency level in reading (%) SE_LSC_RDNG
Participation rate in organized learning (one year before the official primary entry age) (%) SE_PRE_PARTN
Proportion of children at the end of primary achieving at least a minimum proficiency level in mathematics (%) SE_PRM_MATH
Persistence to last grade of primary (% of cohort) SE_PRM_PRSL_ZS
Proportion of children at the end of primary achieving at least a minimum proficiency level in reading (%) SE_PRM_RDNG
Proportion of women aged 15-49 years who make their own informed decisions regarding sexual relations, contraceptive use and reproductive health care (%) SG_DMK_SRCR_FN_ZS
Proportion of children under 5 years of age whose births have been registered with a civil authority SG_REG_BRTH
Proportion of countries that have conducted at least one population and housing census in the last 10 years (%) SG_REG_CENSUS
Number of countries that have conducted at least one population and housing census in the last 10 years SG_REG_CENSUSN
Percentage of children under 15 years exposed to second-hand smoke SHS_1
Second-hand smoke attributable DALYs (’000) in children under 5 years SHS_10
Second-hand smoke attributable DALYs per 100’000 children under 5 years SHS_11
Percentage of women (15+ years) exposed to second-hand smoke SHS_2
Percentage of men (15+ years) exposed to second-hand smoke SHS_3
Second-hand smoke attributable deaths SHS_4
Second-hand smoke attributable DALYs (’000) SHS_5
Second-hand smoke attributable deaths per 100’000 capita SHS_6
Second-hand smoke attributable DALYs per 100’000 capita SHS_7
Second-hand smoke attributable deaths (’000) in children under 5 years SHS_8
Second-hand smoke attributable deaths per 100’000 children under 5 years SHS_9
Proportion of girls and women aged 15-49 years who have undergone female genital mutilation/cutting (FMG/C) (%) SH_STA_FGMS
Proportion of population below the international poverty line of US$1.90 per day (%) SI_POV_DAY1
Employed population below the international poverty line of US\(1.90 per day (the working poor) (%) |SI_POV_EMP1 | |Proportion of women aged 20-24 years who were married or in a union by age 15 (%) |SP_DYN_MRBF15 | |Proportion of women aged 20-24 years who were married or in a union by age 18 (%) |SP_DYN_MRBF18 | |Institutional Births (birth taken place in a facility) (%) |SRHINSTITUTIONALBIRTH | |Existence of national regulation |SUNBEDEXIST | |Existence of subnational regulation |SUNBEDEXISTSUBNATIONAL | |Year of national implementation of regulation |SUNBEDEXISTYEAR | |Access restrictions |SUNBEDREG_ACCESS | |Restriction and inspection of facilities |SUNBEDREG_CONTROL | |Information requirements |SUNBEDREG_INFO | |Safety requirements |SUNBEDREG_SAFETY | |Training requirements |SUNBEDREG_TRAINING | |Tuberculosis treatment coverage |TB_1 | |Case detection rate for all forms of tuberculosis |TB_8_c_cdr | |New cases tested for RR-/MDR-TB (%) |TB_c_dst_rlt_new_pct | |Previously treated cases tested for RR-/MDR-TB (%) |TB_c_dst_rlt_ret_pct | |Laboratories providing tuberculosis diagnostic services using culture (per 5 million population) |TB_c_lab_cul_5m | |Laboratories providing drug susceptibility testing (DST) (per 5 million population) |TB_c_lab_dst_5m | |Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population) |TB_c_lab_sm_100k | |Treatment success rate for patients treated for MDR-TB (%) |TB_c_mdr_tsr | |Cases started on MDR-TB treatment |TB_c_mdr_tx | |Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases |TB_c_new_snep_tsr | |Treatment success rate: new TB cases |TB_c_new_tsr | |Tuberculosis - new and relapse cases |TB_c_newinc | |Total number of notified TB cases |TB_c_notified | |Treatment success rate: previously treated TB cases |TB_c_ret_tsr | |Treatment success rate: HIV-positive TB cases |TB_c_tbhiv_tsr | |Treatment success rate (new smear-positive cases) |TB_c_tsr | |Treatment success rate: XDR-TB cases |TB_c_xdr_tsr | |Confirmed cases of MDR-TB started treatment for MDR-TB (%) |TB_conf_mdr_tx_pct | |Number of incident tuberculosis cases |TB_e_inc_num | |Number of incident tuberculosis cases in children aged 0 - 14 |TB_e_inc_num_014 | |Estimated number of MDR/RR-TB incident cases |TB_e_inc_rr_num | |Incidence of tuberculosis (per 100 000 population) (HIV-positive cases) |TB_e_inc_tbhiv_100k | |Number of incident tuberculosis cases, (HIV-positive cases) |TB_e_inc_tbhiv_num | |Estimated MDR-TB cases among notified pulmonary TB cases |TB_e_mdr_num | |Mortality of TB cases (all forms, excluding HIV) per 100 000 population |TB_e_mort_exc_tbhiv_100k | |Number of deaths due to tuberculosis, excluding HIV |TB_e_mort_exc_tbhiv_num | |Number of deaths from TB (all forms, excluding HIV) |TB_e_mort_exc_tbhiv_num_save | |Number of prevalent tuberculosis cases |TB_e_prev_num | |Estimated MDR/RR-TB cases among notified pulmonary TB cases |TB_e_rr_in_notified_pulm | |Tuberculosis effective treatment coverage (%) |TB_effective_treatment_coverage | |% of patients treated with fixed-dose combinations (FDCs) |TB_fdc_pcnt | |HIV-positive TB patients on ART (antiretroviral therapy) (%) |TB_hiv_art_pct | |HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%) |TB_hiv_cpt_pct | |TB patients with known HIV status (%) |TB_hivtest_pct | |Tested TB patients HIV-positive (%) |TB_hivtest_pos_pct | |Confirmed cases of MDR-TB |TB_mdr | |New or unknown treatment history cases: Pulmonary, clinically diagnosed |TB_new_clindx | |New cases: extrapulmonary |TB_new_ep | |New or unknown treatment history cases: Pulmonary, bacteriologically confirmed |TB_new_labconf | |New cases: other |TB_new_oth | |New cases: pulmonary smear-negative |TB_new_sn | |New cases: Pulmonary, smear-negative/unknown/not done and other new cases |TB_new_snsuoth | |TB_new_snuoth |TB_new_snuoth | |New cases: Pulmonary, smear-positive |TB_new_sp | |New cases: pulmonary smear unknown/not done |TB_new_su | |Tuberculosis - new and relapse cases |TB_newinc | |Treatment history unknown |TB_newret_oth | |National Reference Laboratory (NRL) |TB_nrl | |Paediatric formulations procured for TB patients |TB_paed_form | |Rifampicin used throughout treatment |TB_r_rgmn_new_initcont | |Previously treated cases, excluding relapse |TB_ret_nrel | |Retreatment cases: other |TB_ret_oth | |Relapse cases (pre-2013 definition) |TB_ret_rel | |Relapse cases: Pulmonary, clinically diagnosed |TB_ret_rel_clindx | |Relapse cases: extrapulmonary |TB_ret_rel_ep | |Relapse cases: Pulmonary, bacteriologically confirmed |TB_ret_rel_labconf | |Retreatment cases: treatment after default (pulmonary smear and/or culture positive) |TB_ret_tad | |Retreatment cases: treatment after failure (pulmonary smear and/or culture positive) |TB_ret_taf | |Confirmed cases of RR-/MDR-TB |TB_rr_mdr | |Second-line drug susceptibility testing (DST) available |TB_sldst_avail | |Tuberculosis - new and relapse cases |TB_tot_newrel | |xxx |TB_treatment_coverage | |Monitor |TOBACCO_0000000186 | |Protect from tobacco smoke |TOBACCO_0000000187 | |Offer help to quit tobacco use |TOBACCO_0000000188 | |Warn about the dangers of tobacco |TOBACCO_0000000189 | |Enforce bans on tobacco advertising |TOBACCO_0000000190 | |Raise taxes on tobacco |TOBACCO_0000000191 | |Prevalence of smoking any tobacco product among persons aged >= 15 years |TOBACCO_0000000192 | |Daily smoking of any tobacco product (age-standardized rate) |TOBACCO_0000000193 | |Current smoking of cigarettes (age-standardized rate) |TOBACCO_0000000194 | |Daily smoking of cigarettes (age-standardized rate) |TOBACCO_0000000195 | |Health-care facilities (national legislation) |TOBACCO_0000000196 | |Education facilities except universities (national legislation) |TOBACCO_0000000197 | |Universities (national legislation) |TOBACCO_0000000198 | |Government facilities (national legislation) |TOBACCO_0000000199 | |Indoor offices (national legislation) |TOBACCO_0000000200 | |Restaurants (national legislation) |TOBACCO_0000000201 | |Pubs and bars (national legislation) |TOBACCO_0000000202 | |Public transport (national legislation) |TOBACCO_0000000203 | |All other indoor public places (national legislation) |TOBACCO_0000000204 | |Number of places smoke-free (national legislation) |TOBACCO_0000000205 | |Compliance with regulations on smoke-free environments (national legislation) |TOBACCO_0000000206 | |Subnational smoke-free legislation authority exists |TOBACCO_0000000207 | |Comprehensive bans in place subnationally |TOBACCO_0000000208 | |Fines for violations |TOBACCO_0000000209 | |Fines on the establishment |TOBACCO_0000000210 | |Fines on the patron |TOBACCO_0000000211 | |Dedicated funds for enforcement |TOBACCO_0000000212 | |Citizen complaints and investigations |TOBACCO_0000000213 | |Current smoking of any tobacco product (crude rate) |TOBACCO_0000000337 | |Daily smoking of any tobacco product (crude rate) |TOBACCO_0000000338 | |Current smoking of cigarettes (crude rate) |TOBACCO_0000000339 | |Daily smoking of cigarettes (crude rate) |TOBACCO_0000000340 | |Current users of any smokeless tobacco product (crude rate) |TOBACCO_0000000341 | |Daily users of any smokeless tobacco product (crude rate) |TOBACCO_0000000342 | |Ever users of any smokeless tobacco product (crude rate) |TOBACCO_0000000343 | |Prevalence of current tobacco use among adolescents aged 13-15 years |TOBACCO_0000000344 | |Current smokers of cigarettes (youth rate) |TOBACCO_0000000345 | |Exposure to smoke at home |TOBACCO_0000000346 | |Exposure to smoke outside home |TOBACCO_0000000347 | |Jurisdiction name |TOBACCO_0000000348 | |Number of people covered by subnational legislation |TOBACCO_0000000349 | |Proportion of national population covered by subnational legislation |TOBACCO_0000000350 | |Number of places smoke-free (subnational legislation) |TOBACCO_0000000351 | |Health-care facilities (subnational legislation) |TOBACCO_0000000352 | |Education facilities, except universities (subnational legislation) |TOBACCO_0000000353 | |Universities (subnational legislation) |TOBACCO_0000000354 | |Government facilities (subnational legislation) |TOBACCO_0000000355 | |Indoor offices (subnational legislation) |TOBACCO_0000000356 | |Restaurants (subnational legislation) |TOBACCO_0000000357 | |Pubs and bars (subnational legislation) |TOBACCO_0000000358 | |Public transport (subnational legislation) |TOBACCO_0000000359 | |All other indoor public places (subnational legislation) |TOBACCO_0000000360 | |Access to a toll-free quit line |TOBACCO_0000000361 | |Smoking cessation support is available in hospitals |TOBACCO_0000000362 | |Smoking cessation support is available in health clinics or other primary care facilities |TOBACCO_0000000363 | |Smoking cessation support is available in offices of health professionals |TOBACCO_0000000364 | |Smoking cessation support is available in the community |TOBACCO_0000000365 | |Smoking cessation support is available in other settings |TOBACCO_0000000366 | |Nicotine replacement therapy - legally sold |TOBACCO_0000000367 | |Nicotine replacement therapy - place available |TOBACCO_0000000368 | |Bupropion - legally sold |TOBACCO_0000000369 | |Bupropion - place available |TOBACCO_0000000370 | |Varenicline - legally sold |TOBACCO_0000000371 | |Varenicline - place available |TOBACCO_0000000372 | |Ban on deceitful terms on cigarette packaging |TOBACCO_0000000373 | |Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging |TOBACCO_0000000374 | |Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging |TOBACCO_0000000375 | |Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging |TOBACCO_0000000376 | |Specific health warnings are mandated for cigarette packaging |TOBACCO_0000000377 | |Number of health warnings approved by the law for cigarette packaging |TOBACCO_0000000378 | |Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale |TOBACCO_0000000379 | |Health warnings on cigarette packaging describe the harmful effects of tobacco use on health |TOBACCO_0000000380 | |Font style, font size and colour of health warnings are mandated for cigarette packaging |TOBACCO_0000000381 | |Health warnings on cigarette packaging must be rotated |TOBACCO_0000000382 | |Health warnings on cigarette packaging must be written in the principal language(s) of the country |TOBACCO_0000000383 | |Health warnings on cigarette packaging must include a photograph or graphic |TOBACCO_0000000384 | |Ban on deceitful terms on other smoked tobacco packaging |TOBACCO_0000000385 | |Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging |TOBACCO_0000000386 | |Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging |TOBACCO_0000000387 | |Specific health warnings are mandated for other smoked tobacco packaging |TOBACCO_0000000388 | |Number of health warnings approved by the law for other smoked tobacco packaging |TOBACCO_0000000389 | |Health warnings on other smoked tobacco packaging must be rotated |TOBACCO_0000000390 | |Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging |TOBACCO_0000000391 | |Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale |TOBACCO_0000000392 | |Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health |TOBACCO_0000000393 | |Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging |TOBACCO_0000000394 | |Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country |TOBACCO_0000000395 | |Health warnings on other smoked tobacco packaging must include a photograph or graphic |TOBACCO_0000000396 | |Ban on deceitful terms on smokeless tobacco packaging |TOBACCO_0000000397 | |Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging |TOBACCO_0000000398 | |Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging |TOBACCO_0000000399 | |Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging |TOBACCO_0000000400 | |Specific health warnings are mandated for smokeless tobacco packaging |TOBACCO_0000000401 | |Number of health warnings approved by the law for smokeless tobacco packaging |TOBACCO_0000000402 | |Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale |TOBACCO_0000000403 | |Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health |TOBACCO_0000000404 | |Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging |TOBACCO_0000000405 | |Health warnings on smokeless tobacco packaging must be rotated |TOBACCO_0000000406 | |Most sold brand of bidis - price in US\) at official exchange rates TOBACCO_0000000407
Cheapest brand of bidis - currency reported TOBACCO_0000000408
Cheapest brand of bidis - price in currency reported TOBACCO_0000000409
Cheapest brand of bidis - price in US$ at official exchange rates TOBACCO_0000000410
Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country TOBACCO_0000000411
Health warnings on smokeless tobacco packaging must include a photograph or graphic TOBACCO_0000000412
Billboard and outdoor advertising TOBACCO_0000000413
International magazines and newspapers TOBACCO_0000000414
International television and radio TOBACCO_0000000415
Internet TOBACCO_0000000416
Local magazines and newspapers TOBACCO_0000000417
National television and radio TOBACCO_0000000418
Point of sale TOBACCO_0000000419
Subnational bans on tobacco advertising, promotion and sponsorship TOBACCO_0000000420
Compliance with bans on direct advertising TOBACCO_0000000421
Appearance of tobacco products in TV and/or films TOBACCO_0000000422
Brand name of non-tobacco products used for tobacco product TOBACCO_0000000423
Free distribution in mail or through other means TOBACCO_0000000424
Non-tobacco products identified with tobacco brand names TOBACCO_0000000425
Promotional discounts TOBACCO_0000000426
Sponsored events TOBACCO_0000000427
Compliance with bans on promotion and sponsorship TOBACCO_0000000428
Most sold brand of cigarettes - currency reported TOBACCO_0000000429
Most sold brand of cigarettes - price in currency reported TOBACCO_0000000430
Most sold brand of cigarettes - price in US$ at official exchange rates TOBACCO_0000000431
Cheapest brand of cigarettes - currency reported TOBACCO_0000000432
Cheapest brand of cigarettes - price in currency reported TOBACCO_0000000433
Cheapest brand of cigarettes - price in US$ at official exchange rates TOBACCO_0000000434
Most sold brand of bidis - currency reported TOBACCO_0000000435
Most sold brand of bidis - price in currency reported TOBACCO_0000000436
Most sold brand of cigarettes - taxes as a % of price - ad valorem excise TOBACCO_0000000437
Most sold brand of cigarettes - taxes as a % of price - import duties TOBACCO_0000000438
Most sold brand of cigarettes - taxes as a % of price - specific excise TOBACCO_0000000439
Most sold brand of cigarettes - taxes as a % of price - total tax TOBACCO_0000000440
Cheapest brand of cigarettes - taxes as a % of price - ad valorem excise TOBACCO_0000000441
Cheapest brand of cigarettes - taxes as a % of price - import duties TOBACCO_0000000442
Cheapest brand of cigarettes - taxes as a % of price - specific excise TOBACCO_0000000443
Cheapest brand of cigarettes - taxes as a % of price - total tax TOBACCO_0000000444
Most sold brand of bidis - taxes as a % of price - ad valorem excise TOBACCO_0000000445
Most sold brand of bidis - taxes as a % of price - import duties TOBACCO_0000000446
Most sold brand of bidis - taxes as a % of price - specific excise TOBACCO_0000000447
Most sold brand of bidis - taxes as a % of price - total tax TOBACCO_0000000448
Cheapest brand of bidis - taxes as a % of price - ad valorem excise TOBACCO_0000000449
Cheapest brand of bidis - taxes as a % of price - import duties TOBACCO_0000000450
Cheapest brand of bidis - taxes as a % of price - specific excise TOBACCO_0000000451
Cheapest brand of bidis - taxes as a % of price - total tax TOBACCO_0000000452
Government objectives on tobacco control exist TOBACCO_0000000453
National agency for tobacco control exists TOBACCO_0000000454
Number of full-time equivalent staff in national agency TOBACCO_0000000455
Annual budget for tobacco control in currency reported TOBACCO_0000000456
Reported currency TOBACCO_0000000457
Annual budget for tobacco control in US$ at official exchange rate TOBACCO_0000000458
Budget year TOBACCO_0000000459
Year of survey of adults TOBACCO_0000000502
Representativeness of survey of adults TOBACCO_0000000503
Repeating interval for survey of adults (years) TOBACCO_0000000504
Year of survey of youth TOBACCO_0000000505
Representativeness of youth survey TOBACCO_0000000506
Repeating interval for survey of youth (years) TOBACCO_0000000507
Most sold brand of cigarettes - taxes as a % of price - value added tax TOBACCO_0000000508
Most sold brand of cigarettes - taxes as a % of price - other taxes TOBACCO_0000000509
Most sold brand of bidis - taxes as a % of price - value added tax TOBACCO_0000000524
Most sold brand of bidis - taxes as a % of price - other taxes TOBACCO_0000000525
Anti-tobacco mass media campaigns TOBACCO_0000000526
National tobacco control programmes TOBACCO_0000000527
Survey age range TOBACCO_0000000528
Law mandates that health warnings appear on tobacco packages TOBACCO_0000000529
Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package TOBACCO_0000000530
Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry TOBACCO_0000000531
Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale TOBACCO_0000000532
Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps TOBACCO_0000000533
Health warnings on cigarette packaging law requires or establishes fines for violations TOBACCO_0000000534
Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors TOBACCO_0000000535
Cigarette packaging and labelling must not use descriptors depicting flavours TOBACCO_0000000536
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark TOBACCO_0000000537
The quit line number must appear on cigarette packaging or labelling TOBACCO_0000000538
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) TOBACCO_0000000539
Law mandates that health warnings appear on smokeless tobacco packages TOBACCO_0000000540
Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package TOBACCO_0000000541
Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry TOBACCO_0000000542
Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale TOBACCO_0000000543
Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps TOBACCO_0000000544
Health warnings on smokeless tobacco packaging law requires or establishes fines for violations TOBACCO_0000000545
Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors TOBACCO_0000000546
Smokeless tobacco packaging and labelling must not use descriptors depicting flavours TOBACCO_0000000547
Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark TOBACCO_0000000548
The quit line number must appear on smokeless tobacco packaging or labelling TOBACCO_0000000549
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) TOBACCO_0000000550
At least one national mass media campaign ran during the survey period TOBACCO_0000000551
Campaign was part of a comprehensive tobacco control programme TOBACCO_0000000552
Campaign was pre-tested TOBACCO_0000000553
Formative research was conducted TOBACCO_0000000554
Campaign utilized media planning TOBACCO_0000000555
Earned media/public relations were used to promote the campaign TOBACCO_0000000556
Process evaluation was employed to assess implementation TOBACCO_0000000557
Outcome evaluation was employed to assess effectiveness TOBACCO_0000000558
Ban on appearance of tobacco brands in TV and/or films (product placement) TOBACCO_0000000559
Most sold brand of cigarettes - price in international dollars TOBACCO_0000000560
Cheapest brand of cigarettes - price in international dollars TOBACCO_0000000561
Most sold brand of bidis - price in international dollars TOBACCO_0000000562
Tobacco excises increased over the survey period TOBACCO_0000000563
Deaths attributable to the environment TOTENV_1
Total environment attributable DALYs per 100’000 children under 5 years TOTENV_10
Deaths attributable to the environment in children under 5 years (%) TOTENV_11
DALYs attributable to the environment in children under 5 years (%) TOTENV_12
Age-standardized deaths attributable to the environment (per 100 000 population) TOTENV_2
Disability-adjusted life years (DALYs) attributable to the environment TOTENV_3
Age-standardized DALYs attributable to the environment (per 100 000 population) TOTENV_4
Deaths attributable to the environment (%) TOTENV_5
Disability-adjusted life years (DALYs) attributable to the environment (%) TOTENV_6
Total environment attributable deaths (’000) in children under 5 years TOTENV_7
Total environment attributable deaths in children under 5 years TOTENV_70
Total environment attributable deaths per 100’000 children under 5 years TOTENV_8
Total environment attributable DALYs (’000) in children under 5 years TOTENV_9
Total environment attributable DALYs in children under 5 years TOTENV_90
Best-practice policy implemented for industrially produced trans-fatty acids (TFA) (Y/N) UHCTRANSFATS
Data availability for UHC index of service coverage UHC_AVAILABILITY_SCORE
Data availability for UHC index of service coverage (ranking) UHC_DATA_AVAIL_CODE
Surgeons (per 100 000) UHC_HRHSURGEONDENSITY
Compliance with international health regulations UHC_IHR
Index of Service Coverage (Actual) UHC_INDEX_ACTUAL
UHC index of service coverage (SCI) UHC_INDEX_REPORTED
Mean fasting plasma glucose UHC_NCD_FPG
Prevalence of non-elevated blood pressure (%) UHC_NCD_NONELEVBP
UHC SCI components: Service capacity and access UHC_SCI_CAPACITY
UHC SCI components: Infectious diseases UHC_SCI_INFECT
UHC SCI components: Noncommunicable diseases UHC_SCI_NCD
UHC SCI components: Reproductive, maternal, newborn and child health UHC_SCI_RMNCH
Tuberculosis detection and treatment UHC_TB_DT
Prevalence of non-use of tobacco UHC_TOBACCONO
Proportion of newborns who have postnatal contact with a health provider within 2 days of delivery (%) UNICEF_NEWBORN
Children aged <5 years with diarrhoea receiving ORS (%) UNICEF_ORS
Women age 15-49 years who received a health check within 2 days after delivery of their most recent live birth in the last 2 years (%) UNICEF_PNCMOTHER
Proportion of newborns who have postnatal contact with a health provider within 2 days of delivery (%) UNICEF_PNCNEWBORN
Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%) UNICEF_PNEUMONIACARE
UV radiation UV_1
UV radiation attributable deaths UV_2
UV radiation attributable DALYs (’000) UV_3
UV radiation attributable deaths per 100’000 capita UV_4
UV radiation attributable DALYs per 100’000 capita UV_5
Number of reported cases of poliomyelitis by wild poliovirus (WPV) VACCINEPREVENTABLE_WILDPOLIO
Proportion of young women and men aged 18-29 years who experienced sexual violence by age 18 (%) VC_VAW_SXVLN
Bullied, past 30 days (%) VIOLENCE_BULLIED
Lifetime prevalence of child emotional abuse (%) VIOLENCE_CHILD_EMOTIONAL
Lifetime prevalence of child physical neglect (%) VIOLENCE_CHILD_NEGLECT
Lifetime prevalence of child physical abuse (%) VIOLENCE_CHILD_PHYSICAL
Lifetime prevalence of child sexual abuse (%) VIOLENCE_CHILD_SEXUAL
Extent of implementation of mental health services for victims of all types of violence VIOLENCE_EXTENTIMP_ALLTYPES
Child maltreatment: Extent of implementation of home-visiting programmes VIOLENCE_EXTENTIMP_CHILDHOMEVISIT
Extent of implementation of child protection services VIOLENCE_EXTENTIMP_CHILDPROTECTION
Elder abuse: Extent of implementation of caregiver-support programmes VIOLENCE_EXTENTIMP_ELDERCAREGIVER
Intimate partner violence: Extent of implementation of dating violence prevention programmes VIOLENCE_EXTENTIMP_PARTNERVIOLPREVENTION
Extent of implementation of medico-legal services for victims of sexual violence VIOLENCE_EXTENTIMP_VICTIMSMEDICOLEGAL
Youth violence: Extent of implementation of life-skills and social development programmes VIOLENCE_EXTENTIMP_YOUTHLIFESKILLS
Estimates of number of homicides VIOLENCE_HOMICIDENUM
Estimates of rates of homicides per 100 000 population VIOLENCE_HOMICIDERATE
Physical fighting, past 12 months (%) VIOLENCE_PHYSICAL_FIGHTING
Anti-tobacco mass media campaigns W-MM_Group
Health warnings on cigarette packaging must include a photograph or graphic W10_graphic_A
Health warnings on other smoked tobacco packaging must include a photograph or graphic W10_graphic_B
Health warnings on smokeless tobacco packaging must include a photograph or graphic W10_graphic_C
Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale W11_outside_pack_A
Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale W11_outside_pack_B
Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale W11_outside_pack_C
Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_A
Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_B
Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_C
Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_A
Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_B
Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_C
Health warnings on cigarette packaging describe the harmful effects of tobacco use on health W14_harm_effects_A
Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health W14_harm_effects_B
Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health W14_harm_effects_C
Specific health warnings are mandated for cigarette packaging W15_specific_hw_A
Specific health warnings are mandated for other smoked tobacco packaging W15_specific_hw_B
Specific health warnings are mandated for smokeless tobacco packaging W15_specific_hw_C
Number of health warnings approved by the law for cigarette packaging W16_number_hw_A
Number of health warnings approved by the law for other smoked tobacco packaging W16_number_hw_B
Number of health warnings approved by the law for smokeless tobacco packaging W16_number_hw_C
Health warnings on cigarette packaging law requires or establishes fines for violations W17_fines_A
Health warnings on other smoked tobacco packaging law requires or establishes fines for violations W17_fines_B
Health warnings on smokeless tobacco packaging law requires or establishes fines for violations W17_fines_C
Ban on deceitful terms on cigarette packaging W18_misleading_terms_A
Ban on deceitful terms on other smoked tobacco packaging W18_misleading_terms_B
Ban on deceitful terms on smokeless tobacco packaging W18_misleading_terms_C
Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_Bolours_numbers_B
Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_A
Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_B
Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_C
Law mandates that health warnings appear on cigarette packages W1_HW_law_A
Law mandates that health warnings appear on other smoked tobacco packages W1_HW_law_B
Law mandates that health warnings appear on smokeless tobacco packages W1_HW_law_C
Cigarette packaging and labelling must not use descriptors depicting flavours W20_flavours_A
Other smoked tobacco packaging and labelling must not use descriptors depicting flavours W20_flavours_B
Smokeless tobacco packaging and labelling must not use descriptors depicting flavours W20_flavours_C
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_A
Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_B
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_quant_A
Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_quant_B
Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_quant_C
Cigarette packaging and labelling must display qualitative information on emission yields W22_emissions_qual_A
Other smoked tobacco packaging and labelling must display qualitative information on emission yields W22_emissions_qual_B
Smokeless tobacco packaging and labelling must display qualitative information on emission yields W22_emissions_qual_C
Emission yields must be displayed on one or more principle display areas of cigarette packaging W23_emissions_front_back_A
Emission yields must be displayed on one or more principle display areas of other smoked tobacco packaging W23_emissions_front_back_B
Emission yields must be displayed on one or more principle display areas of smokeless tobacco packaging W23_emissions_front_back_C
Display of expiry dates is prevented on cigarette packaging W24_exp_date_A
Display of expiry dates is prevented on other smoked tobacco packaging W24_exp_date_B
Display of expiry dates is prevented on smokeless tobacco packaging W24_exp_date_C
The quit line number must appear on cigarette packaging or labelling W25_quitline_number_A
The quit line number must appear on other smoked tobacco packaging or labelling W25_quitline_number_B
The quit line number must appear on smokeless tobacco packaging or labelling W25_quitline_number_C
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plainSPACEpackaging_A
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plainSPACEpackaging_C
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) W26_plain_packaging_A
Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) W26_plain_packaging_B
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) W26_plain_packaging_C
Ban on sale of smokeless tobacco products W27_smokeless_prod_ban
Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging W2_pc_front_back_A
Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging W2_pc_front_back_B
Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging W2_pc_front_back_C
Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging W3_pc_front_A
Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging W3_pc_front_B
Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging W3_pc_front_C
Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging W4_pc_back_A
Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging W4_pc_back_B
Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging W4_pc_back_C
Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package W5_top_side_A
Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package W5_top_side_B
Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package W5_top_side_C
Font style, font size and colour of health warnings are mandated for cigarette packaging W6_font_A
Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging W6_font_B
Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging W6_font_C
Health warnings on cigarette packaging must be rotated W7_rotation_A
Health warnings on other smoked tobacco packaging must be rotated W7_rotation_B
Health warnings on smokeless tobacco packaging must be rotated W7_rotation_C
Health warnings on cigarette packaging must be written in the principal language(s) of the country W8_princ_langs_A
Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country W8_princ_langs_B
Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country W8_princ_langs_C
Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_A
Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_B
Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_C
Access to improved drinking water sources WAS_0000000001
Access to improved sanitation WAS_0000000002
Life expectancy at birth (years) WHOSIS_000001
Healthy life expectancy (HALE) at birth (years) WHOSIS_000002
Neonatal mortality rate (per 1000 live births) WHOSIS_000003
Adult mortality rate (probability of dying between 15 and 60 years per 1000 population) WHOSIS_000004
Low-birth-weight newborns (%) WHOSIS_000005
Infants exclusively breastfed for the first six months of life (%) WHOSIS_000006
Healthy life expectancy (HALE) at age 60 (years) WHOSIS_000007
Children aged <5 years underweight (%) WHOSIS_000008
Children aged <5 years overweight (%) WHOSIS_000009
Adults aged ≥ 20 years who are obese (%) WHOSIS_000010
Alcohol consumption among adults aged ≥ 15 years (litres of pure alcohol per person per year) WHOSIS_000011
Prevalence of smoking any tobacco product among adults (≥15 years) (%) WHOSIS_000012
Prevalence of current tobacco use among adolescents (13-15 years) (%) WHOSIS_000013
Stillbirth rate (per 1000 total births) WHOSIS_000014
Life expectancy at age 60 (years) WHOSIS_000015
Most recent census (year) WHS10_1
International Statistical Classification of Diseases and Related Health Problems (ICD) WHS10_10
Number of cause-of-death registration years available WHS10_2
Number of national population surveys - child anthropometry WHS10_3
Number of national population surveys - child mortality WHS10_4
Number of national population surveys - maternal mortality WHS10_5
Number of national population surveys - HIV prevalence WHS10_6
Number of national population surveys - adult health WHS10_7
Civil registration coverage of cause-of-death (%) WHS10_8
Ill-defined causes in cause-of-death registration (%) WHS10_9
Distribution of years of life lost by major cause group WHS2_126
Age-standardized NCD mortality rate (per 100 000 population) WHS2_131
Deaths due to HIV/AIDS (per 100 000 population) WHS2_138
Deaths due to malaria (per 100 000 population) WHS2_152
Distribution of causes of death among children aged <5 years (%) WHS2_155
Age-standardized mortality rate by cause (per 100 000 population) - Cancer WHS2_160
Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular WHS2_161
Age-standardized mortality rate by cause (per 100 000 population) - Injuries WHS2_162
Age-standardized mortality rate by cause (per 100 000 population) - Noncommunicable WHS2_163
Distribution of causes of death among children aged <5 years (%) - Malaria WHS2_164
Distribution of causes of death among children aged <5 years (%) - Pneumonia WHS2_165
Distribution of causes of death among children aged <5 years (%) - Injuries WHS2_166
Distribution of causes of death among children aged <5 years (%) - Diarrhoea WHS2_167
Distribution of causes of death among children aged <5 years (%) - Measles WHS2_168
Distribution of causes of death among children aged <5 years (%) - Causes arising in the perinatal period WHS2_169
Distribution of causes of death among children aged <5 years (%) - HIV/AIDS WHS2_170
Distribution of causes of death among children aged <5 years (%) - Other diseases WHS2_171
Distribution of years of life lost by broader causes (%) - Communicable WHS2_172
Distribution of years of life lost by broader causes (%) - Noncommunicable WHS2_173
Distribution of years of life lost by broader causes (%) - Injuries WHS2_174
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - All causes WHS2_3070_all
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cancer WHS2_3070_cancer
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cardiovasular disease and diabetes WHS2_3070_cdd
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Chronic respiratory conditions WHS2_3070_chronic
Age-standardized mortality rate by cause (per 100 000 population) - Communicable WHS2_513
Distribution of causes of death among children aged <5 years (%) - Prematurity WHS2_514
Distribution of causes of death among children aged <5 years (%) - Neonatal sepsis WHS2_515
Distribution of causes of death among children aged <5 years (%) - Congenital anomalies WHS2_516
Distribution of causes of death among children aged <5 years (%) - Birth asphyxia WHS2_523
Cholera - number of reported cases WHS3_40
Diphtheria - number of reported cases WHS3_41
Japanese encephalitis - number of reported cases WHS3_42
Pertussis - number of reported cases WHS3_43
Number of new leprosy cases WHS3_45
Total tetanus - number of reported cases WHS3_46
Meningitis - number of reported cases WHS3_47
Malaria - number of reported confirmed cases WHS3_48
Poliomyelitis - number of reported cases WHS3_49
Yellow fever - number of reported cases WHS3_50
H5N1 influenza - number of reported cases WHS3_51
Plague - number of reported cases WHS3_52
Number of reported cases of tuberculosis WHS3_522
Mumps - number of reported cases WHS3_53
Number of reported cases of tuberculosis (DOTS) WHS3_54
Congenital Rubella Syndrome - number of reported cases WHS3_55
Neonatal tetanus - number of reported cases WHS3_56
Total rubella - number of reported cases WHS3_57
Measles - number of reported cases WHS3_62
Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) WHS4_100
Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%) WHS4_106
Children aged <5 years with diarrhoea receiving ORT (%) WHS4_107
Children aged <5 years with ARI symptoms who took antibiotic treatment (%) WHS4_108
Antenatal care coverage - at least one visit (%) WHS4_111
Antenatal care coverage - at least one visit, among girls aged 15-19 (%) WHS4_111_AGE1519
Births by caesarean section (%) WHS4_115
Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) WHS4_117
Children aged 6-59 months who received vitamin A supplementation (%) WHS4_124
Neonates protected at birth against neonatal tetanus (PAB) (%) WHS4_128
Hib (Hib3) immunization coverage among 1-year-olds (%) WHS4_129
Antenatal care coverage - at least four visits (%) WHS4_154
Postnatal care visit within two days of birth (%) WHS4_2530
BCG immunization coverage among 1-year-olds (%) WHS4_543
Polio (Pol3) immunization coverage among 1-year-olds (%) WHS4_544
Antiretroviral therapy coverage among HIV-infected pregnant women for PMTCT (%) WHS4_99
Population using improved drinking-water sources (%) WHS5_122
Population using improved sanitation facilities (%) WHS5_158
Population using solid fuels (%) WHS5_512
Radiotherapy units (per 1 000 000 population) WHS6_100
Median availability of selected generic medicines (%) - Private WHS6_101
Hospital beds (per 10 000 population) WHS6_102
Median consumer price ratio of selected generic medicines - Private WHS6_116
Number of dentistry personnel WHS6_123
Physicians density (per 10 000 population) WHS6_125
Number of nursing and midwifery personnel WHS6_127
Number of physicians WHS6_136
Number of community health workers WHS6_140
Dentistry personnel density (per 10 000 population) WHS6_144
Nursing and midwifery personnel density (per 10 000 population) WHS6_148
Community health workers density (per 10 000 population) WHS6_150
Number of other health service providers WHS6_157
Other health service providers density (per 10 000 population) WHS6_159
Number of pharmaceutical personnel WHS6_517
Number of environment and public health workers WHS6_518
Density of pharmaceutical personnel (per 10 000 population) WHS6_519
Density of environment and public health workers (per 10 000 population) WHS6_520
Private prepaid plans as a percentage of private expenditure on health WHS7_103
Per capita government expenditure on health at average exchange rate (US$) WHS7_104
Per capita total expenditure on health (PPP int. $) WHS7_105
Per capita government expenditure on health (PPP int. \() |WHS7_108 | |General government expenditure on health as a percentage of total government expenditure |WHS7_113 | |External resources for health as a percentage of total expenditure on health |WHS7_120 | |Social security expenditure on health as a percentage of general government expenditure on health |WHS7_134 | |Out-of-pocket expenditure as a percentage of private expenditure on health |WHS7_139 | |Total expenditure on health as a percentage of gross domestic product |WHS7_143 | |Private expenditure on health as a percentage of total expenditure on health |WHS7_147 | |General government expenditure on health as a percentage of total expenditure on health |WHS7_149 | |Out-of-pocket expenditure as a percentage of total expenditure on health |WHS7_150 | |Per capita total expenditure on health at average exchange rate (US\)) WHS7_156
Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) WHS8_110
Literacy rate among adults aged >= 15 years (%) WHS9_85
Population (in thousands) total WHS9_86
Net primary school enrolment ratio (%) WHS9_87
Population median age (years) WHS9_88
Population proportion under 15 (%) WHS9_89
Population living on <$1 (PPP int. $) a day (%) WHS9_90
Civil registration coverage of births (%) WHS9_91
Population proportion over 60 (%) WHS9_92
Gross national income per capita (PPP int. $) WHS9_93
Civil registration coverage of causes of deaths (%) WHS9_94
Total fertility rate (per woman) WHS9_95
Population living in urban areas (%) WHS9_96
Annual population growth rate (%) WHS9_97
Crude birth rate (per 1000 population) WHS9_CBR
Crude death rate (per 1000 population) WHS9_CDR
Cellular subscribers (per 100 population) WHS9_CS
Preterm birth rate (per 100 live births) WHS_PBR
Water, sanitation and hygiene - population attributable fractions WSH_09
SDG 3.9.2 WASH deaths WSH_1
Number of diarrhoea deaths from inadequate water, sanitation and hygiene WSH_10
Number of diarrhoea deaths from inadequate hygiene WSH_10_HYG
Number of diarrhoea deaths from inadequate sanitation WSH_10_SAN
Number of diarrhoea deaths from inadequate water WSH_10_WAT
Water, sanitation and hygiene attributable deaths (’000) in children under 5 years WSH_2
Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene WSH_20
Attributable fraction of diarrhoea to inadequate hygiene WSH_20_HYG
Attributable fraction of diarrhoea to inadequate sanitation WSH_20_SAN
Attributable fraction of diarrhoea to inadequate water WSH_20_WAT
Water, sanitation and hygiene attributable deaths per 100’000 capita WSH_3
Number of diarrhoea DALYs from inadequate water, sanitation and hygiene WSH_30
Number of diarrhoea DALYs from inadequate hygiene WSH_30_HYG
Number of diarrhoea DALYs from inadequate sanitation WSH_30_SAN
Number of diarrhoea DALYs from inadequate water WSH_30_WAT
Water, sanitation and hygiene attributable deaths per 100’000 children under 5 years WSH_4
Diarrhoea deaths from inadequate water, sanitation and hygiene in children under 5 years WSH_40
Diarrhoea deaths from inadequate hygiene in children under 5 years WSH_40_HYG
Diarrhoea deaths from inadequate sanitation in children under 5 years WSH_40_SAN
Diarrhoea deaths from inadequate water in children under 5 years WSH_40_WAT
Water, sanitation and hygiene attributable DALYs (’000) WSH_5
Diarrhoea DALYs from inadequate water, sanitation and hygiene in children under 5 years WSH_50
Diarrhoea DALYs from inadequate hygiene in children under 5 years WSH_50_HYG
Diarrhoea DALYs from inadequate sanitation in children under 5 years WSH_50_SAN
Diarrhoea DALYs from inadequate water in children under 5 years WSH_50_WAT
Water, sanitation and hygiene attributable DALYs (’000) in children under 5 years WSH_6
Water, sanitation and hygiene attributable DALYs per 100’000 capita WSH_7
Water, sanitation and hygiene attributable DALYs per 100’000 children under 5 years WSH_8
Population with basic handwashing facilities at home (%) WSH_HYGIENE_BASIC
Population using at least basic sanitation services (%) WSH_SANITATION_BASIC
Population practising open defecation (%) WSH_SANITATION_OD
Population using safely managed sanitation services (%) WSH_SANITATION_SAFELY_MANAGED
Population using at least basic drinking-water services (%) WSH_WATER_BASIC
Population using safely managed drinking-water services (%) WSH_WATER_SAFELY_MANAGED
Warn about the dangers of tobacco W_Group
Title of most recent adolescent survey Youth_survey_title
Age range of most recent adolescent survey Youth_svy_age_range
Representativeness of most recent adolescent survey Youth_svy_national
Year of most recent adolescent survey Youth_svy_yr
Prevalence of current cigarette smoking among adolescents (%) Yth_curr_cig_smoking
Prevalence of current e-cigarette use among adolescents (%) Yth_curr_e-cig
Prevalence of current smokeless tobacco use among adolescents (%) Yth_curr_smokeless
Prevalence of current tobacco smoking among adolescents (%) Yth_curr_tob_smoking
Prevalence of current tobacco use among adolescents (%) Yth_curr_tob_use
Prevalence of daily cigarette smoking among adolescents (%) Yth_daily_cig_smoking
Prevalence of daily e-cigarette use among adolescents (%) Yth_daily_e-cig
Prevalence of daily smokeless tobacco use among adolescents (%) Yth_daily_smokeless
Prevalence of daily tobacco smoking among adolescents (%) Yth_daily_tob_smoking
Prevalence of daily tobacco use among adolescents (%) Yth_daily_tob_use
Age range of latest youth prevalence survey (nonsmoked) Yth_nonsmoked_age_grp
Representation of latest youth prevalence survey (nonsmoked) Yth_nonsmoked_national
Name of latest youth prevalence survey (nonsmoked) Yth_nonsmoked_svy_title
Year of latest youth prevalence survey (nonsmoked) Yth_nonsmoked_svy_yr
Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%) anc1
Antenatal care coverage - at least one visit (in the three years preceding the survey) (%) anc13
Antenatal care coverage - at least one visit (in the five years preceding the survey) (%) anc15
Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%) anc4
Antenatal care coverage - at least four visits (in the three years preceding the survey) (%) anc43
Antenatal care coverage - at least four visits (in the five years preceding the survey) (%) anc45
Adolescent fertility rate (births per 1000 women aged 15-19 years) asfr1
BCG immunization coverage among one-year-olds (%) bcgv
Early initiation of breastfeeding (in the two years preceding the survey) (%) bfearly
Early initiation of breastfeeding (in the five years preceding the survey) (%) bfearly5
Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%) bmi30wm
Children aged < 5 years with pneumonia symptoms taken to a health facility (%) carep
Composite coverage index (%) cci
Composite coverage index (%) cci2030
Child mortality rate (probability of dying between age 1 and age 5 per 1000 live births) cmr
Contraceptive prevalence - modern methods (%) cpmo
Contraceptive prevalence - use of modern methods (%) cpmowho
Contraceptive prevalence - use of modern and traditional methods (%) cpmt
Births by caesarean section (in the two or three years preceding the survey) (%) csection
Births by caesarean section (in the three years preceding the survey) (%) csection3
Births by caesarean section (in the five years preceding the survey) (%) csection5
DTP3 immunization coverage among one-year-olds (%) dptv
Early initiation of breastfeeding (in the two or three years preceding the survey) (%) ebreast
Early initiation of breastfeeding (in the three years preceding the survey) (%) ebreast3
Early initiation of breastfeeding (in the five years preceding the survey) (%) ebreast5
Family planning needs satisfied (%) famplan
Demand for family planning satisfied - use of modern and traditional methods (%) fps
Demand for family planning satisfied - modern methods (%) fpsmo
Demand for family planning satisfied - use of modern methods (%) fpsmowho
Full immunization coverage among 1-year-olds (%) full
Full immunization coverage among one-year-olds (%) fullv
Infant mortality rate (deaths per 1000 live births) imr
Children aged < 5 years sleeping under insecticide-treated nets (%) itnch
Children aged <5 years sleeping under insecticide-treated nets (%) itnchild
Pregnant women sleeping under insecticide-treated nets (%) itnpreg
Pregnant women sleeping under insecticide-treated nets (%) itnwm
Measles (MCV) immunization coverage among 1-year-olds (%) measlesv
Measles immunization coverage among one-year-olds (%) mslv
Neonatal mortality rate (deaths per 1000 live births) nmr
Prevalence of obesity in non-pregnant women aged 15 - 49 years, BMI >= 30 (%) obese
Obesity prevalence in non-pregnant women aged 15-49 years, BMI >= 30 (%) obesewm
Children aged < 5 years with diarrhoea receiving oral rehydration salts (%) ors
Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%) ort
Overweight prevalence in children aged <three years (%) overwgt3
Overweight prevalence in children aged < 5 years (%) overwgt5
Postnatal care visit within two days of birth (in the x years preceding the survey) (%) pncall
Postnatal care visit within two days of birth (in the three years preceding the survey) (%) pncall3
Postnatal care visit within two days of birth (in the five years preceding the survey) (%) pncall5
Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%) pnchome
Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%) pnchome3
Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%) pnchome5
Children aged <5 years with ARI symptoms taken to facility (%) pneumcare
Postneonatal mortality rate (probability of dying between age 30 days and 11 months per 1000 live births) pnmr
Polio immunization coverage among one-year-olds (%) poliov
Births attended by skilled health personnel (in the two or three years preceding the survey) (%) sba
Births attended by skilled health personnel (in the three years preceding the survey) (%) sba3
Births attended by skilled health personnel (in the five years preceding the survey) (%) sba5
Severe wasting prevalence in children aged < 5 years (%) sevwast5
Children aged <5 years stunted (%) stunt
Stunting prevalence in children aged < 3 years (%) stunt3
Stunting prevalence in children aged < 5 years (%) stunt5
Total fertility rate (births per woman) tfr
Under-five mortality rate (deaths per 1000 live births) u5mr
Children aged <5 years underweight (%) uweight
Underweight prevalence in children aged < 3 years (%) uweight3
Underweight prevalence in children aged < 5 years (%) uweight5
Underweight prevalence in children aged < 3 years (%) uwgt3
Underweight prevalence in children aged < 5 years (%) uwgt5
BCG immunization coverage among one-year-olds (%) vbcg
DTP3 immunization coverage among one-year-olds (%) vdpt
Full immunization coverage among one-year-olds (%) vfull
Children aged 6-59 months who received vitamin A supplementation (%) vita
Measles immunization coverage among one-year-olds (%) vmsl
Polio immunization coverage among one-year-olds (%) vpolio
Wasting prevalence in children aged < 3 years (%) wast3
Wasting prevalence in children aged < 5 years (%) wast5